付録 2.7.4- 51　　治験薬の休薬に至った有害事象の一覧

001 試験（パート C 及び F）（安全性解析対象集団）

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0002, Subject ID=003010, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=										
003010	Treatment Cycle 7	133	Pneumonia	3.14 Weeks	Moderate	2	Y	N	Interrupted	Resolved
		133	Tumour pain	2 Days	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=003002, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=162										
003002	Treatment Cycle 5	99	Cough	3.14 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0027, Subject ID=003012, Gender=M, Race=White, Age=40 Years, Rel Day of Study Medication Discontinuance†=43										
003012	Safety Follow-up	44	Pneumonia	5 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0057, Subject ID=003027, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=43										
003027	Safety Follow-up	50	Asthenia	3.14 Weeks	Severe	3	Y	N	Interrupted	Resolved
		50	Dehydration	3.14 Weeks	Moderate	2	Y	N	Interrupted	Resolved
		60	Chills	1.71 Weeks	Moderate	2	Y	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0057, Subject ID=003027, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=43										
003027	Safety Follow-up	60	Pyrexia	1.71 Weeks	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0073, Subject ID=003007, Gender=F, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=72										
003007	Treatment Cycle 1	16	Atelectasis	1.14 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0091, Subject ID=003014, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=108										
003014	Treatment Cycle 1	20	Syncope	1 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0091, Subject ID=003019, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=207										
003019	Treatment Cycle 7	143	Bronchitis	4 Days	Severe	3	Y	N	Interrupted	Resolved
	Treatment Cycle 8	176	Pneumonitis	4.29 Weeks	Moderate	2	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0111, Subject ID=003050, Gender=M, Race=Asian, Age=52 Years, Rel Day of Study Medication Discontinuance†=50										

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0111, Subject ID=003050, Gender=M, Race=Asian, Age=52 Years, Rel Day of Study Medication Discontinuance†=50										
003050	Treatment Cycle 1	10	Fatigue	Continuing	Moderate	2		Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0121, Subject ID=003024, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=										
003024	Treatment Cycle 8	170	Pyrexia	2.86 Weeks	Moderate	2	Y	Y	Interrupted	Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0001, Subject ID=001027, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
001027	Treatment Cycle 11	230	Nausea	3.43 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0001, Subject ID=001120, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=										
001120	Treatment Cycle 12	253	Alanine aminotransferase increased	1.14 Weeks	Moderate	2		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0001, Subject ID=001120, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=										
001120	Treatment Cycle 14	316	Alanine aminotransferase increased	1.18 Months	Severe	3		Y	Interrupted	Resolved
		316	Aspartate aminotransferase increased	1.18 Months	Severe	4		Y	Interrupted	Resolved
		344	Cough	2.3 Months	Moderate	2		N	Interrupted	Resolved
		345	Dyspnoea	2.3 Months	Moderate	2		N	Interrupted	Resolved
		345	Hypoxia	2.3 Months	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0001, Subject ID=001522, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										
001522	Treatment Cycle 10	211	Upper respiratory tract infection	4.14 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0001, Subject ID=001525, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=176										
001525	Treatment Cycle 1	6	Pulmonary oedema	5 Days	Severe	3	Y	N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0003, Subject ID=001533, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=										
001533	Treatment Cycle 3	66	Pneumonia	1.57 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0008, Subject ID=001170, Gender=F, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=										
001170	Treatment Cycle 6	125	Rash	1.91 Months	Moderate	2		Y	Interrupted	Resolved
		126	Hypothyroidism	4.63 Months	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 10	286	Musculoskeletal pain	2.57 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0008, Subject ID=001541, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=190										
001541	Treatment Cycle 10	190	Fatigue	1.25 Months	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000152, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=715										
000152	Treatment Cycle 25	534	Leiomyosarcoma	2 Days	Severe	3	Y	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0010, Subject ID=000201, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=547										
000201	Treatment Cycle 18	358	Diarrhoea	3.71 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000815, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=421										
000815	Treatment Cycle 13	270	Pneumonitis	2.57 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000818, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
000818	Treatment Cycle 9	193	Diarrhoea	3.57 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000189, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=1										
000189	Safety Follow-up	22	Obstructive airways disorder	1 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000915, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=										
000915	Treatment Cycle 19	393	Pneumonitis	Continuing	Moderate	2		Y	Interrupted	Not Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=000915, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=										
000915	Treatment Cycle 19	400	Transaminases increased	1.25 Months	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000947, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=										
000947	Treatment Cycle 1	22	Pulmonary oedema	6 Days	Severe	3	Y	N	Interrupted	Resolved
	Treatment Cycle 5	105	Small intestinal obstruction	4 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000950, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=295										
000950	Treatment Cycle 1	1	Chills	1 Days	Mild	1		Y	Interrupted	Resolved
	Treatment Cycle 11	225	Pneumonia	4.14 Weeks	Mild	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001540, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=										
001540	Treatment Cycle 1	23	Hypertension	1.14 Weeks	Severe	3		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0015, Subject ID=000196, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=										
000196	Treatment Cycle 21	423	Weight decreased	1 Days	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000803, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance†=83										
000803	Treatment Cycle 2	23	Pneumonitis	2.86 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=001130, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
001130	Treatment Cycle 3	43	Nausea	1 Days	Mild	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=001564, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=251										
001564	Treatment Cycle 2	39	Myalgia	3.12 Months	Mild	1		Y	Interrupted	Resolved
	Treatment Cycle 3	42	Arthralgia	2.5 Months	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 6	163	Arthralgia	4.14 Weeks	Moderate	2		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0019, Subject ID=001586, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=30										
001586	Treatment Cycle 1	12	Pneumonia	5 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000908, Gender=F, Race=Black Or African American, Age=28 Years, Rel Day of Study Medication Discontinuance†=71										
000908	Treatment Cycle 1	5	Upper respiratory tract infection	1 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000911, Gender=M, Race=Asian, Age=70 Years, Rel Day of Study Medication Discontinuance†=324										
000911	Treatment Cycle 13	254	Arthritis	3.43 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000923, Gender=M, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=558										
000923	Treatment Cycle 19	402	Laceration	1 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000933, Gender=F, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=29										
000933	Treatment Cycle 1	15	Lung infection	1.43 Weeks	Severe	3	Y	N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0020, Subject ID=000983, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=244										
000983	Treatment Cycle 6	126	Lower respiratory tract infection	1.38 Months	Moderate	2		N	Interrupted	Resolved
	Treatment Cycle 10	211	Acute coronary syndrome	2 Days	Severe	3	Y	N	Interrupted	Resolved
		220	Chest pain	2 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001127, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=57										
001127	Treatment Cycle 1	10	Nausea	2.43 Weeks	Severe	3	Y	Y	Interrupted	Resolved
		13	Vomiting	1.71 Weeks	Severe	3	Y	Y	Interrupted	Resolved
		21	Dehydration	3 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001566, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=300										
001566	Treatment Cycle 3	54	Colitis	1.29 Weeks	Severe	3		Y	Interrupted	Resolved
	Treatment Cycle 4	111	Myxoedema	3.43 Weeks	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 10	272	Hyperkeratosis	3.43 Weeks	Severe	3		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0023, Subject ID=000603, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000603	Treatment Cycle 29	609	Diarrhoea	2 Days	Moderate	2		N	Interrupted	Resolved
		617	Presyncope	1 Days	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=000993, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
000993	Treatment Cycle 4	72	Dermatitis	9.36 Months	Mild	1		Y	Interrupted	Resolved
	Treatment Cycle 5	94	Lichen planus	1.28 Months	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 18	483	Confusional state	2.57 Weeks	Moderate	2	Y	N	Interrupted	Resolved
		485	Hypomagnesaemia	Continuing	Mild	1		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=001503, Gender=M, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=										
001503	Treatment Cycle 2	41	Myasthenic syndrome	1.68 Months	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 5	132	Weight decreased	3.68 Months	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 9	216	Sepsis	3.14 Weeks	Moderate	2	Y	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0023, Subject ID=001503, Gender=M, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=										
001503	Treatment Cycle 9	244	Weight decreased	1.38 Months	Severe	3		Y	Interrupted	Resolved
	Treatment Cycle 17	433	Pyrexia	2.29 Weeks	Mild	1		N	Interrupted	Resolved
	Treatment Cycle 22	548	Lichenoid keratosis	4.14 Weeks	Severe	3		Y	Interrupted	Resolved
		548	Lichenoid keratosis	4.14 Weeks	Severe	3		Y	Interrupted	Resolved
		554	Infective exacerbation of chronic obstructive airways disease	3.86 Weeks	Severe	4	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=001508, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=98										
001508	Treatment Cycle 3	47	Malignant pleural effusion	4.14 Weeks	Severe	3	Y	N	Interrupted	Resolved
		47	Pericardial effusion malignant	4.14 Weeks	Severe	3	Y	N	Interrupted	Resolved
		51	Pulmonary embolism	Continuing	Moderate	2	Y	N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=001589, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=169										

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0023, Subject ID=001589, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=169										
001589	Treatment Cycle 3	62	Splenomegaly	3.55 Months	Mild	1		Y	Interrupted	Resolved
	Treatment Cycle 4	104	Tendonitis	Continuing	Mild	1		Y	Interrupted	Not Resolved
		113	Hypophysitis	4.14 Weeks	Severe	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=001590, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=										
001590	Treatment Cycle 1	11	Pulmonary embolism	6 Days	Severe	4	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0028, Subject ID=001178, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=288										
001178	Treatment Cycle 1	17	Diarrhoea	1.14 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0032, Subject ID=001038, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=142										
001038	Treatment Cycle 7	142	Back pain	Continuing	Severe	3		N	Interrupted	Not Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0033, Subject ID=001037, Gender=F, Race=Asian, Age=54 Years, Rel Day of Study Medication Discontinuance†=										
001037	Treatment Cycle 3	58	Bronchitis	1.14 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0055, Subject ID=001175, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=30										
001175	Treatment Cycle 1	9	Dyspnoea	2.29 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0070, Subject ID=001035, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=287										
001035	Treatment Cycle 1	22	Transaminases increased	1 Weeks	Severe	3		Y	Interrupted	Resolved
	Treatment Cycle 3	84	Transaminases increased	1.14 Weeks	Severe	3		Y	Interrupted	Resolved
		92	Alanine aminotransferase increased	6 Days	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0073, Subject ID=001172, Gender=F, Race=Black Or African American, Age=51 Years, Rel Day of Study Medication Discontinuance†=										
001172	Treatment Cycle 9	201	Irritable bowel syndrome	1.48 Months	Moderate	2		N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0073, Subject ID=001172, Gender=F, Race=Black Or African American, Age=51 Years, Rel Day of Study Medication Discontinuance†=										
001172	Treatment Cycle 11	234	Sinusitis	3.14 Weeks	Mild	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0073, Subject ID=001578, Gender=F, Race=Asian, Age=76 Years, Rel Day of Study Medication Discontinuance†=										
001578	Treatment Cycle 5	106	Adrenal insufficiency	Continuing	Moderate	2	Y	Y	Interrupted	Not Resolved
		106	Hyponatraemia	3.14 Weeks	Moderate	2	Y	Y	Interrupted	Resolved
		106	Hypothyroidism	Continuing	Moderate	2	Y	Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0081, Subject ID=001040, Gender=M, Race=Asian, Age=65 Years, Rel Day of Study Medication Discontinuance†=386										
001040	Treatment Cycle 6	122	Pneumothorax	4 Days	Moderate	2	Y	N	Interrupted	Resolved
		127	Pneumothorax	1 Weeks	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0082, Subject ID=001082, Gender=M, Race=Asian, Age=60 Years, Rel Day of Study Medication Discontinuance†=106										
001082	Treatment Cycle 6	106	Pneumonia	1.81 Months	Severe	3	Y	N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0082, Subject ID=001110, Gender=M, Race=Asian, Age=69 Years, Rel Day of Study Medication Discontinuance†=										
001110	Treatment Cycle 3	62	Arthritis bacterial	3.86 Weeks	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0083, Subject ID=001007, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=97										
001007	Treatment Cycle 1	6	Pneumonia viral	4.29 Weeks	Moderate	2	Y	Y	Interrupted	Resolved
		20	Blood bilirubin increased	2 Days	Moderate	2		Y	Interrupted	Resolved
		21	Blood bilirubin increased	2 Days	Severe	3	Y	Y	Interrupted	Resolved
		22	Pneumothorax	6 Days	Moderate	2	Y	Y	Interrupted	Resolved
		23	Blood bilirubin increased	5 Days	Moderate	2		Y	Interrupted	Resolved
		26	Alanine aminotransferase increased	2 Days	Moderate	2		Y	Interrupted	Resolved
		27	Alanine aminotransferase increased	4.14 Weeks	Severe	3		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0083, Subject ID=001007, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=97										
001007	Treatment Cycle 1	27	Aspartate aminotransferase increased	1.14 Weeks	Moderate	2		Y	Interrupted	Resolved
		55	Alanine aminotransferase increased	1.29 Weeks	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 2	64	Cardiac tamponade	1.14 Weeks	Severe	4	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0083, Subject ID=001046, Gender=M, Race=Asian, Age=51 Years, Rel Day of Study Medication Discontinuance†=218										
001046	Treatment Cycle 8	169	Pneumonia	1 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0083, Subject ID=001090, Gender=F, Race=Asian, Age=65 Years, Rel Day of Study Medication Discontinuance†=26										
001090	Treatment Cycle 1	13	Pleural effusion	2 Weeks	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0090, Subject ID=001584, Gender=M, Race=White, Age=39 Years, Rel Day of Study Medication Discontinuance†=190										

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0090, Subject ID=001584, Gender=M, Race=White, Age=39 Years, Rel Day of Study Medication Discontinuance†=190										
001584	Treatment Cycle 4	92	Asthenia	2.2 Months	Mild	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0091, Subject ID=001061, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=231										
001061	Treatment Cycle 1	21	Lung infection	1.14 Weeks	Moderate	2	Y	N	Interrupted	Resolved
	Treatment Cycle 10	216	Oesophageal candidiasis	1.43 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0092, Subject ID=001180, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
001180	Treatment Cycle 17	353	Hypokalaemia	1.43 Weeks	Severe	3		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0112, Subject ID=001091, Gender=F, Race=Asian, Age=40 Years, Rel Day of Study Medication Discontinuance†=22										
001091	Safety Follow-up	23	Dysuria	Continuing	Severe	3	Y	Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0120, Subject ID=001087, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=296										

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0120, Subject ID=001087, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=296										
001087	Treatment Cycle 2	18	Infusion related reaction	1 Days	Moderate	2		Y	Interrupted	Resolved
	Safety Follow-up	309	Intervertebral disc protrusion	Continuing	Mild	1		N	Interrupted	Not Resolved
		323	Gastric perforation	1 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0121, Subject ID=001125, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=										
001125	Treatment Cycle 7	127	Fatigue	7.03 Months	Mild	1		N	Interrupted	Resolved
		135	Myalgia	Continuing	Mild	1		Y	Interrupted	Not Resolved
	Treatment Cycle 14	341	Fatigue	1.51 Months	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0134, Subject ID=001140, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
001140	Treatment Cycle 7	148	Aspartate aminotransferase increased	3.14 Weeks	Mild	1		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0134, Subject ID=001140, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
001140	Treatment Cycle 7	169	Aspartate aminotransferase increased	3.14 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0134, Subject ID=001153, Gender=M, Race=Black Or African American, Age=82 Years, Rel Day of Study Medication Discontinuance†=170										
001153	Safety Follow-up	191	Hip fracture	2.43 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0134, Subject ID=001160, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=										
001160	Treatment Cycle 8	162	Adrenal insufficiency	1.29 Weeks	Severe	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0134, Subject ID=001185, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=91										
001185	Treatment Cycle 2	41	Cerebrovascular accident	3 Days	Moderate	2	Y	N	Interrupted	Resolved
MK-3475 10 mg/kg Q2W										

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0001, Subject ID=001089, Gender=F, Race=White, Age=41 Years, Rel Day of Study Medication Discontinuance†=365										
001089	Treatment Cycle 4	56	Cardio-respiratory arrest	1.71 Weeks	Severe	4	Y	N	Interrupted	Resolved
	Treatment Cycle 15	337	Tumour pain	4 Weeks	Severe	3		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0001, Subject ID=001530, Gender=M, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=134										
001530	Treatment Cycle 9	127	Upper respiratory tract infection	Continuing	Moderate	2		N	Interrupted	Not Resolved
	Safety Follow-up	145	Dermatitis	4 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0001, Subject ID=001554, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=43										
001554	Treatment Cycle 4	43	Fatigue	3.29 Weeks	Severe	3		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0001, Subject ID=001570, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=										
001570	Treatment Cycle 7	92	Pyrexia	1 Weeks	Severe	3	Y	N	Interrupted	Resolved
	Treatment Cycle 15	219	Diverticulitis	5 Days	Severe	3	Y	N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0003, Subject ID=001074, Gender=M, Race=Black Or African American, Age=60 Years, Rel Day of Study Medication Discontinuance†=62										
001074	Treatment Cycle 2	31	Chronic obstructive pulmonary disease	6 Days	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000949, Gender=F, Race=, Age=53 Years, Rel Day of Study Medication Discontinuance†=57										
000949	Treatment Cycle 2	15	Infusion related reaction	1 Days	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000951, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=79										
000951	Treatment Cycle 3	43	Hyponatraemia	1.18 Months	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001021, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=113										
001021	Treatment Cycle 3	29	Arthralgia	Continuing	Mild	1		Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001129, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=15										

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0011, Subject ID=001129, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=15										
001129	Treatment Cycle 2	15	Hypersensitivity	2 Days	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001721, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=293										
001721	Treatment Cycle 19	264	Tooth infection	2.29 Weeks	Mild	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001727, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=188										
001727	Treatment Cycle 3	34	Cough	2.14 Weeks	Mild	1		N	Interrupted	Resolved
		34	Decreased appetite	2.14 Weeks	Mild	1		N	Interrupted	Resolved
		34	Diarrhoea	2.14 Weeks	Mild	1		N	Interrupted	Resolved
		34	Fatigue	2.14 Weeks	Mild	1		N	Interrupted	Resolved
		34	Pyrexia	2.14 Weeks	Mild	1		N	Interrupted	Resolved
		34	Rhinorrhoea	2.14 Weeks	Mild	1		N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0013, Subject ID=001134, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=										
001134	Treatment Cycle 3	43	Nausea	3 Days	Severe	3	Y	Y	Interrupted	Resolved
		43	Vomiting	3 Days	Severe	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0013, Subject ID=001154, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=43										
001154	Treatment Cycle 1	1	Infusion related reaction	1 Days	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000906, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=91										
000906	Treatment Cycle 3	35	Dyspnoea	Continuing	Moderate	2		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000912, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
000912	Treatment Cycle 7	85	Hypersensitivity	1 Days	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000946, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0015, Subject ID=000946, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=										
000946	Treatment Cycle 29	403	Diarrhoea	1.51 Months	Severe	3		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=001534, Gender=F, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=364										
001534	Treatment Cycle 18	277	Asthenia	5 Days	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=001588, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=53										
001588	Treatment Cycle 2	22	Vasogenic cerebral oedema	4 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=001703, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=109										
001703	Treatment Cycle 3	27	Pleural effusion	6 Days	Moderate	2		N	Interrupted	Resolved
		56	Pericardial effusion	5 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=001732, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0015, Subject ID=001732, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
001732	Treatment Cycle 25	347	Chronic obstructive pulmonary disease	6 Days	Severe	4	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=001066, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=										
001066	Treatment Cycle 12	168	Microalbuminuria	Continuing	Mild	1		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=001706, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=44										
001706	Safety Follow-up	65	Anaemia	Continuing	Severe	3		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000987, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=272										
000987	Treatment Cycle 9	133	Convulsion	1 Days	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001701, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0020, Subject ID=001701, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
001701	Treatment Cycle 30	441	Viral infection	4 Days	Mild	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001710, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=40										
001710	Treatment Cycle 1	10	Hepatic pain	1.86 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001715, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=56										
001715	Treatment Cycle 1	15	Lung infection	1.14 Weeks	Moderate	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001717, Gender=F, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=34										
001717	Treatment Cycle 3	34	Vomiting	Continuing	Moderate	2		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=001006, Gender=M, Race=Asian, Age=67 Years, Rel Day of Study Medication Discontinuance†=1										
001006	Safety Follow-up	2	Back pain	1.14 Weeks	Severe	3		N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0023, Subject ID=001509, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
001509	Treatment Cycle 3	45	Peripheral ischaemia	3 Days	Moderate	2	Y	N	Interrupted	Resolved
	Treatment Cycle 32	467	Lower respiratory tract infection	3 Days	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0027, Subject ID=001515, Gender=M, Race=Black Or African American, Age=72 Years, Rel Day of Study Medication Discontinuance†=253										
001515	Treatment Cycle 12	177	Pneumonia cryptococcal	5 Days	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0028, Subject ID=000972, Gender=F, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=29										
000972	Safety Follow-up	43	Hypercalcaemia	1 Days	Severe	4	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0028, Subject ID=001507, Gender=M, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=										
001507	Treatment Cycle 14	183	Blood creatine phosphokinase increased	4.14 Weeks	Severe	3		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0031, Subject ID=001041, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
001041	Treatment Cycle 9	129	General physical health deterioration	5 Days	Severe	3	Y	N	Interrupted	Resolved
	Treatment Cycle 20	294	Rectal haemorrhage	4 Days	Severe	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0040, Subject ID=001019, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=27										
001019	Treatment Cycle 1	11	Dyspnoea	2.29 Weeks	Severe	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0041, Subject ID=001591, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=										
001591	Treatment Cycle 3	29	Dyspnoea	1 Days	Moderate	2		Y	Interrupted	Resolved
		29	Restless legs syndrome	1 Days	Mild	1		Y	Interrupted	Resolved
		29	Throat tightness	1 Days	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0070, Subject ID=000999, Gender=M, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=										

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0070, Subject ID=000999, Gender=M, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=										
000999	Treatment Cycle 22	308	Alanine aminotransferase increased	1.29 Weeks	Mild	1		Y	Interrupted	Resolved
		308	Aspartate aminotransferase increased	2.29 Weeks	Mild	1		Y	Interrupted	Resolved
		317	Alanine aminotransferase increased	1.86 Weeks	Moderate	2		Y	Interrupted	Resolved
		330	Alanine aminotransferase increased	1.14 Weeks	Severe	3		Y	Interrupted	Resolved
		330	Aspartate aminotransferase increased	1 Days	Severe	3		Y	Interrupted	Resolved
		331	Aspartate aminotransferase increased	4 Days	Moderate	2		Y	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0073, Subject ID=001111, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
001111	Treatment Cycle 1	1	Pneumonia	1.43 Weeks	Moderate	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0081, Subject ID=001139, Gender=M, Race=Asian, Age=57 Years, Rel Day of Study Medication Discontinuance†=126										
001139	Treatment Cycle 4	57	Pneumonitis	4.14 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0082, Subject ID=001054, Gender=M, Race=Asian, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
001054	Treatment Cycle 22	310	Alanine aminotransferase increased	3 Weeks	Severe	3		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0082, Subject ID=001565, Gender=M, Race=Asian, Age=71 Years, Rel Day of Study Medication Discontinuance†=1										
001565	Safety Follow-up	5 26	Pneumonia Pneumonia	3 Weeks 5 Days	Severe Moderate	3 2	Y	N N	Interrupted Interrupted	Resolved Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0090, Subject ID=001568, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=166										
001568	Treatment Cycle 8	103	Asthenia	1.18 Months	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 9	138	Asthenia	Continuing	Mild	1		Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0120, Subject ID=001580, Gender=F, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=267										
001580	Treatment Cycle 2	15	Infusion related reaction	1 Days	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0134, Subject ID=001182, Gender=M, Race=Black Or African American, Age=59 Years, Rel Day of Study Medication Discontinuance†=292										

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
All Subjects with NSCLC by Dose
(All Subjects as Treated)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0134, Subject ID=001182, Gender=M, Race=Black Or African American, Age=59 Years, Rel Day of Study Medication Discontinuance†=292										
001182	Treatment Cycle 13	180	Erythema multiforme	2.43 Weeks	Severe	3	Y	N	Interrupted	Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.
Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.
Related: Investigator-assessed relationship of the adverse event to study medication.
Grades are based on NCI CTCAE version 4.0.
MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.
(Database Cutoff Date: [redacted]

Confidential

付録 2.7.4- 52　　治験薬の投与中止に至った有害事象

（いずれかの投与群で発現割合 0%超）

010 試験（MK-3475 併合、安全性解析対象集団）（PD-L1 発現陽性）

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Subjects in population	309		682	
with one or more adverse events	42	(13.6)	54	(7.9)
with no adverse events	267	(86.4)	628	(92.1)
Blood and lymphatic system disorders	**1**	**(0.3)**	**0**	**(0.0)**
Thrombocytopenia	1	(0.3)	0	(0.0)
Cardiac disorders	**2**	**(0.6)**	**4**	**(0.6)**
Acute coronary syndrome	0	(0.0)	1	(0.1)
Acute myocardial infarction	0	(0.0)	1	(0.1)
Arteriosclerosis coronary artery	1	(0.3)	0	(0.0)
Atrial fibrillation	0	(0.0)	1	(0.1)
Atrioventricular block complete	0	(0.0)	1	(0.1)
Ventricular fibrillation	1	(0.3)	0	(0.0)
Endocrine disorders	**0**	**(0.0)**	**1**	**(0.1)**
Hypothyroidism	0	(0.0)	1	(0.1)
Eye disorders	**1**	**(0.3)**	**0**	**(0.0)**
Lacrimation increased	1	(0.3)	0	(0.0)
Gastrointestinal disorders	**4**	**(1.3)**	**1**	**(0.1)**
Abdominal pain	1	(0.3)	0	(0.0)
Colitis ischaemic	1	(0.3)	0	(0.0)
Gastritis	0	(0.0)	1	(0.1)
Gastrointestinal inflammation	1	(0.3)	0	(0.0)

Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups)
MK-3475 Treatment Groups Pooled
APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Gastrointestinal disorders	**4**	**(1.3)**	**1**	**(0.1)**
Stomatitis	1	(0.3)	0	(0.0)
General disorders and administration site conditions	**6**	**(1.9)**	**4**	**(0.6)**
Adverse drug reaction	1	(0.3)	0	(0.0)
Asthenia	3	(1.0)	0	(0.0)
Death	0	(0.0)	1	(0.1)
Fatigue	1	(0.3)	1	(0.1)
General physical health deterioration	0	(0.0)	1	(0.1)
Multi-organ failure	0	(0.0)	1	(0.1)
Oedema	1	(0.3)	0	(0.0)
Infections and infestations	**5**	**(1.6)**	**2**	**(0.3)**
Herpes zoster	1	(0.3)	0	(0.0)
Lung infection	1	(0.3)	0	(0.0)
Pneumonia	1	(0.3)	2	(0.3)
Respiratory tract infection	1	(0.3)	0	(0.0)
Septic shock	1	(0.3)	0	(0.0)
Injury, poisoning and procedural complications	**1**	**(0.3)**	**2**	**(0.3)**
Pneumonitis chemical	0	(0.0)	1	(0.1)
Radiation pneumonitis	0	(0.0)	1	(0.1)
Toxicity to various agents	1	(0.3)	0	(0.0)
Investigations	**0**	**(0.0)**	**1**	**(0.1)**
Aspartate aminotransferase increased	0	(0.0)	1	(0.1)

Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups)
MK-3475 Treatment Groups Pooled
APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Metabolism and nutrition disorders	**0**	**(0.0)**	**1**	**(0.1)**
Hyponatraemia	0	(0.0)	1	(0.1)
Musculoskeletal and connective tissue disorders	**3**	**(1.0)**	**3**	**(0.4)**
Arthralgia	0	(0.0)	1	(0.1)
Arthritis	0	(0.0)	1	(0.1)
Muscle necrosis	0	(0.0)	1	(0.1)
Musculoskeletal chest pain	1	(0.3)	0	(0.0)
Myalgia	1	(0.3)	0	(0.0)
Neck pain	1	(0.3)	0	(0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**1**	**(0.3)**	**3**	**(0.4)**
Gastric cancer	0	(0.0)	1	(0.1)
Lung neoplasm malignant	0	(0.0)	1	(0.1)
Malignant neoplasm progression	0	(0.0)	1	(0.1)
Metastases to central nervous system	1	(0.3)	0	(0.0)
Nervous system disorders	**6**	**(1.9)**	**6**	**(0.9)**
Ataxia	0	(0.0)	1	(0.1)
Cerebrovascular accident	1	(0.3)	1	(0.1)
Cognitive disorder	1	(0.3)	0	(0.0)
Ischaemic stroke	0	(0.0)	1	(0.1)
Myelitis transverse	0	(0.0)	1	(0.1)
Neuropathy peripheral	1	(0.3)	0	(0.0)
Peripheral sensory neuropathy	1	(0.3)	0	(0.0)

Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups)
MK-3475 Treatment Groups Pooled
APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Nervous system disorders	**6**	**(1.9)**	**6**	**(0.9)**
Polyneuropathy	2	(0.6)	0	(0.0)
Spinal cord compression	0	(0.0)	1	(0.1)
Toxic leukoencephalopathy	0	(0.0)	1	(0.1)
Psychiatric disorders	**0**	**(0.0)**	**1**	**(0.1)**
Disorientation	0	(0.0)	1	(0.1)
Renal and urinary disorders	**0**	**(0.0)**	**1**	**(0.1)**
Tubulointerstitial nephritis	0	(0.0)	1	(0.1)
Respiratory, thoracic and mediastinal disorders	**8**	**(2.6)**	**20**	**(2.9)**
Bronchostenosis	0	(0.0)	1	(0.1)
Dyspnoea	0	(0.0)	2	(0.3)
Hypoxia	0	(0.0)	1	(0.1)
Interstitial lung disease	2	(0.6)	0	(0.0)
Pleural effusion	1	(0.3)	1	(0.1)
Pneumonia aspiration	0	(0.0)	1	(0.1)
Pneumonitis	3	(1.0)	12	(1.8)
Pulmonary embolism	1	(0.3)	0	(0.0)
Pulmonary haemorrhage	0	(0.0)	1	(0.1)
Respiratory distress	0	(0.0)	1	(0.1)
Respiratory failure	1	(0.3)	1	(0.1)
Skin and subcutaneous tissue disorders	**3**	**(1.0)**	**1**	**(0.1)**
Alopecia	1	(0.3)	0	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups)
MK-3475 Treatment Groups Pooled
APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Skin and subcutaneous tissue disorders	**3**	**(1.0)**	**1**	**(0.1)**
Lichen planus	0	(0.0)	1	(0.1)
Onycholysis	1	(0.3)	0	(0.0)
Rash	1	(0.3)	0	(0.0)
Vascular disorders	**2**	**(0.6)**	**3**	**(0.4)**
Deep vein thrombosis	1	(0.3)	0	(0.0)
Embolism	0	(0.0)	1	(0.1)
Femoral artery occlusion	0	(0.0)	1	(0.1)
Peripheral ischaemia	0	(0.0)	1	(0.1)
Superior vena cava syndrome	1	(0.3)	0	(0.0)

Every subject is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
MedDRA preferred terms 'Neoplasm Progression' ,'Malignant Neoplasm Progression'　and 'Disease Progression' not related to the drug are excluded.
After the end of treatment, each subject will be followed for a minimum of 30 days for adverse event monitoring. SAE is monitored until 90 days after last dose.
(Database Cutoff Date: 30SEP2015)

C Confidential

付録 2.7.4- 53　　治験薬の投与中止に至った副作用

（いずれかの投与群で発現割合 0%超）

010 試験（安全性解析対象集団）（PD-L1 発現陽性）

	Docetaxel 75 mg/m2 Q3W		MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)
Subjects in population	309		339		343	
with one or more adverse events	31	(10.0)	15	(4.4)	17	(5.0)
with no adverse events	278	(90.0)	324	(95.6)	326	(95.0)
Blood and lymphatic system disorders	**1**	**(0.3)**	**0**	**(0.0)**	**0**	**(0.0)**
Thrombocytopenia	1	(0.3)	0	(0.0)	0	(0.0)
Cardiac disorders	**1**	**(0.3)**	**0**	**(0.0)**	**1**	**(0.3)**
Arteriosclerosis coronary artery	1	(0.3)	0	(0.0)	0	(0.0)
Atrioventricular block complete	0	(0.0)	0	(0.0)	1	(0.3)
Endocrine disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.3)**
Hypothyroidism	0	(0.0)	0	(0.0)	1	(0.3)
Eye disorders	**1**	**(0.3)**	**0**	**(0.0)**	**0**	**(0.0)**
Lacrimation increased	1	(0.3)	0	(0.0)	0	(0.0)
Gastrointestinal disorders	**3**	**(1.0)**	**0**	**(0.0)**	**1**	**(0.3)**
Colitis ischaemic	1	(0.3)	0	(0.0)	0	(0.0)
Gastritis	0	(0.0)	0	(0.0)	1	(0.3)
Gastrointestinal inflammation	1	(0.3)	0	(0.0)	0	(0.0)
Stomatitis	1	(0.3)	0	(0.0)	0	(0.0)
General disorders and administration site conditions	**6**	**(1.9)**	**1**	**(0.3)**	**0**	**(0.0)**
Adverse drug reaction	1	(0.3)	0	(0.0)	0	(0.0)
Asthenia	3	(1.0)	0	(0.0)	0	(0.0)

Confidential

Subjects With Drug-Related Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups)
APaT Population (TPS ≥ 1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)
General disorders and administration site conditions	**6**	**(1.9)**	**1**	**(0.3)**	**0**	**(0.0)**
Fatigue	1	(0.3)	1	(0.3)	0	(0.0)
Oedema	1	(0.3)	0	(0.0)	0	(0.0)
Infections and infestations	**4**	**(1.3)**	**1**	**(0.3)**	**0**	**(0.0)**
Herpes zoster	1	(0.3)	0	(0.0)	0	(0.0)
Pneumonia	1	(0.3)	1	(0.3)	0	(0.0)
Respiratory tract infection	1	(0.3)	0	(0.0)	0	(0.0)
Septic shock	1	(0.3)	0	(0.0)	0	(0.0)
Injury, poisoning and procedural complications	**1**	**(0.3)**	**0**	**(0.0)**	**1**	**(0.3)**
Pneumonitis chemical	0	(0.0)	0	(0.0)	1	(0.3)
Toxicity to various agents	1	(0.3)	0	(0.0)	0	(0.0)
Investigations	**0**	**(0.0)**	**1**	**(0.3)**	**0**	**(0.0)**
Aspartate aminotransferase increased	0	(0.0)	1	(0.3)	0	(0.0)
Metabolism and nutrition disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.3)**
Hyponatraemia	0	(0.0)	0	(0.0)	1	(0.3)
Musculoskeletal and connective tissue disorders	**1**	**(0.3)**	**2**	**(0.6)**	**0**	**(0.0)**
Arthritis	0	(0.0)	1	(0.3)	0	(0.0)
Muscle necrosis	0	(0.0)	1	(0.3)	0	(0.0)
Myalgia	1	(0.3)	0	(0.0)	0	(0.0)

C Confidential

Subjects With Drug-Related Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups)
APaT Population (TPS ≥ 1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.3)**
Malignant neoplasm progression	0	(0.0)	0	(0.0)	1	(0.3)
Nervous system disorders	**5**	**(1.6)**	**3**	**(0.9)**	**1**	**(0.3)**
Ataxia	0	(0.0)	1	(0.3)	0	(0.0)
Cerebrovascular accident	0	(0.0)	1	(0.3)	0	(0.0)
Cognitive disorder	1	(0.3)	0	(0.0)	0	(0.0)
Myelitis transverse	0	(0.0)	0	(0.0)	1	(0.3)
Neuropathy peripheral	1	(0.3)	0	(0.0)	0	(0.0)
Peripheral sensory neuropathy	1	(0.3)	0	(0.0)	0	(0.0)
Polyneuropathy	2	(0.6)	0	(0.0)	0	(0.0)
Toxic leukoencephalopathy	0	(0.0)	1	(0.3)	0	(0.0)
Psychiatric disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.3)**
Disorientation	0	(0.0)	0	(0.0)	1	(0.3)
Renal and urinary disorders	**0**	**(0.0)**	**1**	**(0.3)**	**0**	**(0.0)**
Tubulointerstitial nephritis	0	(0.0)	1	(0.3)	0	(0.0)
Respiratory, thoracic and mediastinal disorders	**6**	**(1.9)**	**6**	**(1.8)**	**7**	**(2.0)**
Dyspnoea	0	(0.0)	0	(0.0)	1	(0.3)
Hypoxia	0	(0.0)	0	(0.0)	1	(0.3)
Interstitial lung disease	2	(0.6)	0	(0.0)	0	(0.0)
Pleural effusion	1	(0.3)	0	(0.0)	0	(0.0)
Pneumonitis	3	(1.0)	6	(1.8)	6	(1.7)

C Confidential

Subjects With Drug-Related Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups)
APaT Population (TPS ≥ 1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)
Skin and subcutaneous tissue disorders	**3**	**(1.0)**	**0**	**(0.0)**	**1**	**(0.3)**
Alopecia	1	(0.3)	0	(0.0)	0	(0.0)
Lichen planus	0	(0.0)	0	(0.0)	1	(0.3)
Onycholysis	1	(0.3)	0	(0.0)	0	(0.0)
Rash	1	(0.3)	0	(0.0)	0	(0.0)
Vascular disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.3)**
Peripheral ischaemia	0	(0.0)	0	(0.0)	1	(0.3)

Every subject is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
After the end of treatment, each subject will be followed for a minimum of 30 days for adverse event monitoring. SAE is monitored until 90 days after last dose.
(Database Cutoff Date: 30SEP2015)

C Confidential

付録 2.7.4- 54　　治験薬の投与中止に至った有害事象の一覧

010 試験（安全性解析対象集団）（PD-L1 発現陽性）

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W								
Study Number=3475-010, Site Number=0002, AN=310915, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=127								
310915	Safety Follow-up	146	Pneumonitis	3	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0051, AN=306663, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=127								
306663	Safety Follow-up	146	Pleural effusion	3	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0051, AN=307442, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=63								
307442	Safety Follow-up	69	Cognitive disorder	2	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0051, AN=313974, Gender=M, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=20								
313974	Safety Follow-up	33	Deep vein thrombosis	3	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0081, AN=301651, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=189								
301651	Treatment Cycle 9	189	Superior vena cava syndrome	3	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0082, AN=307310, Gender=M, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=83								
307310	Safety Follow-up	96	Arteriosclerosis coronary artery	3	Y	Y	Discontinued	Sequelae
Study Number=3475-010, Site Number=0086, AN=304216, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=1								
304216	Safety Follow-up	2	Gastrointestinal inflammation	3	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0088, AN=311180, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=132								
311180	Treatment Cycle 6	124	Toxicity to various agents	1	N	Y	Discontinued	Not Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W								
Study Number=3475-010, Site Number=0089, AN=302678, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=86								
302678	Safety Follow-up	100	Oedema	3	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0167, AN=300143, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=1								
300143	Safety Follow-up	6	Colitis ischaemic	3	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0201, AN=303362, Gender=F, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=42								
303362	Safety Follow-up	66	Metastases to central nervous system	1	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0201, AN=307904, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=25								
307904	Safety Follow-up	47	Adverse drug reaction	3	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0201, AN=310001, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=63								
310001	Treatment Cycle 2	42	Thrombocytopenia	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0202, AN=311034, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=1								
311034	Safety Follow-up	20	Respiratory failure	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0204, AN=313727, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=249								
313727	Treatment Cycle 10	235	Asthenia	3	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0208, AN=306146, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=169								
306146	Treatment Cycle 1	3	Asthenia	2	N	Y	Discontinued	Not Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W								
Study Number=3475-010, Site Number=0282, AN=303550, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=43								
303550	Treatment Cycle 3	43	Neck pain	3	N	N	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0284, AN=302057, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=127								
302057	Safety Follow-up	148	Ventricular fibrillation	4	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0326, AN=313199, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=22								
313199	Safety Follow-up	26	Cerebrovascular accident	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0401, AN=300174, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=1								
300174	Safety Follow-up	6	Respiratory tract infection	5	Y	Y	Discontinued	Fatal
Study Number=3475-010, Site Number=0444, AN=312765, Gender=M, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=22								
312765	Safety Follow-up	32	Lung infection	2	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0601, AN=308747, Gender=F, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=197								
308747	Treatment Cycle 4	70	Neuropathy peripheral	2	N	Y	Discontinued	Resolving
		71	Asthenia	2	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0604, AN=305125, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=42								
305125	Safety Follow-up	52	Pulmonary embolism	4	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0760, AN=308746, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=85								
308746	Safety Follow-up	106	Polyneuropathy	3	N	Y	Discontinued	Resolving

C Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W								
Study Number=3475-010, Site Number=0760, AN=313573, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=85								
313573	Safety Follow-up	88	Polyneuropathy	3	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=1080, AN=300835, Gender=M, Race=Asian, Age=71 Years, Rel Day of Study Medication Discontinuance†=22								
300835	Safety Follow-up	25	Musculoskeletal chest pain	2	N	N	Discontinued	Not Resolved
Study Number=3475-010, Site Number=1241, AN=304425, Gender=M, Race=Asian, Age=58 Years, Rel Day of Study Medication Discontinuance†=106								
304425	Treatment Cycle 1	3	Abdominal pain	2	N	N	Discontinued	Resolving
Study Number=3475-010, Site Number=1241, AN=305727, Gender=M, Race=Asian, Age=64 Years, Rel Day of Study Medication Discontinuance†=64								
305727	Safety Follow-up	85	Pneumonitis	2	Y	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=1241, AN=307953, Gender=M, Race=Asian, Age=72 Years, Rel Day of Study Medication Discontinuance†=64								
307953	Safety Follow-up	74	Pneumonia	4	Y	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=1241, AN=309667, Gender=F, Race=Asian, Age=47 Years, Rel Day of Study Medication Discontinuance†=162								
309667	Treatment Cycle 4	73	Lacrimation increased	2	N	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=1243, AN=301184, Gender=F, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=150								
301184	Safety Follow-up	157	Herpes zoster	2	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=1243, AN=312969, Gender=M, Race=Asian, Age=78 Years, Rel Day of Study Medication Discontinuance†=206								
312969	Safety Follow-up	209	Peripheral sensory neuropathy	2	N	Y	Discontinued	Not Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W								
Study Number=3475-010, Site Number=1244, AN=305282, Gender=M, Race=Asian, Age=68 Years, Rel Day of Study Medication Discontinuance†=69								
305282	Safety Follow-up	72	Stomatitis	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=1244, AN=307448, Gender=F, Race=Asian, Age=59 Years, Rel Day of Study Medication Discontinuance†=106								
307448	Safety Follow-up	109	Myalgia	2	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=1244, AN=308180, Gender=M, Race=Asian, Age=51 Years, Rel Day of Study Medication Discontinuance†=111								
308180	Safety Follow-up	123	Onycholysis	2	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=1366, AN=309433, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=176								
309433	Treatment Cycle 2	49	Fatigue	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=1403, AN=309360, Gender=M, Race=Asian, Age=68 Years, Rel Day of Study Medication Discontinuance†=30								
309360	Safety Follow-up	41	Interstitial lung disease	5	Y	Y	Discontinued	Fatal
Study Number=3475-010, Site Number=1404, AN=309254, Gender=F, Race=Asian, Age=41 Years, Rel Day of Study Medication Discontinuance†=1								
309254	Safety Follow-up	13	Alopecia	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=1406, AN=308153, Gender=M, Race=Asian, Age=40 Years, Rel Day of Study Medication Discontinuance†=109								
308153	Safety Follow-up	127	Interstitial lung disease	1	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=1413, AN=300717, Gender=M, Race=Asian, Age=76 Years, Rel Day of Study Medication Discontinuance†=24								
300717	Treatment Cycle 2	24	Rash	2	N	Y	Discontinued	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W								
Study Number=3475-010, Site Number=1419, AN=301064, Gender=M, Race=Asian, Age=68 Years, Rel Day of Study Medication Discontinuance†=81								
301064	Safety Follow-up	88	Septic shock	4	Y	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=1429, AN=308116, Gender=F, Race=Asian, Age=76 Years, Rel Day of Study Medication Discontinuance†=1								
308116	Safety Follow-up	21	Pneumonitis	2	N	Y	Discontinued	Resolved
MK-3475 2 mg/kg Q3W								
Study Number=3475-010, Site Number=0006, AN=313655, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=208								
313655	Safety Follow-up	229	Ataxia	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0014, AN=301535, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=232								
301535	Safety Follow-up	253	Acute myocardial infarction	3	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0026, AN=304255, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=51								
304255	Safety Follow-up	58	Pneumonitis	4	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0028, AN=308356, Gender=M, Race=American Indian Or Alaska Native, Age=62 Years, Rel Day of Study Medication Discontinuance†=1								
308356	Safety Follow-up	10	Pneumonia	5	Y	Y	Discontinued	Fatal
Study Number=3475-010, Site Number=0046, AN=314043, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=417								
314043	Safety Follow-up	431	Arthritis	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0050, AN=313837, Gender=F, Race=Black Or African American, Age=73 Years, Rel Day of Study Medication Discontinuance†=1								

Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W								
Study Number=3475-010, Site Number=0050, AN=313837, Gender=F, Race=Black Or African American, Age=73 Years, Rel Day of Study Medication Discontinuance†=1								
313837	Extended Safety Follow-up	32	Multi-organ failure	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0084, AN=302927, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=218								
302927	Safety Follow-up	229	Fatigue	3	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0129, AN=304272, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=43								
304272	Safety Follow-up	56	Radiation pneumonitis	3	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0138, AN=310772, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=173								
310772	Safety Follow-up	181	Toxic leukoencephalopathy	3	Y	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=0162, AN=302404, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=22								
302404	Safety Follow-up	32	Ischaemic stroke	4	Y	N	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0180, AN=310957, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=84								
310957	Safety Follow-up	93	Cerebrovascular accident	3	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0180, AN=311647, Gender=F, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=1								
311647	Safety Follow-up	4	Dyspnoea	4	Y	N	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0181, AN=303188, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=64								
303188	Safety Follow-up	82	Aspartate aminotransferase increased	3	Y	Y	Discontinued	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W								
Study Number=3475-010, Site Number=0200, AN=306369, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=21								
306369	Safety Follow-up	39	Pneumonitis	5	Y	Y	Discontinued	Fatal
Study Number=3475-010, Site Number=0200, AN=311151, Gender=F, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=1								
311151	Safety Follow-up	6	Respiratory failure	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0209, AN=313318, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=279								
313318	Safety Follow-up	283	Pneumonitis	4	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0211, AN=310073, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=21								
310073	Safety Follow-up	23	Muscle necrosis	2	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0361, AN=306719, Gender=F, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=92								
306719	Safety Follow-up	97	Pneumonitis	2	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0562, AN=301548, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=1								
301548	Safety Follow-up	20	Tubulointerstitial nephritis	3	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0563, AN=313241, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=1								
313241	Safety Follow-up	23	Femoral artery occlusion	4	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0602, AN=302229, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=176								
302229	Safety Follow-up	190	Pneumonitis	2	N	Y	Discontinued	Not Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W								
Study Number=3475-010, Site Number=0764, AN=307665, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=43								
307665	Safety Follow-up	70	Atrial fibrillation	3	Y	N	Discontinued	Resolved
Study Number=3475-010, Site Number=0805, AN=310425, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=296								
310425	Safety Follow-up	316	Acute coronary syndrome	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0964, AN=311245, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=104								
311245	Safety Follow-up	118	Pleural effusion	3	Y	N	Discontinued	Resolving
Study Number=3475-010, Site Number=1080, AN=305559, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=1								
305559	Safety Follow-up	16	Pneumonitis	3	Y	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=1241, AN=301658, Gender=M, Race=Asian, Age=77 Years, Rel Day of Study Medication Discontinuance†=50								
301658	Safety Follow-up	60	Pneumonia aspiration	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=1245, AN=308563, Gender=M, Race=Asian, Age=77 Years, Rel Day of Study Medication Discontinuance†=1								
308563	Safety Follow-up	22	Lung neoplasm malignant	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=1423, AN=301923, Gender=M, Race=Asian, Age=68 Years, Rel Day of Study Medication Discontinuance†=85								
301923	Extended Safety Follow-up	141	Gastric cancer	3	Y	N	Discontinued	Not Resolved
MK-3475 10 mg/kg Q3W								

Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W								
Study Number=3475-010, Site Number=0005, AN=303231, Gender=F, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=232								
303231	Treatment Cycle 6	176	Dyspnoea	2	N	Y	Discontinued	Not Resolved
	Treatment Cycle 8	232	Hypoxia	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0014, AN=302077, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=141								
302077	Treatment Cycle 3	86	Hypothyroidism	2	N	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0037, AN=309567, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=1								
309567	Safety Follow-up	22	Malignant neoplasm progression	3	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0045, AN=300012, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=45								
300012	Safety Follow-up	64	Pneumonitis	4	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0055, AN=300953, Gender=M, Race=, Age=37 Years, Rel Day of Study Medication Discontinuance†=91								
300953	Safety Follow-up	98	Myelitis transverse	3	Y	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=0081, AN=301391, Gender=M, Race=Multiple, Age=62 Years, Rel Day of Study Medication Discontinuance†=43								
301391	Safety Follow-up	52	Spinal cord compression	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0081, AN=305369, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=130								
305369	Safety Follow-up	140	Gastritis	3	Y	Y	Discontinued	Sequelae
Study Number=3475-010, Site Number=0081, AN=307798, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=43								

C Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W								
Study Number=3475-010, Site Number=0081, AN=307798, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=43								
307798	Extended Safety Follow-up	74	Respiratory distress	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0094, AN=300608, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=23								
300608	Safety Follow-up	43	Hyponatraemia	4	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0122, AN=310300, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=248								
310300	Extended Safety Follow-up	281	General physical health deterioration	3	Y	N	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0180, AN=311829, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=526								
311829	Treatment Cycle 17	516	Arthralgia	1	N	N	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0204, AN=307524, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=204								
307524	Safety Follow-up	209	Pneumonitis chemical	3	Y	Y	Discontinued	Sequelae
Study Number=3475-010, Site Number=0208, AN=302999, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=22								
302999	Safety Follow-up	38	Disorientation	3	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0360, AN=313958, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=1								
313958	Safety Follow-up	8	Pneumonitis	3	Y	Y	Discontinued	Resolving
Study Number=3475-010, Site Number=0361, AN=305971, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=169								

C Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W								
Study Number=3475-010, Site Number=0361, AN=305971, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=169								
305971	Treatment Cycle 5	105	Lichen planus	3	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0560, AN=309087, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=359								
309087	Safety Follow-up	362	Pneumonitis	2	N	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=0561, AN=300941, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=45								
300941	Safety Follow-up	64	Pneumonitis	3	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=0563, AN=312499, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=281								
312499	Safety Follow-up	287	Pneumonia	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0602, AN=304067, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=20								
304067	Safety Follow-up	32	Death	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=0920, AN=308160, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=120								
308160	Safety Follow-up	133	Pneumonitis	5	Y	Y	Discontinued	Fatal
Study Number=3475-010, Site Number=1003, AN=310688, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=47								
310688	Safety Follow-up	56	Pneumonitis	3	Y	Y	Discontinued	Resolved
Study Number=3475-010, Site Number=1242, AN=314137, Gender=F, Race=Asian, Age=63 Years, Rel Day of Study Medication Discontinuance†=64								
314137	Safety Follow-up	81	Embolism	5	Y	N	Discontinued	Fatal

C Confidential

Listing of Subjects With Adverse Events Resulting in Discontinuation
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W								
Study Number=3475-010, Site Number=1243, AN=313804, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=220								
313804	Safety Follow-up	228	Pulmonary haemorrhage	5	Y	N	Discontinued	Fatal
Study Number=3475-010, Site Number=1401, AN=311426, Gender=F, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=1								
311426	Safety Follow-up	4	Bronchostenosis	4	N	N	Discontinued	Resolved
Study Number=3475-010, Site Number=1410, AN=308147, Gender=M, Race=Asian, Age=78 Years, Rel Day of Study Medication Discontinuance†=22								
308147	Safety Follow-up	39	Atrioventricular block complete	4	Y	Y	Discontinued	Not Resolved
Study Number=3475-010, Site Number=1434, AN=314187, Gender=M, Race=Asian, Age=60 Years, Rel Day of Study Medication Discontinuance†=70								
314187	Safety Follow-up	75	Peripheral ischaemia	3	Y	Y	Discontinued	Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

MedDRA preferred terms 'Neoplasm Progression' ,'Malignant Neoplasm Progression' and 'Disease Progression' not related to the drug are excluded.

After the end of treatment, each subject will be followed for a minimum of 30 days for adverse event monitoring. SAE is monitored until 90 days after last dose.

(Database Cutoff Date: 30SEP2015)

C Confidential

付録 2.7.4- 55　　治験薬の休薬に至った有害事象
（いずれかの投与群で発現割合 0%超）
010 試験（MK-3475 併合、安全性解析対象集団）（PD-L1 発現陽性）

Subjects With Adverse Events Resulting in Treatment Interruption
(Incidence > 0% in One or More Treatment Groups)
MK-3475 Treatment Groups Pooled
APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Subjects in population	309		682	
with one or more adverse events	73	(23.6)	156	(22.9)
with no adverse events	236	(76.4)	526	(77.1)
Blood and lymphatic system disorders	**6**	**(1.9)**	**7**	**(1.0)**
Anaemia	2	(0.6)	5	(0.7)
Febrile neutropenia	1	(0.3)	0	(0.0)
Leukopenia	1	(0.3)	1	(0.1)
Neutropenia	3	(1.0)	0	(0.0)
Normochromic normocytic anaemia	0	(0.0)	1	(0.1)
Thrombocytopenia	1	(0.3)	0	(0.0)
Cardiac disorders	**0**	**(0.0)**	**8**	**(1.2)**
Atrial fibrillation	0	(0.0)	1	(0.1)
Bradycardia	0	(0.0)	1	(0.1)
Cardiac failure	0	(0.0)	1	(0.1)
Coronary artery disease	0	(0.0)	1	(0.1)
Palpitations	0	(0.0)	1	(0.1)
Pericardial effusion	0	(0.0)	3	(0.4)
Congenital, familial and genetic disorders	**0**	**(0.0)**	**1**	**(0.1)**
Pyloric stenosis	0	(0.0)	1	(0.1)
Ear and labyrinth disorders	**0**	**(0.0)**	**1**	**(0.1)**
Vertigo	0	(0.0)	1	(0.1)
Endocrine disorders	**0**	**(0.0)**	**9**	**(1.3)**
Adrenal insufficiency	0	(0.0)	3	(0.4)
Hyperthyroidism	0	(0.0)	3	(0.4)
Hypopituitarism	0	(0.0)	1	(0.1)
Hypothalamo-pituitary disorder	0	(0.0)	1	(0.1)
Hypothyroidism	0	(0.0)	3	(0.4)
Eye disorders	**0**	**(0.0)**	**3**	**(0.4)**
Cataract	0	(0.0)	1	(0.1)
Vision blurred	0	(0.0)	1	(0.1)
Visual impairment	0	(0.0)	1	(0.1)
Gastrointestinal disorders	**8**	**(2.6)**	**18**	**(2.6)**
Abdominal pain	0	(0.0)	2	(0.3)
Colitis	0	(0.0)	4	(0.6)
Constipation	1	(0.3)	2	(0.3)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) MK-3475 Treatment Groups Pooled APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Gastrointestinal disorders	**8**	**(2.6)**	**18**	**(2.6)**
Diarrhoea	3	(1.0)	7	(1.0)
Flatulence	1	(0.3)	0	(0.0)
Gastric haemorrhage	0	(0.0)	1	(0.1)
Gastritis erosive	0	(0.0)	1	(0.1)
Gastrointestinal disorder	0	(0.0)	1	(0.1)
Large intestinal obstruction	0	(0.0)	2	(0.3)
Melaena	1	(0.3)	0	(0.0)
Nausea	1	(0.3)	1	(0.1)
Pancreatitis	0	(0.0)	1	(0.1)
Paraesthesia oral	1	(0.3)	0	(0.0)
Vomiting	0	(0.0)	3	(0.4)
General disorders and administration site conditions	**18**	**(5.8)**	**20**	**(2.9)**
Asthenia	3	(1.0)	2	(0.3)
Chest discomfort	1	(0.3)	0	(0.0)
Chest pain	0	(0.0)	2	(0.3)
Fatigue	6	(1.9)	9	(1.3)
Influenza like illness	0	(0.0)	3	(0.4)
Infusion site discomfort	1	(0.3)	0	(0.0)
Malaise	0	(0.0)	2	(0.3)
Oedema	2	(0.6)	0	(0.0)
Oedema peripheral	1	(0.3)	0	(0.0)
Pain	0	(0.0)	1	(0.1)
Pyrexia	4	(1.3)	2	(0.3)
Hepatobiliary disorders	**0**	**(0.0)**	**5**	**(0.7)**
Autoimmune hepatitis	0	(0.0)	2	(0.3)
Bile duct obstruction	0	(0.0)	1	(0.1)
Hepatic function abnormal	0	(0.0)	1	(0.1)
Hepatocellular injury	0	(0.0)	1	(0.1)
Immune system disorders	**5**	**(1.6)**	**2**	**(0.3)**
Anaphylactic reaction	0	(0.0)	1	(0.1)
Drug hypersensitivity	4	(1.3)	1	(0.1)
Hypersensitivity	1	(0.3)	0	(0.0)
Infections and infestations	**23**	**(7.4)**	**36**	**(5.3)**
Aspergillus infection	0	(0.0)	1	(0.1)
Atypical pneumonia	0	(0.0)	1	(0.1)
Bronchitis	3	(1.0)	0	(0.0)
Gastroenteritis	1	(0.3)	1	(0.1)

Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) MK-3475 Treatment Groups Pooled APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Infections and infestations	**23**	**(7.4)**	**36**	**(5.3)**
Herpes simplex	0	(0.0)	1	(0.1)
Herpes zoster	0	(0.0)	2	(0.3)
Infected dermal cyst	0	(0.0)	1	(0.1)
Infection masked	1	(0.3)	0	(0.0)
Infectious colitis	0	(0.0)	1	(0.1)
Infectious pleural effusion	0	(0.0)	1	(0.1)
Influenza	0	(0.0)	2	(0.3)
Laryngitis	1	(0.3)	0	(0.0)
Lower respiratory tract infection	2	(0.6)	1	(0.1)
Lung infection	1	(0.3)	2	(0.3)
Nail infection	1	(0.3)	0	(0.0)
Nasopharyngitis	0	(0.0)	1	(0.1)
Pleural infection	1	(0.3)	0	(0.0)
Pneumonia	7	(2.3)	7	(1.0)
Pneumonia pneumococcal	0	(0.0)	1	(0.1)
Rash pustular	0	(0.0)	1	(0.1)
Respiratory tract infection	2	(0.6)	4	(0.6)
Sepsis	1	(0.3)	0	(0.0)
Sinusitis	0	(0.0)	1	(0.1)
Spinal cord infection	0	(0.0)	1	(0.1)
Staphylococcal infection	1	(0.3)	1	(0.1)
Tooth abscess	0	(0.0)	1	(0.1)
Tooth infection	0	(0.0)	1	(0.1)
Upper respiratory tract infection	4	(1.3)	4	(0.6)
Urinary tract infection	1	(0.3)	0	(0.0)
Urosepsis	0	(0.0)	1	(0.1)
Viral infection	0	(0.0)	1	(0.1)
Injury, poisoning and procedural complications	**7**	**(2.3)**	**6**	**(0.9)**
Infusion related reaction	7	(2.3)	4	(0.6)
Post procedural urine leak	0	(0.0)	1	(0.1)
Radiation pneumonitis	0	(0.0)	1	(0.1)
Investigations	**3**	**(1.0)**	**19**	**(2.8)**
Alanine aminotransferase increased	1	(0.3)	6	(0.9)
Amylase increased	0	(0.0)	1	(0.1)
Aspartate aminotransferase increased	1	(0.3)	8	(1.2)
Blood alkaline phosphatase increased	0	(0.0)	2	(0.3)
Blood creatinine increased	0	(0.0)	4	(0.6)
C-reactive protein increased	0	(0.0)	2	(0.3)
Gamma-glutamyltransferase increased	0	(0.0)	1	(0.1)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) MK-3475 Treatment Groups Pooled APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Investigations	**3**	**(1.0)**	**19**	**(2.8)**
Neutrophil count decreased	2	(0.6)	0	(0.0)
Transaminases increased	0	(0.0)	1	(0.1)
Weight decreased	0	(0.0)	3	(0.4)
Metabolism and nutrition disorders	**3**	**(1.0)**	**23**	**(3.4)**
Decreased appetite	3	(1.0)	9	(1.3)
Dehydration	0	(0.0)	2	(0.3)
Hyperamylasaemia	0	(0.0)	1	(0.1)
Hypercalcaemia	0	(0.0)	3	(0.4)
Hyperglycaemia	0	(0.0)	2	(0.3)
Hypertriglyceridaemia	0	(0.0)	2	(0.3)
Hypokalaemia	0	(0.0)	1	(0.1)
Hyponatraemia	0	(0.0)	1	(0.1)
Hypophosphataemia	0	(0.0)	1	(0.1)
Type 1 diabetes mellitus	0	(0.0)	1	(0.1)
Musculoskeletal and connective tissue disorders	**2**	**(0.6)**	**13**	**(1.9)**
Arthralgia	0	(0.0)	4	(0.6)
Arthritis	0	(0.0)	1	(0.1)
Back pain	0	(0.0)	1	(0.1)
Bone pain	0	(0.0)	2	(0.3)
Musculoskeletal chest pain	1	(0.3)	1	(0.1)
Myalgia	0	(0.0)	1	(0.1)
Myopathy	0	(0.0)	1	(0.1)
Polyarthritis	0	(0.0)	1	(0.1)
Spinal osteoarthritis	1	(0.3)	0	(0.0)
Synovitis	0	(0.0)	1	(0.1)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**0**	**(0.0)**	**1**	**(0.1)**
Metastases to central nervous system	0	(0.0)	1	(0.1)
Nervous system disorders	**3**	**(1.0)**	**7**	**(1.0)**
Cerebral ischaemia	0	(0.0)	1	(0.1)
Dizziness	2	(0.6)	4	(0.6)
Headache	0	(0.0)	1	(0.1)
Hemiparesis	0	(0.0)	1	(0.1)
Memory impairment	1	(0.3)	0	(0.0)
Transient ischaemic attack	0	(0.0)	1	(0.1)
Psychiatric disorders	**0**	**(0.0)**	**2**	**(0.3)**

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) MK-3475 Treatment Groups Pooled APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Psychiatric disorders	**0**	**(0.0)**	**2**	**(0.3)**
Binge eating	0	(0.0)	1	(0.1)
Depression	0	(0.0)	1	(0.1)
Renal and urinary disorders	**1**	**(0.3)**	**6**	**(0.9)**
Acute kidney injury	0	(0.0)	2	(0.3)
Haematuria	1	(0.3)	0	(0.0)
Proteinuria	0	(0.0)	1	(0.1)
Renal failure	0	(0.0)	2	(0.3)
Urinary bladder polyp	0	(0.0)	1	(0.1)
Respiratory, thoracic and mediastinal disorders	**13**	**(4.2)**	**25**	**(3.7)**
Chronic obstructive pulmonary disease	0	(0.0)	3	(0.4)
Cough	1	(0.3)	2	(0.3)
Dyspnoea	7	(2.3)	3	(0.4)
Haemoptysis	0	(0.0)	1	(0.1)
Hypercapnia	0	(0.0)	1	(0.1)
Hypoxia	0	(0.0)	1	(0.1)
Interstitial lung disease	0	(0.0)	1	(0.1)
Oropharyngeal pain	1	(0.3)	0	(0.0)
Pleural effusion	2	(0.6)	3	(0.4)
Pneumonitis	0	(0.0)	7	(1.0)
Pneumothorax	2	(0.6)	0	(0.0)
Pulmonary embolism	1	(0.3)	3	(0.4)
Pulmonary vascular disorder	0	(0.0)	1	(0.1)
Rhinorrhoea	0	(0.0)	1	(0.1)
Tachypnoea	0	(0.0)	1	(0.1)
Skin and subcutaneous tissue disorders	**3**	**(1.0)**	**7**	**(1.0)**
Drug eruption	0	(0.0)	1	(0.1)
Erythema	1	(0.3)	0	(0.0)
Pain of skin	0	(0.0)	1	(0.1)
Palmar-plantar erythrodysaesthesia syndrome	1	(0.3)	0	(0.0)
Psoriasis	0	(0.0)	1	(0.1)
Rash	0	(0.0)	3	(0.4)
Rash maculo-papular	0	(0.0)	1	(0.1)
Telangiectasia	1	(0.3)	0	(0.0)
Vascular disorders	**3**	**(1.0)**	**6**	**(0.9)**
Flushing	2	(0.6)	0	(0.0)
Hypertension	0	(0.0)	2	(0.3)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption
(Incidence > 0% in One or More Treatment Groups)
MK-3475 Treatment Groups Pooled
APaT Population (TPS ≥1%)

	Docetaxel 75 mg/m2 Q3W		MK-3475 Pooled	
	n	(%)	n	(%)
Vascular disorders	**3**	**(1.0)**	**6**	**(0.9)**
Hypotension	0	(0.0)	1	(0.1)
Peripheral vascular disorder	1	(0.3)	0	(0.0)
Superior vena cava occlusion	0	(0.0)	1	(0.1)
Superior vena cava syndrome	0	(0.0)	1	(0.1)
Thrombosis	0	(0.0)	1	(0.1)

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms 'Neoplasm Progression' ,'Malignant Neoplasm Progression' and 'Disease Progression' not related to the drug are excluded.

After the end of treatment, each subject will be followed for a minimum of 30 days for adverse event monitoring. SAE is monitored until 90 days after last dose.

(Database Cutoff Date: 30SEP2015)

C Confidential

付録 2.7.4- 56　　治験薬の休薬に至った有害事象の一覧

010 試験（安全性解析対象集団）（PD-L1 発現陽性）

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=0004, AN=309836, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=99									
309836	Treatment Cycle 2	22	Flatulence	Unknown		N	Y	Interrupted	Unknown
Study Number=3475-010, Site Number=0015, AN=310885, Gender=F, Race=Asian, Age=71 Years, Rel Day of Study Medication Discontinuance†=146									
310885	Treatment Cycle 1	2	Fatigue	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0017, AN=309938, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=205									
309938	Treatment Cycle 5	93	Leukopenia	2.14 Weeks		N	Y	Interrupted	Resolved
		93	Neutropenia	2 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 9	186	Leukopenia	2.86 Weeks		N	Y	Interrupted	Resolved
	Safety Follow-up	226	Leukopenia	2 Days		N	Y	Interrupted	Resolved
		226	Neutropenia	2 Days		N	Y	Interrupted	Resolved
		226	Thrombocytopenia	3.29 Weeks		N	Y	Interrupted	Resolved
		234	Leukopenia	1.14 Weeks		N	Y	Interrupted	Resolved
		234	Neutropenia	1.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0027, AN=301485, Gender=F, Race=Black Or African American, Age=68 Years, Rel Day of Study Medication Discontinuance†=173									
301485	Treatment Cycle 8	164	Dyspnoea	2 Days		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0028, AN=307272, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=122									
307272	Treatment Cycle 4	87	Fatigue	Unknown		N	Y	Interrupted	Unknown
		87	Nausea	2.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0040, AN=302006, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=317									

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=0040, AN=302006, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=317									
302006	Treatment Cycle 12	253	Dizziness	3.14 Weeks		N	Y	Interrupted	Resolved
		253	Fatigue	3.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0046, AN=305963, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=92									
305963	Treatment Cycle 3	60	Dyspnoea	4 Days		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0049, AN=307494, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=22									
307494	Treatment Cycle 2	22	Infusion related reaction	45 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0051, AN=303197, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=127									
303197	Treatment Cycle 4	84	Dyspnoea	1 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 5	105	Bronchitis	1.14 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0051, AN=306663, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=127									
306663	Treatment Cycle 6	106	Infusion site discomfort	5 Minutes		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0051, AN=310401, Gender=F, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=47									
310401	Treatment Cycle 2	25	Flushing	45 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0051, AN=313974, Gender=M, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=20									
313974	Treatment Cycle 1	8	Neutropenia	4 Days		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0054, AN=306174, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=1									

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=0054, AN=306174, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=1									
306174	Safety Follow-up	3	Fatigue	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0055, AN=303539, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=29									
303539	Treatment Cycle 1	7	Fatigue	3.14 Weeks		N	Y	Interrupted	Resolved
	Safety Follow-up	37	Pneumonia	4 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0063, AN=309676, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=92									
309676	Treatment Cycle 1	22	Pulmonary embolism	1.14 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 2	29	Infusion related reaction	5 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0081, AN=301651, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=189									
301651	Treatment Cycle 8	186	Telangiectasia	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0081, AN=307583, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=210									
307583	Safety Follow-up	231	Asthenia	3.29 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0094, AN=302688, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=217									
302688	Treatment Cycle 3	43	Peripheral vascular disorder	Continuing		N	N	Interrupted	Not Resolved
		48	Melaena	1.57 Weeks		N	N	Interrupted	Resolved
		64	Bronchitis	2.46 Months		N	N	Interrupted	Resolved
	Treatment Cycle 8	162	Asthenia	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0160, AN=302004, Gender=F, Race=Asian, Age=54 Years, Rel Day of Study Medication Discontinuance†=114									

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=0160, AN=302004, Gender=F, Race=Asian, Age=54 Years, Rel Day of Study Medication Discontinuance†=114									
302004	Treatment Cycle 1	4	Pyrexia	2 Days		N	N	Interrupted	Resolved
		23	Pyrexia	6 Days		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0160, AN=305711, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=1									
305711	Safety Follow-up	20	Pneumothorax	Continuing		Y	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0166, AN=301698, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=113									
301698	Treatment Cycle 3	50	Decreased appetite	1.12 Months		N	N	Interrupted	Sequelae
	Treatment Cycle 4	84	Decreased appetite	Continuing		Y	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0180, AN=300441, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=155									
300441	Treatment Cycle 4	112	Lower respiratory tract infection	2.14 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 5	147	Constipation	1.14 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0182, AN=303567, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=64									
303567	Treatment Cycle 2	22	Drug hypersensitivity	2.63 Hours		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0183, AN=310493, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=29									
310493	Treatment Cycle 1	20	Decreased appetite	4.14 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0184, AN=307849, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=72									
307849	Treatment Cycle 1	5	Fatigue	Continuing		N	Y	Interrupted	Not Resolved
		12	Memory impairment	Continuing		N	N	Interrupted	Not Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=0184, AN=308281, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=50									
308281	Treatment Cycle 2	40	Spinal osteoarthritis	5 Days		Y	N	Interrupted	Sequelae
Study Number=3475-010, Site Number=0185, AN=313294, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=131									
313294	Treatment Cycle 1	15	Lower respiratory tract infection	6 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0200, AN=309408, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=40									
309408	Treatment Cycle 1	13	Haematuria	Continuing		Y	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0200, AN=313799, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=44									
313799	Treatment Cycle 2	23	Infusion related reaction	1 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0201, AN=307903, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=47									
307903	Treatment Cycle 2	23	Erythema	23 Hours		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0201, AN=307904, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=25									
307904	Treatment Cycle 1	23	Infusion related reaction	23 Hours		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0201, AN=312546, Gender=M, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=52									
312546	Treatment Cycle 2	41	Anaemia	Continuing		N	N	Interrupted	Resolving
		41	Respiratory tract infection	1.71 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0205, AN=301943, Gender=M, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=22									
301943	Safety Follow-up	40	Pneumothorax	1.71 Weeks		Y	N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=0282, AN=308906, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=48									
308906	Treatment Cycle 1	8	Diarrhoea	2.86 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0324, AN=302221, Gender=F, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=218									
302221	Treatment Cycle 2	22	Drug hypersensitivity	20 Minutes		N	Y	Interrupted	Resolved
	Treatment Cycle 4	65	Paraesthesia oral	10 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0324, AN=308553, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=191									
308553	Treatment Cycle 2	22	Drug hypersensitivity	15 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0360, AN=306000, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=50									
306000	Treatment Cycle 1	16	Bronchitis	1.57 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0445, AN=309652, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=119									
309652	Treatment Cycle 2	41	Pneumonia	2.83 Months		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0522, AN=310853, Gender=M, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance†=112									
310853	Treatment Cycle 4	72	Pneumonia	2 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0560, AN=308319, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=22									
308319	Treatment Cycle 2	22	Hypersensitivity	41.02 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0560, AN=310979, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=73									
310979	Treatment Cycle 3	63	Upper respiratory tract infection	1.29 Weeks		N	Y	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=0601, AN=308747, Gender=F, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=197									
308747	Treatment Cycle 2	42	Urinary tract infection	1.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0604, AN=313808, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=37									
313808	Treatment Cycle 1	4	Infection masked	1.12 Months		N	N	Interrupted	Resolved
		22	Anaemia	2.29 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 2	37	Diarrhoea	2.43 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0760, AN=313097, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=29									
313097	Treatment Cycle 1	18	Dyspnoea	3 Days		N	N	Interrupted	Resolved
		18	Pyrexia	3 Days		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0764, AN=305414, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=64									
305414	Treatment Cycle 1	9	Dyspnoea	2 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0960, AN=308933, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=									
308933	Treatment Cycle 4	69	Respiratory tract infection	3.14 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 8	162	Pneumonia	1.29 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1004, AN=309747, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=113									
309747	Treatment Cycle 1	13	Pleural effusion	1.57 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 3	64	Pleural infection	4.57 Months		Y	N	Interrupted	Resolved
		74	Pleural effusion	1 Weeks		N	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=1080, AN=307406, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=41									
307406	Treatment Cycle 2	20	Infusion related reaction	25 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1080, AN=311257, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=107									
311257	Treatment Cycle 2	26	Infusion related reaction	23 Hours		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1081, AN=301002, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=1									
301002	Safety Follow-up	8	Musculoskeletal chest pain	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1081, AN=301965, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=175									
301965	Treatment Cycle 4 Treatment Cycle 7	75 159	Pneumonia Gastroenteritis	1.43 Weeks 5 Days		Y Y	N N	Interrupted Interrupted	Resolved Resolved
Study Number=3475-010, Site Number=1081, AN=313877, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=43									
313877	Treatment Cycle 2	22	Drug hypersensitivity	5 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1084, AN=303319, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=31									
303319	Treatment Cycle 1	24	Palmar-plantar erythrodysaesthesia syndrome	1.14 Weeks		N	Y	Interrupted	Unknown
Study Number=3475-010, Site Number=1240, AN=311863, Gender=M, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=									
311863	Treatment Cycle 4 Treatment Cycle 13	65 302	Asthenia Diarrhoea	Continuing 1.86 Weeks		N Y	Y Y	Interrupted Interrupted	Not Resolved Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=1240, AN=312295, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=129									
312295	Safety Follow-up	150	Pneumonia	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1242, AN=304164, Gender=M, Race=Asian, Age=51 Years, Rel Day of Study Medication Discontinuance†=85									
304164	Treatment Cycle 5	85	Chest discomfort	30 Minutes		N	Y	Interrupted	Resolved
		85	Flushing	30 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1243, AN=302438, Gender=M, Race=Asian, Age=63 Years, Rel Day of Study Medication Discontinuance†=27									
302438	Treatment Cycle 1	6	Laryngitis	2.14 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1243, AN=312969, Gender=M, Race=Asian, Age=78 Years, Rel Day of Study Medication Discontinuance†=206									
312969	Treatment Cycle 4	82	Upper respiratory tract infection	1.86 Weeks		Y	Y	Interrupted	Resolved
	Treatment Cycle 6	119	Lung infection	3.57 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1243, AN=313082, Gender=F, Race=Asian, Age=62 Years, Rel Day of Study Medication Discontinuance†=246									
313082	Treatment Cycle 1	12	Sepsis	2 Weeks		Y	Y	Interrupted	Resolved
	Treatment Cycle 11	233	Pyrexia	2 Hours		N	Y	Interrupted	Resolved
		233	Upper respiratory tract infection	1.14 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1244, AN=305051, Gender=M, Race=Asian, Age=57 Years, Rel Day of Study Medication Discontinuance†=47									
305051	Treatment Cycle 1	4	Dizziness	3 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1244, AN=308180, Gender=M, Race=Asian, Age=51 Years, Rel Day of Study Medication Discontinuance†=111									
308180	Treatment Cycle 2	43	Alanine aminotransferase increased	6 Days		N	Y	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=1244, AN=308180, Gender=M, Race=Asian, Age=51 Years, Rel Day of Study Medication Discontinuance†=111									
308180	Treatment Cycle 2	43	Aspartate aminotransferase increased	6 Days		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1245, AN=300286, Gender=F, Race=Asian, Age=77 Years, Rel Day of Study Medication Discontinuance†=114									
300286	Treatment Cycle 2	22	Infusion related reaction	3 Days		N	Y	Interrupted	Resolved
	Treatment Cycle 5	103	Cough	2.57 Weeks		N	N	Interrupted	Resolved
		103	Oropharyngeal pain	2.57 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1245, AN=304607, Gender=F, Race=Asian, Age=39 Years, Rel Day of Study Medication Discontinuance†=416									
304607	Treatment Cycle 1	24	Neutrophil count decreased	2.14 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 15	383	Neutrophil count decreased	1.71 Weeks		N	N	Interrupted	Resolved
	Safety Follow-up	437	Neutrophil count decreased	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1245, AN=309049, Gender=M, Race=Asian, Age=60 Years, Rel Day of Study Medication Discontinuance†=40									
309049	Safety Follow-up	57	Pneumonia	2.1 Months		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1366, AN=309433, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=176									
309433	Treatment Cycle 2	34	Dyspnoea	Continuing		N	N	Interrupted	Not Resolved
		41	Pyrexia	1.29 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1366, AN=312557, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=									
312557	Treatment Cycle 4	86	Neutrophil count decreased	1 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 9	205	Neutropenia	1.14 Weeks		N	Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Docetaxel 75 mg/m2 Q3W									
Study Number=3475-010, Site Number=1400, AN=306948, Gender=M, Race=Asian, Age=64 Years, Rel Day of Study Medication Discontinuance†=239									
306948	Treatment Cycle 3	64	Upper respiratory tract infection	1.71 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 5	96	Oedema	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1401, AN=308537, Gender=F, Race=Asian, Age=76 Years, Rel Day of Study Medication Discontinuance†=									
308537	Treatment Cycle 5	102	Nail infection	Continuing		N	Y	Interrupted	Not Resolved
	Treatment Cycle 10	238	Oedema peripheral	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1417, AN=309461, Gender=M, Race=Asian, Age=61 Years, Rel Day of Study Medication Discontinuance†=349									
309461	Treatment Cycle 10	195	Pleural effusion	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1419, AN=301064, Gender=M, Race=Asian, Age=68 Years, Rel Day of Study Medication Discontinuance†=81									
301064	Treatment Cycle 1	3	Dyspnoea	Continuing		Y	Y	Interrupted	Resolving
	Treatment Cycle 3	59	Decreased appetite	Continuing		Y	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1422, AN=313588, Gender=M, Race=Asian, Age=75 Years, Rel Day of Study Medication Discontinuance†=192									
313588	Safety Follow-up	204	Febrile neutropenia	1.43 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1434, AN=301442, Gender=F, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
301442	Treatment Cycle 5	83	Oedema	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1437, AN=311287, Gender=M, Race=Asian, Age=34 Years, Rel Day of Study Medication Discontinuance†=159									
311287	Treatment Cycle 3	45	Staphylococcal infection	4.14 Weeks		Y	N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0003, AN=304076, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=115									
304076	Treatment Cycle 5	101	Abdominal pain	1.57 Weeks		N	Y	Interrupted	Sequelae
Study Number=3475-010, Site Number=0003, AN=311429, Gender=M, Race=Black Or African American, Age=57 Years, Rel Day of Study Medication Discontinuance†=									
311429	Treatment Cycle 4	85	Hyperglycaemia	5.55 Hours		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0004, AN=300573, Gender=M, Race=, Age=70 Years, Rel Day of Study Medication Discontinuance†=28									
300573	Treatment Cycle 1	6	Pneumonitis	3 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0004, AN=301679, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=49									
301679	Treatment Cycle 1	21	Rhinorrhoea	4.14 Weeks		N	N	Interrupted	Resolved
		21	Weight decreased	1.14 Weeks		N	N	Interrupted	Resolved
	Safety Follow-up	67	Blood alkaline phosphatase increased	1.57 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0005, AN=311089, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=									
311089	Treatment Cycle 12	253	Chronic obstructive pulmonary disease	1.14 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0006, AN=307697, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=138									
307697	Treatment Cycle 5	104	Arthritis	3.14 Weeks		Y	Y	Interrupted	Resolved
		104	Pericardial effusion	1.15 Months		N	Y	Interrupted	Resolved
		104	Pleural effusion	3.14 Weeks		Y	Y	Interrupted	Resolved
	Safety Follow-up	160	Dyspnoea	Continuing		Y	Y	Interrupted	Not Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0006, AN=307697, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=138									
307697	Safety Follow-up	160	Pericardial effusion	Continuing		Y	N	Interrupted	Not Resolved
		160	Pleural effusion	Continuing		Y	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0006, AN=311420, Gender=F, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=									
311420	Treatment Cycle 4	85	Respiratory tract infection	1.87 Months		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0006, AN=312907, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=									
312907	Treatment Cycle 6	128	Blood creatinine increased	3 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0007, AN=307955, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=239									
307955	Treatment Cycle 1	20	Gastric haemorrhage	6 Days		Y	N	Interrupted	Resolved
		22	Gastritis erosive	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0014, AN=301535, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=232									
301535	Treatment Cycle 2	41	Sinusitis	2.4 Months		N	N	Interrupted	Resolved
	Treatment Cycle 6	185	Fatigue	1.58 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0015, AN=306219, Gender=M, Race=Asian, Age=56 Years, Rel Day of Study Medication Discontinuance†=239									
306219	Treatment Cycle 1	14	Herpes zoster	2.14 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0026, AN=304255, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=51									
304255	Treatment Cycle 2	39	Influenza	1.29 Weeks		Y	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0028, AN=310007, Gender=M, Race=Black Or African American, Age=75 Years, Rel Day of Study Medication Discontinuance†=									
310007	Treatment Cycle 3	62	Pleural effusion	4 Days		N	N	Interrupted	Resolved
		64	Hyperthyroidism	1.18 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0040, AN=307770, Gender=F, Race=Black Or African American, Age=78 Years, Rel Day of Study Medication Discontinuance†=149									
307770	Treatment Cycle 5	106	Musculoskeletal chest pain	2 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0046, AN=302932, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=274									
302932	Treatment Cycle 7	141	Rash	1.3 Years		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0046, AN=314043, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=417									
314043	Treatment Cycle 18	389	Anaemia	2 Days		Y	N	Interrupted	Sequelae
Study Number=3475-010, Site Number=0050, AN=306601, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=169									
306601	Treatment Cycle 3	44	Large intestinal obstruction	2 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0063, AN=303281, Gender=F, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=178									
303281	Treatment Cycle 5	96	Pulmonary embolism	4 Days		Y	Y	Interrupted	Resolved
	Treatment Cycle 7	155	Hypoxia	4 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0063, AN=307342, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
307342	Treatment Cycle 7	146	Herpes simplex	3.43 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0094, AN=302933, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0094, AN=302933, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=									
302933	Treatment Cycle 14	295	Hemiparesis	Continuing		Y	N	Interrupted	Resolving
Study Number=3475-010, Site Number=0094, AN=303077, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=219									
303077	Treatment Cycle 7	129	Lower respiratory tract infection	3.86 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0130, AN=308513, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=246									
308513	Treatment Cycle 9	189	Adrenal insufficiency	2.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0138, AN=310772, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=173									
310772	Treatment Cycle 7	136	Infectious colitis	1.61 Months		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0162, AN=302096, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=									
302096	Treatment Cycle 18	370	Herpes zoster	3 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 26	557	Transient ischaemic attack	2 Days		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0162, AN=304742, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=74									
304742	Treatment Cycle 2	42	Atrial fibrillation	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0162, AN=309544, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=121									
309544	Treatment Cycle 1	8	Anaemia	Continuing		N	N	Interrupted	Not Resolved
	Treatment Cycle 3	53	Pneumonia	3.29 Weeks		N	Y	Interrupted	Resolved
		53	Pulmonary embolism	2.14 Months		Y	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0167, AN=305230, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=43									
305230	Treatment Cycle 1	21	Asthenia	3.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0167, AN=310382, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=									
310382	Treatment Cycle 2	39	Hypercalcaemia	Continuing		N	N	Interrupted	Resolving
Study Number=3475-010, Site Number=0180, AN=306653, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=									
306653	Treatment Cycle 10	223	Alanine aminotransferase increased	Continuing		N	Y	Interrupted	Not Resolved
		223	Aspartate aminotransferase increased	Continuing		N	Y	Interrupted	Not Resolved
		223	Blood alkaline phosphatase increased	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0180, AN=310957, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=84									
310957	Treatment Cycle 3	52	Dizziness	Continuing		N	N	Interrupted	Resolving
		52	Visual impairment	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0182, AN=301067, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=22									
301067	Safety Follow-up	23	Decreased appetite	3.71 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0182, AN=301330, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=125									
301330	Treatment Cycle 2	20	Infusion related reaction	5 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0183, AN=314351, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=1									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0183, AN=314351, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=1									
314351	Safety Follow-up	21	Autoimmune hepatitis	Continuing		Y	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0184, AN=305795, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=177									
305795	Treatment Cycle 1	11	Decreased appetite	2.29 Weeks		N	Y	Interrupted	Resolved
		11	Pain of skin	2.29 Weeks		N	N	Interrupted	Resolved
		15	Constipation	1.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0184, AN=309469, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=									
309469	Treatment Cycle 1	3	Dyspnoea	Continuing		Y	N	Interrupted	Resolving
	Treatment Cycle 21	437	Vision blurred	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0184, AN=311208, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=									
311208	Treatment Cycle 8	157	Dizziness	1.71 Weeks		N	N	Interrupted	Resolved
		168	Anaemia	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0201, AN=300176, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=368									
300176	Treatment Cycle 6	127	Pneumonitis	1.29 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0201, AN=309551, Gender=M, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=100									
309551	Treatment Cycle 2	44	Superior vena cava occlusion	1.61 Months		Y	N	Interrupted	Resolved
	Treatment Cycle 3	73	Pancreatitis	2 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0206, AN=307279, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0206, AN=307279, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=									
307279	Treatment Cycle 12	239	Diarrhoea	1.43 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 16	344	Renal failure	1.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0209, AN=314106, Gender=F, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=133									
314106	Treatment Cycle 4	67	Respiratory tract infection	3.43 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0211, AN=302459, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=									
302459	Treatment Cycle 8	175	Chronic obstructive pulmonary disease	5 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0282, AN=307169, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=331									
307169	Treatment Cycle 6	114	Colitis	2.86 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 7	144	Diarrhoea	1.12 Months		N	Y	Interrupted	Resolved
	Treatment Cycle 10	230	Gastrointestinal disorder	2.57 Weeks		N	Y	Interrupted	Resolved
		230	Vomiting	2.14 Weeks		N	Y	Interrupted	Resolved
		234	Diarrhoea	2 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 11	273	Acute kidney injury	3 Days		Y	N	Interrupted	Resolved
		273	Dehydration	3 Days		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0283, AN=306310, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=88									
306310	Treatment Cycle 2	26	Psoriasis	4.73 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0284, AN=300992, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=386									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0284, AN=300992, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=386									
300992	Treatment Cycle 11	229	Influenza	1.57 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0284, AN=307284, Gender=M, Race=Asian, Age=47 Years, Rel Day of Study Medication Discontinuance†=29									
307284	Treatment Cycle 1	12	Pneumonitis	1.71 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0324, AN=303296, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=323									
303296	Treatment Cycle 2	27	Anaemia	4.14 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0401, AN=311762, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=									
311762	Treatment Cycle 3	64	Staphylococcal infection	1.86 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0404, AN=307180, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=232									
307180	Treatment Cycle 5	98	Fatigue	Unknown		N	Y	Interrupted	Unknown
Study Number=3475-010, Site Number=0407, AN=306573, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=									
306573	Treatment Cycle 5	106	Fatigue	1.14 Weeks		N	N	Interrupted	Resolved
		108	Pyrexia	2 Days		N	N	Interrupted	Resolved
	Treatment Cycle 11	241	Hypothyroidism	Continuing		Y	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0563, AN=308798, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=									
308798	Treatment Cycle 1	20	C-reactive protein increased	2.6 Months		Y	N	Interrupted	Resolved
		20	Normochromic normocytic anaemia	3.29 Months		Y	N	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=0602, AN=302229, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=176									
302229	Treatment Cycle 1	21	Respiratory tract infection	5 Days		N	N	Interrupted	Resolved
	Treatment Cycle 3	62	Pneumonitis	2.17 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0604, AN=311210, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=51									
311210	Treatment Cycle 2	39	Dizziness	1.86 Weeks		N	N	Interrupted	Resolved
		39	Headache	1.86 Weeks		N	N	Interrupted	Resolved
		39	Vomiting	1.86 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0604, AN=313614, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=									
313614	Treatment Cycle 4	69	Diarrhoea	1.02 Months		N	Y	Interrupted	Resolved
	Treatment Cycle 8	183	Decreased appetite	Continuing		N	N	Interrupted	Resolving
		190	Diarrhoea	2 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0804, AN=306827, Gender=F, Race=Black Or African American, Age=56 Years, Rel Day of Study Medication Discontinuance†=134									
306827	Treatment Cycle 4	87	Cough	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0926, AN=307528, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=407									
307528	Treatment Cycle 7	140	Polyarthritis	Unknown		N	Y	Interrupted	Unknown
	Treatment Cycle 13	290	Pericardial effusion	6 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1003, AN=304043, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
304043	Treatment Cycle 6	134	Binge eating	2 Days		N	N	Interrupted	Resolved
		134	Pyrexia	2 Days		N	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=1080, AN=304049, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=64									
304049	Treatment Cycle 1	13	Synovitis	4.29 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1080, AN=312970, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=94									
312970	Treatment Cycle 4	83	Gamma-glutamyltransferase increased	Continuing		N	N	Interrupted	Resolving
		86	Myopathy	Continuing		Y	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=1241, AN=301658, Gender=M, Race=Asian, Age=77 Years, Rel Day of Study Medication Discontinuance†=50									
301658	Treatment Cycle 1	15	Decreased appetite	2.4 Months		N	Y	Interrupted	Unknown
		15	Depression	2.4 Months		N	N	Interrupted	Unknown
		15	Fatigue	2.4 Months		N	Y	Interrupted	Unknown
Study Number=3475-010, Site Number=1244, AN=302203, Gender=M, Race=Asian, Age=56 Years, Rel Day of Study Medication Discontinuance†=									
302203	Treatment Cycle 1	21	Alanine aminotransferase increased	2.14 Months		N	Y	Interrupted	Resolved
		21	Aspartate aminotransferase increased	2.14 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1244, AN=304504, Gender=F, Race=Asian, Age=72 Years, Rel Day of Study Medication Discontinuance†=27									
304504	Treatment Cycle 1	11	Superior vena cava syndrome	Continuing		N	N	Interrupted	Resolving
Study Number=3475-010, Site Number=1245, AN=301979, Gender=M, Race=Asian, Age=71 Years, Rel Day of Study Medication Discontinuance†=									
301979	Treatment Cycle 12	249	Gastroenteritis	1.71 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 26	554	Alanine aminotransferase increased	4.14 Weeks		N	Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=1245, AN=301979, Gender=M, Race=Asian, Age=71 Years, Rel Day of Study Medication Discontinuance†=									
301979	Treatment Cycle 26	554	Aspartate aminotransferase increased	4.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1245, AN=308516, Gender=M, Race=Asian, Age=55 Years, Rel Day of Study Medication Discontinuance†=113									
308516	Treatment Cycle 1	26	Rash maculo-papular	1.43 Weeks		Y	Y	Interrupted	Resolved
	Treatment Cycle 3	68	Atypical pneumonia	1.48 Months		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1322, AN=312348, Gender=M, Race=Asian, Age=57 Years, Rel Day of Study Medication Discontinuance†=230									
312348	Treatment Cycle 6	124	Decreased appetite	5.91 Months		N	Y	Interrupted	Resolved
		124	Fatigue	3.48 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1324, AN=307306, Gender=F, Race=Asian, Age=51 Years, Rel Day of Study Medication Discontinuance†=									
307306	Treatment Cycle 2	42	Diarrhoea	2 Days		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1363, AN=300416, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=43									
300416	Treatment Cycle 1	12	Fatigue	1.61 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1366, AN=310223, Gender=M, Race=American Indian Or Alaska Native, Age=57 Years, Rel Day of Study Medication Discontinuance†=385									
310223	Treatment Cycle 5	105	Alanine aminotransferase increased	2.3 Months		N	Y	Interrupted	Resolved
		105	Aspartate aminotransferase increased	2.99 Months		N	Y	Interrupted	Resolved
		105	Blood creatinine increased	5.75 Months		N	Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Study Number=3475-010, Site Number=1405, AN=304574, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
304574	Treatment Cycle 2	43	Alanine aminotransferase increased	1.64 Months		N	Y	Interrupted	Resolved
		43	Aspartate aminotransferase increased	2.89 Months		N	Y	Interrupted	Resolved
	Treatment Cycle 4	118	Colitis	Continuing		Y	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=1420, AN=302578, Gender=F, Race=Asian, Age=48 Years, Rel Day of Study Medication Discontinuance†=90									
302578	Treatment Cycle 1	15	Arthralgia	3.15 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1422, AN=308873, Gender=M, Race=Asian, Age=70 Years, Rel Day of Study Medication Discontinuance†=									
308873	Treatment Cycle 1	10	Pneumonia	3.86 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1423, AN=301923, Gender=M, Race=Asian, Age=68 Years, Rel Day of Study Medication Discontinuance†=85									
301923	Safety Follow-up	88	Arthralgia	Continuing		N	Y	Interrupted	Not Resolved
		97	Rash	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1434, AN=302434, Gender=M, Race=Asian, Age=69 Years, Rel Day of Study Medication Discontinuance†=									
302434	Treatment Cycle 1	3	Decreased appetite	3.57 Weeks		Y	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1438, AN=312992, Gender=F, Race=Asian, Age=65 Years, Rel Day of Study Medication Discontinuance†=259									
312992	Safety Follow-up	273	Adrenal insufficiency	Continuing		N	Y	Interrupted	Not Resolved
		273	Hypothalamo-pituitary disorder	Continuing		N	Y	Interrupted	Not Resolved
MK-3475 10 mg/kg Q3W									

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0002, AN=301310, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=1									
301310	Safety Follow-up	5	Fatigue	Continuing		Y	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0003, AN=300217, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=99									
300217	Treatment Cycle 1	22	Chest pain	1.29 Weeks		N	N	Interrupted	Resolved
		22	Dyspnoea	1.14 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 4	92	Pneumonitis	1.18 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0003, AN=305802, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=36									
305802	Treatment Cycle 1	27	Weight decreased	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0004, AN=305817, Gender=F, Race=Black Or African American, Age=63 Years, Rel Day of Study Medication Discontinuance†=									
305817	Treatment Cycle 7	142	Coronary artery disease	1.86 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 12	250	Cataract	1.43 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0005, AN=303231, Gender=F, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=232									
303231	Treatment Cycle 2	46	Pneumonia	2.71 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 6	176	Lung infection	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0006, AN=300114, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=66									
300114	Treatment Cycle 4	66	Anaphylactic reaction	1.5 Hours		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0007, AN=307774, Gender=F, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=43									
307774	Treatment Cycle 3	43	Infusion related reaction	1.25 Hours		N	Y	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0014, AN=302077, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=141									
302077	Treatment Cycle 3	62	Autoimmune hepatitis	4.14 Weeks		N	Y	Interrupted	Resolved
		63	Rash pustular	4.29 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0024, AN=310749, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=									
310749	Treatment Cycle 1	8	Pain	2.1 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0027, AN=312104, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=									
312104	Treatment Cycle 6	128	Hypertension	1.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0037, AN=302733, Gender=F, Race=Asian, Age=61 Years, Rel Day of Study Medication Discontinuance†=244									
302733	Treatment Cycle 8	161	Aspartate aminotransferase increased	4.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0037, AN=305210, Gender=F, Race=Black Or African American, Age=60 Years, Rel Day of Study Medication Discontinuance†=									
305210	Treatment Cycle 7	147	Palpitations	3 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0046, AN=305415, Gender=M, Race=Black Or African American, Age=20 Years, Rel Day of Study Medication Discontinuance†=302									
305415	Treatment Cycle 4	83	Diarrhoea	5 Days		N	Y	Interrupted	Resolved
		83	Nausea	5 Days		N	Y	Interrupted	Resolved
		83	Vomiting	3 Days		N	Y	Interrupted	Resolved
		84	Decreased appetite	4 Days		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0048, AN=301360, Gender=M, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=50									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0048, AN=301360, Gender=M, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=50									
301360	Treatment Cycle 1	22	Blood creatinine increased	1.14 Weeks		N	N	Interrupted	Resolved
		22	Bone pain	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0049, AN=302367, Gender=F, Race=Asian, Age=48 Years, Rel Day of Study Medication Discontinuance†=125									
302367	Safety Follow-up	146	Leukopenia	Continuing		N	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=0055, AN=300953, Gender=M, Race=, Age=37 Years, Rel Day of Study Medication Discontinuance†=91									
300953	Treatment Cycle 1	12	Bone pain	4.11 Months		N	Y	Interrupted	Resolved
		12	Dizziness	2.14 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 2	40	Hypophosphataemia	4 Days		N	Y	Interrupted	Resolved
	Treatment Cycle 4	82	Hypophosphataemia	1.43 Weeks		N	Y	Interrupted	Resolved
	Safety Follow-up	98	Vertigo	1.28 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0055, AN=311446, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
311446	Treatment Cycle 2	23	Hypertriglyceridaemia	3.48 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0055, AN=312063, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=315									
312063	Safety Follow-up	331	Post procedural urine leak	1.14 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0058, AN=305706, Gender=M, Race=Black Or African American, Age=76 Years, Rel Day of Study Medication Discontinuance†=									
305706	Treatment Cycle 7	143	Haemoptysis	1.71 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0059, AN=304649, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=87									

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0059, AN=304649, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=87									
304649	Treatment Cycle 2	22	Weight decreased	Continuing		N	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=0063, AN=313118, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=302									
313118	Treatment Cycle 7	145	Tooth abscess	3.14 Weeks		N	N	Interrupted	Resolved
		167	Blood creatinine increased	3 Days		N	Y	Interrupted	Resolved
	Treatment Cycle 8	189	Thrombosis	4 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0081, AN=305939, Gender=M, Race=Asian, Age=57 Years, Rel Day of Study Medication Discontinuance†=471									
305939	Treatment Cycle 3	60	Hepatocellular injury	1.54 Months		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0081, AN=307798, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=43									
307798	Safety Follow-up	64	Spinal cord infection	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0083, AN=302776, Gender=F, Race=, Age=70 Years, Rel Day of Study Medication Discontinuance†=106									
302776	Treatment Cycle 2	22	Infusion related reaction	1.58 Hours		N	Y	Interrupted	Resolved
	Treatment Cycle 3	42	Infusion related reaction	23 Hours		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0084, AN=312799, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=227									
312799	Treatment Cycle 6	124	Pneumonia	1.86 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0085, AN=312745, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=113									
312745	Treatment Cycle 4	85	Proteinuria	1.14 Weeks		N	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0094, AN=304283, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=76									
304283	Treatment Cycle 2	41	Hyponatraemia	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0095, AN=303533, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=211									
303533	Treatment Cycle 9	189	Transaminases increased	3.14 Weeks		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0095, AN=313597, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=55									
313597	Treatment Cycle 1	22	Chronic obstructive pulmonary disease	1.14 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 2	48	Hypercalcaemia	3.38 Months		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0122, AN=310300, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=248									
310300	Treatment Cycle 3	64	Infectious pleural effusion	3.94 Months		Y	N	Interrupted	Sequelae
Study Number=3475-010, Site Number=0162, AN=309081, Gender=F, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=									
309081	Treatment Cycle 4	82	Diarrhoea	4.96 Months		N	Y	Interrupted	Resolved
	Treatment Cycle 15	396	Diarrhoea	1.14 Weeks		N	N	Interrupted	Resolved
		399	Hypokalaemia	5 Days		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0180, AN=310195, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=168									
310195	Treatment Cycle 4	82	Decreased appetite	2.14 Weeks		N	Y	Interrupted	Resolved
		82	Fatigue	Continuing		N	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=0180, AN=311829, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=526									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0180, AN=311829, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=526									
311829	Treatment Cycle 5	120	Dehydration	3.86 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 7	167	Influenza like illness	1.14 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 15	397	Arthralgia	1.87 Months		N	Y	Interrupted	Resolved
	Treatment Cycle 16	454	Arthralgia	2.04 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0181, AN=301137, Gender=F, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=									
301137	Treatment Cycle 2	40	Influenza like illness	1 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 5	110	Upper respiratory tract infection	1.57 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0181, AN=307020, Gender=F, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=105									
307020	Treatment Cycle 3	63	Nasopharyngitis	6 Days		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0181, AN=313988, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
313988	Treatment Cycle 3	61	Pyloric stenosis	3.29 Weeks		Y	N	Interrupted	Resolved
		67	Diarrhoea	2 Days		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0182, AN=301268, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=162									
301268	Treatment Cycle 1	2	Decreased appetite	1.77 Months		N	Y	Interrupted	Resolved
		2	Fatigue	1.08 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0182, AN=311519, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=182									
311519	Treatment Cycle 5	89	Cough	4.14 Weeks		N	N	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0183, AN=301027, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=									
301027	Treatment Cycle 11	230	Viral infection	1.14 Weeks		N	N	Interrupted	Resolved
		239	Bradycardia	1 Weeks		Y	N	Interrupted	Resolved
		239	Hypotension	1 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0183, AN=307906, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=225									
307906	Treatment Cycle 5	125	Amylase increased	3.35 Months		N	Y	Interrupted	Resolved
	Treatment Cycle 6	208	Pulmonary embolism	5 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0183, AN=311755, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=323									
311755	Treatment Cycle 8	160	Pneumonia	1.29 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0200, AN=308329, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=469									
308329	Treatment Cycle 2	22	Hyperthyroidism	2.1 Months		N	Y	Interrupted	Resolved
	Treatment Cycle 9	203	Colitis	1.22 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0200, AN=309392, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=302									
309392	Treatment Cycle 2	43	Metastases to central nervous system	5 Days		N	N	Interrupted	Resolved
	Treatment Cycle 7	169	Renal failure	1.14 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0201, AN=305454, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=238									
305454	Treatment Cycle 9	188	Acute kidney injury	Continuing		Y	N	Interrupted	Resolving

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0202, AN=301495, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=551									
301495	Treatment Cycle 24	523	Cardiac failure	3 Days		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0202, AN=303051, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=									
303051	Treatment Cycle 4	92	Hyperamylasaemia	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0202, AN=309813, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
309813	Treatment Cycle 5	90	Rash	Continuing		N	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=0206, AN=301738, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=									
301738	Treatment Cycle 14	296	Urinary bladder polyp	1 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 21	456	Upper respiratory tract infection	4.14 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0208, AN=312441, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=21									
312441	Treatment Cycle 2	21	Back pain	3 Minutes		N	Y	Interrupted	Resolved
		21	Hypertension	3 Minutes		N	Y	Interrupted	Resolved
		21	Tachypnoea	3 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0209, AN=310208, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=68									
310208	Treatment Cycle 1	10	Respiratory tract infection	1.05 Months		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0211, AN=308531, Gender=M, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=									
308531	Treatment Cycle 1	16	Pericardial effusion	1.29 Weeks		Y	Y	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0211, AN=313160, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=147									
313160	Treatment Cycle 7	126	Infusion related reaction	23.02 Hours		N	Y	Interrupted	Resolved
	Treatment Cycle 8	147	Infusion related reaction	23.02 Hours		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0282, AN=306612, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=									
306612	Treatment Cycle 6	129	Alanine aminotransferase increased	1.18 Months		N	N	Interrupted	Resolved
		129	Aspartate aminotransferase increased	1.18 Months		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0560, AN=300343, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=266									
300343	Treatment Cycle 10	216	Chest pain	3.71 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0560, AN=307270, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=									
307270	Treatment Cycle 8	170	Influenza like illness	1 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 18	381	Pneumonitis	1.84 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0560, AN=309087, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=359									
309087	Treatment Cycle 16	319	Pneumonitis	1.35 Months		Y	Y	Interrupted	Resolved
		331	Hyperglycaemia	1.64 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0561, AN=303230, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=									
303230	Treatment Cycle 16	319	Pulmonary vascular disorder	3 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0563, AN=303662, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=85									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=0563, AN=303662, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=85									
303662	Treatment Cycle 2	22	Drug hypersensitivity	10 Minutes		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=0563, AN=310319, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=50									
310319	Treatment Cycle 1	8	Urosepsis	1.57 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0563, AN=312499, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=281									
312499	Treatment Cycle 7	154	Pleural effusion	1 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 8	169	Aspergillus infection	1.02 Months		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=0764, AN=311609, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=									
311609	Treatment Cycle 8	168	Aspartate aminotransferase increased	1.14 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1080, AN=312055, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=106									
312055	Treatment Cycle 2	34	Abdominal pain	Continuing		Y	N	Interrupted	Not Resolved
		34	Arthralgia	1.05 Months		N	Y	Interrupted	Resolved
		34	Constipation	Continuing		N	N	Interrupted	Not Resolved
		57	Hypercalcaemia	1.58 Months		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1240, AN=301043, Gender=M, Race=Asian, Age=71 Years, Rel Day of Study Medication Discontinuance†=									
301043	Treatment Cycle 8	170	Hypertriglyceridaemia	2.86 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 9	213	Hypertriglyceridaemia	3 Weeks		N	Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=1240, AN=303343, Gender=M, Race=Asian, Age=67 Years, Rel Day of Study Medication Discontinuance†=82									
303343	Safety Follow-up	97	Asthenia	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1243, AN=302791, Gender=M, Race=Asian, Age=73 Years, Rel Day of Study Medication Discontinuance†=									
302791	Treatment Cycle 22	454	Large intestinal obstruction	1.29 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1243, AN=313473, Gender=F, Race=Asian, Age=55 Years, Rel Day of Study Medication Discontinuance†=									
313473	Treatment Cycle 2 Treatment Cycle 7	22 155	Hyperthyroidism Hypothyroidism	4.37 Months Continuing		N N	Y N	Interrupted Interrupted	Resolved Resolving
Study Number=3475-010, Site Number=1243, AN=313501, Gender=M, Race=Asian, Age=68 Years, Rel Day of Study Medication Discontinuance†=									
313501	Treatment Cycle 4	64	Hypothyroidism	Continuing		N	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=1243, AN=313804, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=220									
313804	Treatment Cycle 1	21	Lung infection	2.33 Months		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1243, AN=314100, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
314100	Treatment Cycle 4	86	Radiation pneumonitis	1.14 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1245, AN=305139, Gender=M, Race=Asian, Age=56 Years, Rel Day of Study Medication Discontinuance†=22									
305139	Safety Follow-up	42	Bile duct obstruction	Continuing		N	N	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1245, AN=310534, Gender=M, Race=Asian, Age=67 Years, Rel Day of Study Medication Discontinuance†=									
310534	Treatment Cycle 7	127	Type 1 diabetes mellitus	Continuing		Y	Y	Interrupted	Not Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=1320, AN=309190, Gender=M, Race=Asian, Age=55 Years, Rel Day of Study Medication Discontinuance†=66									
309190	Treatment Cycle 1	19	Pneumonia	2.2 Months		Y	N	Interrupted	Resolved
	Treatment Cycle 2	36	Hypercapnia	1.64 Months		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1363, AN=300545, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=									
300545	Treatment Cycle 4	84	Upper respiratory tract infection	1 Weeks		N	N	Interrupted	Resolved
	Treatment Cycle 5	119	Tooth infection	1.14 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1400, AN=302342, Gender=M, Race=Asian, Age=54 Years, Rel Day of Study Medication Discontinuance†=									
302342	Treatment Cycle 1	6	Pneumonia pneumococcal	3.29 Weeks		Y	N	Interrupted	Resolved
		14	Anaemia	2.14 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 8	175	Upper respiratory tract infection	1.43 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1400, AN=308317, Gender=M, Race=Asian, Age=73 Years, Rel Day of Study Medication Discontinuance†=53									
308317	Treatment Cycle 1	9	Cerebral ischaemia	2.57 Weeks		Y	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1405, AN=312141, Gender=M, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=40									
312141	Treatment Cycle 1	16	Colitis	1.81 Months		N	Y	Interrupted	Resolved
Study Number=3475-010, Site Number=1410, AN=307796, Gender=M, Race=Asian, Age=69 Years, Rel Day of Study Medication Discontinuance†=									
307796	Treatment Cycle 3	43	Malaise	Continuing		N	Y	Interrupted	Not Resolved
	Treatment Cycle 4	102	Interstitial lung disease	Continuing		Y	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1411, AN=300216, Gender=M, Race=Asian, Age=60 Years, Rel Day of Study Medication Discontinuance†=									

C Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=1411, AN=300216, Gender=M, Race=Asian, Age=60 Years, Rel Day of Study Medication Discontinuance†=									
300216	Treatment Cycle 12	254	C-reactive protein increased	1.14 Weeks		N	Y	Interrupted	Resolved
	Treatment Cycle 13	279	Infected dermal cyst	1.57 Weeks		N	N	Interrupted	Resolved
Study Number=3475-010, Site Number=1421, AN=311479, Gender=M, Race=Asian, Age=49 Years, Rel Day of Study Medication Discontinuance†=									
311479	Treatment Cycle 11	278	Hypopituitarism	Continuing		Y	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1422, AN=313656, Gender=M, Race=Asian, Age=42 Years, Rel Day of Study Medication Discontinuance†=148									
313656	Treatment Cycle 1	15	Pneumonia	Continuing		Y	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=1424, AN=301369, Gender=F, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=									
301369	Treatment Cycle 16	323	Adrenal insufficiency	Continuing		Y	Y	Interrupted	Not Resolved
Study Number=3475-010, Site Number=1430, AN=304201, Gender=F, Race=Asian, Age=54 Years, Rel Day of Study Medication Discontinuance†=29									
304201	Treatment Cycle 1	13	Hepatic function abnormal	Continuing		N	Y	Interrupted	Not Resolved
	Safety Follow-up	36	Drug eruption	Continuing		Y	Y	Interrupted	Resolving
Study Number=3475-010, Site Number=1434, AN=314187, Gender=M, Race=Asian, Age=60 Years, Rel Day of Study Medication Discontinuance†=70									
314187	Treatment Cycle 2	32	Myalgia	1.41 Months		N	Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events Resulting in Treatment Interruption
APaT Population (TPS ≥1%)

AN	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Study Number=3475-010, Site Number=1434, AN=314187, Gender=M, Race=Asian, Age=60 Years, Rel Day of Study Medication Discontinuance[†]=70									
314187	Treatment Cycle 3	52	Malaise	3.29 Weeks		N	Y	Interrupted	Resolved

[†]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.
Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.
Related: Investigator-assessed relationship of the adverse event to study medication.
MedDRA preferred terms 'Malignant neoplasm progression' ,'Neoplasm Progression' and 'Disease Progression' not related to the drug are excluded.
After the end of treatment, each subject will be followed for a minimum of 30 days for adverse event monitoring. SAE is monitored until 90 days after last dose.
(Database Cutoff Date: 30SEP2015).

Confidential

付録 2.7.4- 57　　治験薬の投与中止に至った有害事象
（いずれかの投与群で発現割合 0%超）
001 試験＋002 試験＋006 試験＋010 試験
MK-3475 を投与された悪性黒色腫及び非小細胞肺癌患者（安全性解析対象集団）

Subjects With Adverse Events Resulting in Discontinuation
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	54	(7.9)	139	(11.3)	195	(12.4)	334	(11.9)
with no adverse events	628	(92.1)	1,093	(88.7)	1,372	(87.6)	2,465	(88.1)
Blood and lymphatic system disorders	**0**	**(0.0)**	**2**	**(0.2)**	**6**	**(0.4)**	**8**	**(0.3)**
Anaemia	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Autoimmune haemolytic anaemia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Haemolytic anaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Neutropenia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Thrombocytopenia	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Cardiac disorders	**4**	**(0.6)**	**5**	**(0.4)**	**8**	**(0.5)**	**13**	**(0.5)**
Acute coronary syndrome	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Acute myocardial infarction	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Atrial fibrillation	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Atrioventricular block complete	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Cardiac arrest	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cardiac failure	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Cardiac failure congestive	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Cardiac ventricular disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cardio-respiratory arrest	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Myocardial infarction	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Endocrine disorders	**1**	**(0.1)**	**1**	**(0.1)**	**6**	**(0.4)**	**7**	**(0.3)**
Adrenal insufficiency	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyperthyroidism	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hypophysitis	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hypopituitarism	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hypothyroidism	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Eye disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.1)**	**1**	**(0.0)**
Uveitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Gastrointestinal disorders	**1**	**(0.1)**	**7**	**(0.6)**	**31**	**(2.0)**	**38**	**(1.4)**
Abdominal distension	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Abdominal pain	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Abdominal pain upper	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Ascites	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Autoimmune pancreatitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Colitis	0	(0.0)	2	(0.2)	12	(0.8)	14	(0.5)
Diarrhoea	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Enterocolitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gastric disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gastritis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Gastrointestinal haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gastrointestinal perforation	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Impaired gastric emptying	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Intestinal perforation	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Intussusception	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Large intestine perforation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Oesophagitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pancreatitis	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Retroperitoneal haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Salivary gland disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Upper gastrointestinal haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
General disorders and administration site conditions	**4**	**(0.6)**	**19**	**(1.5)**	**27**	**(1.7)**	**46**	**(1.6)**
Asthenia	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Death	1	(0.1)	3	(0.2)	7	(0.4)	10	(0.4)
Fatigue	1	(0.1)	5	(0.4)	5	(0.3)	10	(0.4)
Gait disturbance	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
General physical health deterioration	1	(0.1)	3	(0.2)	5	(0.3)	8	(0.3)
Generalised oedema	0	(0.0)	1	(0.1)	3	(0.2)	4	(0.1)
Malaise	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
General disorders and administration site conditions	**4**	**(0.6)**	**19**	**(1.5)**	**27**	**(1.7)**	**46**	**(1.6)**
Multi-organ failure	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Oedema	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Pain	0	(0.0)	4	(0.3)	3	(0.2)	7	(0.3)
Hepatobiliary disorders	**0**	**(0.0)**	**1**	**(0.1)**	**11**	**(0.7)**	**12**	**(0.4)**
Autoimmune hepatitis	0	(0.0)	0	(0.0)	4	(0.3)	4	(0.1)
Bile duct obstruction	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Drug-induced liver injury	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hepatic failure	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Hepatic function abnormal	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hepatitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyperbilirubinaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Immune system disorders	**0**	**(0.0)**	**1**	**(0.1)**	**3**	**(0.2)**	**4**	**(0.1)**
Anaphylactoid reaction	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Autoimmune disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Drug hypersensitivity	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Serum sickness	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Infections and infestations	**2**	**(0.3)**	**14**	**(1.1)**	**9**	**(0.6)**	**23**	**(0.8)**
Bronchitis	0	(0.0)	2	(0.2)	0	(0.0)	2	(0.1)
Cellulitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Encephalitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Herpes zoster	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Infectious pleural effusion	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Localised infection	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Lung infection	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pneumonia	2	(0.3)	6	(0.5)	1	(0.1)	7	(0.3)
Pulmonary sepsis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Respiratory tract infection	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Sepsis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Septic shock	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Soft tissue infection	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Infections and infestations	**2**	**(0.3)**	**14**	**(1.1)**	**9**	**(0.6)**	**23**	**(0.8)**
Thrombophlebitis septic	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Urinary tract infection	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Injury, poisoning and procedural complications	**2**	**(0.3)**	**2**	**(0.2)**	**4**	**(0.3)**	**6**	**(0.2)**
Facial bones fracture	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pneumonitis chemical	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Radiation pneumonitis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Traumatic intracranial haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Wound decomposition	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Wound haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Investigations	**1**	**(0.1)**	**3**	**(0.2)**	**5**	**(0.3)**	**8**	**(0.3)**
Alanine aminotransferase increased	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Aspartate aminotransferase increased	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Blood bilirubin increased	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Gamma-glutamyltransferase increased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Intraocular pressure decreased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Lipase increased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Weight decreased	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Metabolism and nutrition disorders	**1**	**(0.1)**	**4**	**(0.3)**	**12**	**(0.8)**	**16**	**(0.6)**
Cachexia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Decreased appetite	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Failure to thrive	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Gout	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hypercalcaemia	0	(0.0)	2	(0.2)	1	(0.1)	3	(0.1)
Hypoalbuminaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Metabolism and nutrition disorders	**1**	**(0.1)**	**4**	**(0.3)**	**12**	**(0.8)**	**16**	**(0.6)**
Hypoglycaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyponatraemia	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
Insulin resistant diabetes	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Malnutrition	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Type 1 diabetes mellitus	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Musculoskeletal and connective tissue disorders	**3**	**(0.4)**	**8**	**(0.6)**	**17**	**(1.1)**	**25**	**(0.9)**
Arthralgia	1	(0.1)	2	(0.2)	4	(0.3)	6	(0.2)
Arthritis	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Back pain	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Bone pain	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Joint stiffness	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Muscle necrosis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Musculoskeletal pain	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myalgia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myopathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myositis	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Neck pain	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Pain in extremity	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Polyarthritis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Rhabdomyolysis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Sjogren's syndrome	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Tenosynovitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**3**	**(0.4)**	**5**	**(0.4)**	**13**	**(0.8)**	**18**	**(0.6)**
Cancer pain	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Gastric cancer	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Intracranial tumour haemorrhage	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Invasive ductal breast carcinoma	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Lung neoplasm malignant	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**3**	**(0.4)**	**5**	**(0.4)**	**13**	**(0.8)**	**18**	**(0.6)**
Lymphangiosis carcinomatosa	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Malignant neoplasm progression	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Metastases to central nervous system	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Metastases to meninges	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Metastatic malignant melanoma	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Prostate cancer	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Squamous cell carcinoma	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Tumour necrosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Tumour pain	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Nervous system disorders	**6**	**(0.9)**	**8**	**(0.6)**	**19**	**(1.2)**	**27**	**(1.0)**
Ataxia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Axonal neuropathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Brain oedema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cerebrovascular accident	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Cognitive disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Embolic stroke	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Epilepsy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Haemorrhage intracranial	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hemiparesis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Ischaemic stroke	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Migraine	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myelitis transverse	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Neuralgia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Optic neuritis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Partial seizures	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Peripheral sensory neuropathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Polyneuropathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Seizure	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Nervous system disorders	**6**	**(0.9)**	**8**	**(0.6)**	**19**	**(1.2)**	**27**	**(1.0)**
Spinal cord compression	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
Toxic leukoencephalopathy	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Vasogenic cerebral oedema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Psychiatric disorders	**1**	**(0.1)**	**1**	**(0.1)**	**2**	**(0.1)**	**3**	**(0.1)**
Completed suicide	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Depression	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Disorientation	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Renal and urinary disorders	**1**	**(0.1)**	**2**	**(0.2)**	**5**	**(0.3)**	**7**	**(0.3)**
Acute kidney injury	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Hydronephrosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Renal failure	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Tubulointerstitial nephritis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Respiratory, thoracic and mediastinal disorders	**20**	**(2.9)**	**55**	**(4.5)**	**23**	**(1.5)**	**78**	**(2.8)**
Acute respiratory failure	0	(0.0)	2	(0.2)	0	(0.0)	2	(0.1)
Bronchostenosis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Chronic obstructive pulmonary disease	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Cough	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Diffuse alveolar damage	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Dyspnoea	2	(0.3)	6	(0.5)	5	(0.3)	11	(0.4)
Haemoptysis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Hypoxia	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Interstitial lung disease	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Pleural effusion	1	(0.1)	6	(0.5)	1	(0.1)	7	(0.3)
Pneumonia aspiration	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Pneumonitis	12	(1.8)	23	(1.9)	11	(0.7)	34	(1.2)
Pneumothorax	0	(0.0)	2	(0.2)	1	(0.1)	3	(0.1)
Pulmonary embolism	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)

C Confidential

Subjects With Adverse Events Resulting in Discontinuation
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Respiratory, thoracic and mediastinal disorders	**20**	**(2.9)**	**55**	**(4.5)**	**23**	**(1.5)**	**78**	**(2.8)**
Pulmonary haemorrhage	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Pulmonary vascular disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Respiratory distress	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Respiratory failure	1	(0.1)	7	(0.6)	1	(0.1)	8	(0.3)
Skin and subcutaneous tissue disorders	**1**	**(0.1)**	**3**	**(0.2)**	**6**	**(0.4)**	**9**	**(0.3)**
Hyperkeratosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Lichen planus	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Pruritus	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Psoriasis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Rash	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Skin lesion	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Stevens-Johnson syndrome	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Vitiligo	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Vascular disorders	**3**	**(0.4)**	**5**	**(0.4)**	**2**	**(0.1)**	**7**	**(0.3)**
Arterial thrombosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Embolism	1	(0.1)	3	(0.2)	0	(0.0)	3	(0.1)
Femoral artery occlusion	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Haemorrhagic infarction	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Peripheral ischaemia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.

Include all treated subjects in PN001 Part B1, B2, B3, D, C, F1, F2, F3 and all subjects in PN002 treated with Pembrolizumab in the original phase , and all subjects in PN006 and PN010 treated with Pembrolizumab.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

付録 2.7.4- 58　　治験薬の投与中止に至った副作用
（いずれかの投与群で発現割合 0%超）
001 試験＋002 試験＋006 試験＋010 試験
MK-3475 を投与された悪性黒色腫及び非小細胞肺癌患者（安全性解析対象集団）

Subjects With Drug-Related Adverse Events Resulting in Discontinuation
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	32	(4.7)	57	(4.6)	89	(5.7)	146	(5.2)
with no adverse events	650	(95.3)	1,175	(95.4)	1,478	(94.3)	2,653	(94.8)
Blood and lymphatic system disorders	**0**	**(0.0)**	**2**	**(0.2)**	**2**	**(0.1)**	**4**	**(0.1)**
Autoimmune haemolytic anaemia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Haemolytic anaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Neutropenia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Thrombocytopenia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cardiac disorders	**1**	**(0.1)**	**2**	**(0.2)**	**0**	**(0.0)**	**2**	**(0.1)**
Atrioventricular block complete	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Cardio-respiratory arrest	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Endocrine disorders	**1**	**(0.1)**	**1**	**(0.1)**	**6**	**(0.4)**	**7**	**(0.3)**
Adrenal insufficiency	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyperthyroidism	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hypophysitis	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hypopituitarism	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hypothyroidism	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Eye disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.1)**	**1**	**(0.0)**
Uveitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gastrointestinal disorders	**1**	**(0.1)**	**4**	**(0.3)**	**20**	**(1.3)**	**24**	**(0.9)**
Autoimmune pancreatitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Colitis	0	(0.0)	2	(0.2)	12	(0.8)	14	(0.5)
Diarrhoea	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Enterocolitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gastritis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Impaired gastric emptying	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Oesophagitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pancreatitis	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Salivary gland disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

C Confidential

Subjects With Drug-Related Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
General disorders and administration site conditions	**1**	**(0.1)**	**2**	**(0.2)**	**6**	**(0.4)**	**8**	**(0.3)**
Fatigue	1	(0.1)	1	(0.1)	4	(0.3)	5	(0.2)
Generalised oedema	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Hepatobiliary disorders	**0**	**(0.0)**	**0**	**(0.0)**	**7**	**(0.4)**	**7**	**(0.3)**
Autoimmune hepatitis	0	(0.0)	0	(0.0)	4	(0.3)	4	(0.1)
Drug-induced liver injury	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hepatitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyperbilirubinaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Immune system disorders	**0**	**(0.0)**	**1**	**(0.1)**	**3**	**(0.2)**	**4**	**(0.1)**
Anaphylactoid reaction	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Autoimmune disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Drug hypersensitivity	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Serum sickness	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Infections and infestations	**1**	**(0.1)**	**1**	**(0.1)**	**1**	**(0.1)**	**2**	**(0.1)**
Encephalitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pneumonia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Injury, poisoning and procedural complications	**1**	**(0.1)**	**1**	**(0.1)**	**0**	**(0.0)**	**1**	**(0.0)**
Pneumonitis chemical	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Investigations	**1**	**(0.1)**	**2**	**(0.2)**	**5**	**(0.3)**	**7**	**(0.3)**
Alanine aminotransferase increased	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Aspartate aminotransferase increased	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Blood bilirubin increased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gamma-glutamyltransferase increased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

Confidential

Subjects With Drug-Related Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Investigations	**1**	**(0.1)**	**2**	**(0.2)**	**5**	**(0.3)**	**7**	**(0.3)**
Intraocular pressure decreased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Lipase increased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Weight decreased	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Metabolism and nutrition disorders	**1**	**(0.1)**	**1**	**(0.1)**	**4**	**(0.3)**	**5**	**(0.2)**
Decreased appetite	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyponatraemia	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Insulin resistant diabetes	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Type 1 diabetes mellitus	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Musculoskeletal and connective tissue disorders	**2**	**(0.3)**	**3**	**(0.2)**	**12**	**(0.8)**	**15**	**(0.5)**
Arthralgia	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Arthritis	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Joint stiffness	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Muscle necrosis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Myalgia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myopathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myositis	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Polyarthritis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Rhabdomyolysis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Sjogren's syndrome	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Tenosynovitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**1**	**(0.1)**	**1**	**(0.1)**	**0**	**(0.0)**	**1**	**(0.0)**
Malignant neoplasm progression	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Nervous system disorders	**4**	**(0.6)**	**5**	**(0.4)**	**6**	**(0.4)**	**11**	**(0.4)**
Ataxia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Cerebrovascular accident	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

Confidential

Subjects With Drug-Related Adverse Events Resulting in Discontinuation (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Nervous system disorders	**4**	**(0.6)**	**5**	**(0.4)**	**6**	**(0.4)**	**11**	**(0.4)**
Cognitive disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Epilepsy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myelitis transverse	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Neuralgia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Optic neuritis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Partial seizures	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Peripheral sensory neuropathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Polyneuropathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Toxic leukoencephalopathy	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Psychiatric disorders	**1**	**(0.1)**	**1**	**(0.1)**	**0**	**(0.0)**	**1**	**(0.0)**
Disorientation	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Renal and urinary disorders	**1**	**(0.1)**	**2**	**(0.2)**	**2**	**(0.1)**	**4**	**(0.1)**
Acute kidney injury	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Renal failure	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Tubulointerstitial nephritis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Respiratory, thoracic and mediastinal disorders	**13**	**(1.9)**	**26**	**(2.1)**	**14**	**(0.9)**	**40**	**(1.4)**
Cough	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Dyspnoea	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Hypoxia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Interstitial lung disease	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Pleural effusion	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pneumonitis	12	(1.8)	23	(1.9)	11	(0.7)	34	(1.2)
Respiratory failure	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Skin and subcutaneous tissue disorders	**1**	**(0.1)**	**3**	**(0.2)**	**4**	**(0.3)**	**7**	**(0.3)**
Hyperkeratosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Lichen planus	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Pruritus	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Psoriasis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Rash	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Drug-Related Adverse Events Resulting in Discontinuation
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Skin and subcutaneous tissue disorders	**1**	**(0.1)**	**3**	**(0.2)**	**4**	**(0.3)**	**7**	**(0.3)**
Stevens-Johnson syndrome	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Vitiligo	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Vascular disorders	**1**	**(0.1)**	**1**	**(0.1)**	**1**	**(0.1)**	**2**	**(0.1)**
Arterial thrombosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Peripheral ischaemia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Include all treated subjects in PN001 Part B1, B2, B3, D, C, F1, F2, F3 and all subjects in PN002 treated with Pembrolizumab in the original phase , and all subjects in PN006 and PN010 treated with Pembrolizumab.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

付録 2.7.4- 59　　治験薬の休薬に至った有害事象
（いずれかの投与群で発現割合 0%超）
001 試験＋002 試験＋006 試験＋010 試験
MK-3475 を投与された悪性黒色腫及び非小細胞肺癌患者（安全性解析対象集団）

Subjects With Adverse Events Resulting in Treatment Interruption
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	156	(22.9)	265	(21.5)	357	(22.8)	622	(22.2)
with no adverse events	526	(77.1)	967	(78.5)	1,210	(77.2)	2,177	(77.8)
Blood and lymphatic system disorders	**7**	**(1.0)**	**9**	**(0.7)**	**19**	**(1.2)**	**28**	**(1.0)**
Anaemia	5	(0.7)	6	(0.5)	14	(0.9)	20	(0.7)
Leukopenia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Neutropenia	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Normochromic normocytic anaemia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Splenomegaly	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Thrombocytopenia	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Cardiac disorders	**8**	**(1.2)**	**12**	**(1.0)**	**8**	**(0.5)**	**20**	**(0.7)**
Acute coronary syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Angina unstable	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Atrial fibrillation	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
Atrial thrombosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Bradycardia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Cardiac failure	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Cardiac failure congestive	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cardiac tamponade	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Cardio-respiratory arrest	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Coronary artery disease	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Palpitations	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Pericardial effusion	3	(0.4)	4	(0.3)	1	(0.1)	5	(0.2)
Congenital, familial and genetic disorders	**1**	**(0.1)**	**1**	**(0.1)**	**0**	**(0.0)**	**1**	**(0.0)**
Pyloric stenosis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Ear and labyrinth disorders	**1**	**(0.1)**	**1**	**(0.1)**	**1**	**(0.1)**	**2**	**(0.1)**
Deafness	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Vertigo	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Endocrine disorders	**9**	**(1.3)**	**14**	**(1.1)**	**20**	**(1.3)**	**34**	**(1.2)**
Adrenal insufficiency	3	(0.4)	5	(0.4)	3	(0.2)	8	(0.3)
Hyperthyroidism	3	(0.4)	3	(0.2)	4	(0.3)	7	(0.3)
Hypophysitis	0	(0.0)	1	(0.1)	4	(0.3)	5	(0.2)
Hypopituitarism	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Hypothalamo-pituitary disorder	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Hypothyroidism	3	(0.4)	5	(0.4)	8	(0.5)	13	(0.5)
Myxoedema	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Thyroiditis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Eye disorders	**3**	**(0.4)**	**3**	**(0.2)**	**11**	**(0.7)**	**14**	**(0.5)**
Cataract	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Conjunctival haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Eye irritation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Eye pruritus	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Eyelash discolouration	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Iritis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Papilloedema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Retinal tear	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Uveitis	0	(0.0)	0	(0.0)	4	(0.3)	4	(0.1)
Vision blurred	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Visual impairment	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Gastrointestinal disorders	**18**	**(2.6)**	**34**	**(2.8)**	**67**	**(4.3)**	**101**	**(3.6)**
Abdominal pain	2	(0.3)	2	(0.2)	4	(0.3)	6	(0.2)
Abdominal pain lower	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Abdominal pain upper	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Colitis	4	(0.6)	5	(0.4)	8	(0.5)	13	(0.5)
Constipation	2	(0.3)	2	(0.2)	2	(0.1)	4	(0.1)
Diarrhoea	7	(1.0)	13	(1.1)	32	(2.0)	45	(1.6)
Dry mouth	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Dysphagia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Faeces soft	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gastric haemorrhage	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Gastric perforation	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Gastritis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gastritis erosive	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Gastrointestinal disorders	**18**	**(2.6)**	**34**	**(2.8)**	**67**	**(4.3)**	**101**	**(3.6)**
Gastrointestinal disorder	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Gastrointestinal haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Glossitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Haematochezia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Intestinal obstruction	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Intussusception	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Irritable bowel syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Large intestinal obstruction	2	(0.3)	2	(0.2)	0	(0.0)	2	(0.1)
Melaena	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Nausea	1	(0.1)	5	(0.4)	9	(0.6)	14	(0.5)
Pancreatitis	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
Rectal haemorrhage	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Small intestinal obstruction	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Small intestinal perforation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Stomatitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Vomiting	3	(0.4)	6	(0.5)	5	(0.3)	11	(0.4)
General disorders and administration site conditions	**20**	**(2.9)**	**35**	**(2.8)**	**51**	**(3.3)**	**86**	**(3.1)**
Adverse drug reaction	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Asthenia	2	(0.3)	6	(0.5)	4	(0.3)	10	(0.4)
Chest discomfort	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Chest pain	2	(0.3)	3	(0.2)	1	(0.1)	4	(0.1)
Chills	0	(0.0)	2	(0.2)	1	(0.1)	3	(0.1)
Face oedema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Fatigue	9	(1.3)	14	(1.1)	13	(0.8)	27	(1.0)
Feeling hot	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
General physical health deterioration	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Generalised oedema	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Inflammation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Influenza like illness	3	(0.4)	3	(0.2)	3	(0.2)	6	(0.2)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
General disorders and administration site conditions	**20**	**(2.9)**	**35**	**(2.8)**	**51**	**(3.3)**	**86**	**(3.1)**
Infusion site extravasation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Injection site extravasation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Localised oedema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Malaise	2	(0.3)	2	(0.2)	4	(0.3)	6	(0.2)
Mucosal inflammation	0	(0.0)	0	(0.0)	4	(0.3)	4	(0.1)
Nodule	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Oedema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Oedema peripheral	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)
Pain	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
Pyrexia	2	(0.3)	7	(0.6)	7	(0.4)	14	(0.5)
Systemic inflammatory response syndrome	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hepatobiliary disorders	**5**	**(0.7)**	**6**	**(0.5)**	**14**	**(0.9)**	**20**	**(0.7)**
Autoimmune hepatitis	2	(0.3)	2	(0.2)	3	(0.2)	5	(0.2)
Bile duct obstruction	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Biliary dilatation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cholecystitis	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Cholestasis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Drug-induced liver injury	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hepatic function abnormal	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Hepatic pain	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Hepatitis	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Hepatocellular injury	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Hepatomegaly	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyperbilirubinaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Liver disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Immune system disorders	**2**	**(0.3)**	**4**	**(0.3)**	**4**	**(0.3)**	**8**	**(0.3)**
Anaphylactic reaction	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Drug hypersensitivity	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Hypersensitivity	0	(0.0)	2	(0.2)	3	(0.2)	5	(0.2)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Infections and infestations	**36**	**(5.3)**	**63**	**(5.1)**	**56**	**(3.6)**	**119**	**(4.3)**
Appendicitis perforated	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Arthritis bacterial	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Aspergillus infection	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Atypical pneumonia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Bronchitis	0	(0.0)	2	(0.2)	2	(0.1)	4	(0.1)
Bronchopneumonia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Catheter site infection	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cellulitis	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Cellulitis streptococcal	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Conjunctivitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Diverticulitis	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Erysipelas	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Gastroenteritis	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
Herpes simplex	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Herpes zoster	2	(0.3)	2	(0.2)	0	(0.0)	2	(0.1)
Infected dermal cyst	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Infectious colitis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Infectious pleural effusion	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Infective exacerbation of chronic obstructive airways disease	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Influenza	2	(0.3)	2	(0.2)	4	(0.3)	6	(0.2)
Lower respiratory tract infection	1	(0.1)	3	(0.2)	3	(0.2)	6	(0.2)
Lung infection	2	(0.3)	5	(0.4)	1	(0.1)	6	(0.2)
Nasopharyngitis	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
Oesophageal candidiasis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Pelvic abscess	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pneumonia	7	(1.0)	16	(1.3)	4	(0.3)	20	(0.7)
Pneumonia cryptococcal	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Pneumonia klebsiella	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pneumonia pneumococcal	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Pneumonia viral	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Rash pustular	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Infections and infestations	**36**	**(5.3)**	**63**	**(5.1)**	**56**	**(3.6)**	**119**	**(4.3)**
Respiratory tract infection	4	(0.6)	4	(0.3)	1	(0.1)	5	(0.2)
Respiratory tract infection viral	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Sepsis	0	(0.0)	1	(0.1)	3	(0.2)	4	(0.1)
Sinusitis	1	(0.1)	2	(0.2)	0	(0.0)	2	(0.1)
Skin infection	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Soft tissue infection	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Spinal cord infection	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Staphylococcal infection	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Tooth abscess	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Tooth infection	1	(0.1)	2	(0.2)	0	(0.0)	2	(0.1)
Tuberculosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Upper respiratory tract infection	4	(0.6)	7	(0.6)	10	(0.6)	17	(0.6)
Urinary tract infection	0	(0.0)	0	(0.0)	8	(0.5)	8	(0.3)
Urosepsis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Viral infection	1	(0.1)	2	(0.2)	2	(0.1)	4	(0.1)
Injury, poisoning and procedural complications	**6**	**(0.9)**	**12**	**(1.0)**	**11**	**(0.7)**	**23**	**(0.8)**
Hip fracture	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Infusion related reaction	4	(0.6)	8	(0.6)	8	(0.5)	16	(0.6)
Laceration	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Ligament sprain	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Post procedural urine leak	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Procedural pain	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Radiation necrosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Radiation pneumonitis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Investigations	**19**	**(2.8)**	**29**	**(2.4)**	**43**	**(2.7)**	**72**	**(2.6)**
Alanine aminotransferase increased	6	(0.9)	11	(0.9)	17	(1.1)	28	(1.0)
Amylase increased	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Investigations	**19**	**(2.8)**	**29**	**(2.4)**	**43**	**(2.7)**	**72**	**(2.6)**
Aspartate aminotransferase increased	8	(1.2)	12	(1.0)	16	(1.0)	28	(1.0)
Bilirubin conjugated increased	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Blood alkaline phosphatase increased	2	(0.3)	2	(0.2)	2	(0.1)	4	(0.1)
Blood bilirubin increased	0	(0.0)	1	(0.1)	9	(0.6)	10	(0.4)
Blood corticotrophin decreased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Blood cortisol decreased	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Blood creatine phosphokinase increased	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Blood creatinine increased	4	(0.6)	4	(0.3)	4	(0.3)	8	(0.3)
Blood prolactin increased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Blood testosterone decreased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
C-reactive protein increased	2	(0.3)	2	(0.2)	1	(0.1)	3	(0.1)
Cardiac murmur functional	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Gamma-glutamyltransferase increased	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
Haemoglobin decreased	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Liver function test abnormal	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Quality of life decreased	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Transaminases increased	1	(0.1)	3	(0.2)	1	(0.1)	4	(0.1)
Weight decreased	3	(0.4)	5	(0.4)	1	(0.1)	6	(0.2)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Metabolism and nutrition disorders	**23**	**(3.4)**	**31**	**(2.5)**	**30**	**(1.9)**	**61**	**(2.2)**
Cell death	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Decreased appetite	9	(1.3)	10	(0.8)	4	(0.3)	14	(0.5)
Dehydration	2	(0.3)	4	(0.3)	5	(0.3)	9	(0.3)
Diabetic metabolic decompensation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Failure to thrive	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Hyperamylasaemia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Hypercalcaemia	3	(0.4)	4	(0.3)	0	(0.0)	4	(0.1)
Hyperglycaemia	2	(0.3)	2	(0.2)	0	(0.0)	2	(0.1)
Hyperkalaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hypermagnesaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hyperphosphataemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hypertriglyceridaemia	2	(0.3)	2	(0.2)	2	(0.1)	4	(0.1)
Hyperuricaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hypoalbuminaemia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hypokalaemia	1	(0.1)	2	(0.2)	1	(0.1)	3	(0.1)
Hypomagnesaemia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Hyponatraemia	1	(0.1)	3	(0.2)	10	(0.6)	13	(0.5)
Hypophosphataemia	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
Lactic acidosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Type 1 diabetes mellitus	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Musculoskeletal and connective tissue disorders	**13**	**(1.9)**	**22**	**(1.8)**	**34**	**(2.2)**	**56**	**(2.0)**
Arthralgia	4	(0.6)	6	(0.5)	12	(0.8)	18	(0.6)
Arthritis	1	(0.1)	2	(0.2)	3	(0.2)	5	(0.2)
Arthropathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Back pain	1	(0.1)	3	(0.2)	7	(0.4)	10	(0.4)
Bone pain	2	(0.3)	2	(0.2)	0	(0.0)	2	(0.1)
Chondrocalcinosis pyrophosphate	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Intervertebral disc protrusion	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Muscle spasms	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Muscular weakness	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Musculoskeletal chest pain	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Musculoskeletal and connective tissue disorders	**13**	**(1.9)**	**22**	**(1.8)**	**34**	**(2.2)**	**56**	**(2.0)**
Musculoskeletal pain	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Myalgia	1	(0.1)	3	(0.2)	5	(0.3)	8	(0.3)
Myopathy	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Myositis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pathological fracture	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Polyarthritis	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Spinal osteoarthritis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Synovitis	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Tendonitis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**1**	**(0.1)**	**5**	**(0.4)**	**6**	**(0.4)**	**11**	**(0.4)**
Leiomyosarcoma	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Malignant pleural effusion	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Metastases to central nervous system	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Metastases to large intestine	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Metastatic malignant melanoma	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Neoplasm malignant	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Oncologic complication	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pericardial effusion malignant	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Tumour haemorrhage	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Tumour pain	0	(0.0)	2	(0.2)	0	(0.0)	2	(0.1)
Nervous system disorders	**7**	**(1.0)**	**14**	**(1.1)**	**21**	**(1.3)**	**35**	**(1.3)**
Amnesia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Aphasia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Cerebral ischaemia	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Cerebrovascular accident	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Cognitive disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Nervous system disorders	**7**	**(1.0)**	**14**	**(1.1)**	**21**	**(1.3)**	**35**	**(1.3)**
Dizziness	4	(0.6)	4	(0.3)	0	(0.0)	4	(0.1)
Epilepsy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Headache	1	(0.1)	1	(0.1)	4	(0.3)	5	(0.2)
Hemiparesis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Ischaemic stroke	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Meningitis noninfective	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Myasthenic syndrome	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Neuralgia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Neuropathy peripheral	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Normal pressure hydrocephalus	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Polyneuropathy	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Presyncope	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Restless legs syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Seizure	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Syncope	0	(0.0)	1	(0.1)	2	(0.1)	3	(0.1)
Transient ischaemic attack	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Vasogenic cerebral oedema	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Psychiatric disorders	**2**	**(0.3)**	**3**	**(0.2)**	**5**	**(0.3)**	**8**	**(0.3)**
Anxiety	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Binge eating	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Confusional state	0	(0.0)	1	(0.1)	3	(0.2)	4	(0.1)
Depression	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Insomnia	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Mental status changes	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Renal and urinary disorders	**6**	**(0.9)**	**8**	**(0.6)**	**9**	**(0.6)**	**17**	**(0.6)**
Acute kidney injury	2	(0.3)	2	(0.2)	2	(0.1)	4	(0.1)
Chronic kidney disease	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Dysuria	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Microalbuminuria	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Proteinuria	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Renal failure	2	(0.3)	2	(0.2)	4	(0.3)	6	(0.2)
Tubulointerstitial nephritis	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Renal and urinary disorders	**6**	**(0.9)**	**8**	**(0.6)**	**9**	**(0.6)**	**17**	**(0.6)**
Urinary bladder polyp	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Respiratory, thoracic and mediastinal disorders	**25**	**(3.7)**	**49**	**(4.0)**	**46**	**(2.9)**	**95**	**(3.4)**
Atelectasis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Bronchiectasis	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Bronchospasm	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Chronic obstructive pulmonary disease	3	(0.4)	5	(0.4)	1	(0.1)	6	(0.2)
Cough	2	(0.3)	5	(0.4)	6	(0.4)	11	(0.4)
Dyspnoea	3	(0.4)	9	(0.7)	11	(0.7)	20	(0.7)
Haemoptysis	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
Hypercapnia	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Hypoxia	1	(0.1)	2	(0.2)	0	(0.0)	2	(0.1)
Interstitial lung disease	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Laryngeal inflammation	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Lung disorder	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Nasal congestion	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Obstructive airways disorder	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Pleural effusion	3	(0.4)	5	(0.4)	3	(0.2)	8	(0.3)
Pneumonitis	7	(1.0)	12	(1.0)	12	(0.8)	24	(0.9)
Pneumothorax	0	(0.0)	2	(0.2)	0	(0.0)	2	(0.1)
Pneumothorax spontaneous	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Productive cough	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Pulmonary embolism	3	(0.4)	5	(0.4)	5	(0.3)	10	(0.4)
Pulmonary oedema	0	(0.0)	2	(0.2)	1	(0.1)	3	(0.1)
Pulmonary thrombosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pulmonary vascular disorder	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Respiratory failure	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Rhinorrhoea	1	(0.1)	2	(0.2)	0	(0.0)	2	(0.1)
Tachypnoea	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Throat tightness	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Skin and subcutaneous tissue disorders	**7**	**(1.0)**	**13**	**(1.1)**	**37**	**(2.4)**	**50**	**(1.8)**

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption (Incidence > 0% in One or More Treatment Groups) PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475 (APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Skin and subcutaneous tissue disorders	**7**	**(1.0)**	**13**	**(1.1)**	**37**	**(2.4)**	**50**	**(1.8)**
Dermatitis	0	(0.0)	2	(0.2)	0	(0.0)	2	(0.1)
Drug eruption	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Eczema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Erythema	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Erythema multiforme	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Hyperkeratosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Lichen planus	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Lichenoid keratosis	0	(0.0)	1	(0.1)	1	(0.1)	2	(0.1)
Neutrophilic dermatosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Night sweats	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pain of skin	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Palmar-plantar erythrodysaesthesia syndrome	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pemphigoid	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Penile ulceration	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Pruritus	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)
Psoriasis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Rash	3	(0.4)	4	(0.3)	10	(0.6)	14	(0.5)
Rash erythematous	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Rash generalised	0	(0.0)	0	(0.0)	3	(0.2)	3	(0.1)
Rash maculo-papular	1	(0.1)	1	(0.1)	11	(0.7)	12	(0.4)
Vitiligo	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Vascular disorders	**6**	**(0.9)**	**8**	**(0.6)**	**6**	**(0.4)**	**14**	**(0.5)**
Aortic stenosis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Embolism	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Flushing	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hypertension	2	(0.3)	3	(0.2)	1	(0.1)	4	(0.1)
Hypotension	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Pallor	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Peripheral ischaemia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Superior vena cava occlusion	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Superior vena cava syndrome	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

C Confidential

Subjects With Adverse Events Resulting in Treatment Interruption
(Incidence > 0% in One or More Treatment Groups)
PN001, PN002, PN006 and PN010 Melanoma and Lung Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Vascular disorders	**6**	**(0.9)**	**8**	**(0.6)**	**6**	**(0.4)**	**14**	**(0.5)**
Thrombosis	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.

Include all treated subjects in PN001 Part B1, B2, B3, D, C, F1, F2, F3 and all subjects in PN002 treated with Pembrolizumab in the original phase , and all subjects in PN006 and PN010 treated with Pembrolizumab.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

付録 2.7.4- 60　　AEOSI の PT リスト

（v9 RMST 16-Oct-2015）010 試験

Adverse Events of Special Interest (AEOSI) Preferred Terms
(v9 RMST 16-Oct-2015)

Important identified risks
Pneumonitis Acute interstitial pneumonitis, interstitial lung disease, pneumonitis, and idiopathic pneumonia syndrome
Colitis Colitis, colitis microscopic, enterocolitis, enterocolitis haemorrhagic, necrotising colitis, colitis erosive
Hepatic Hepatitis, Autoimmune hepatitis, hepatitis acute, hepatitis fulminant, drug-induced liver injury
Renal Nephritis, nephritis autoimmune, chronic autoimmune glomerulonephritis, fibrillary glomerulonephritis, focal segmental glomerulosclerosis, glomerulonephritis, glomerulonephritis acute, glomerulonephritis membranoproliferative, glomerulonephritis membranous, glomerulonephritis minimal lesion, glomerulonephritis proliferative, glomerulonephritis rapidly progressive, mesangioproliferative glomerulonephritis, nephritis haemorrhagic, tubulointerstitial nephritis, nephrotic syndrome
Endocrine disorders Adrenal insufficiency: Adrenal insufficiency, adrenocortical insufficiency acute, secondary adrenocortical insufficiency Hypophysitis: Hypophysitis, hypopituitarism, lymphocytic hypophysitis Hyperthyroidisim: Hyperthyroidism, Basedow's disease, thyrotoxic crisis Hypothyroidism: Hypothyroidism, hypothyroidic goitre, myxoedema, myxoedema coma, primary hypothyroidism Thyroiditis: Thyroid disorder, thyroiditis, autoimmune thyroiditis, thyroiditis acute Type I Diabetes Mellitus: Diabetic ketoacidosis, diabetic ketoacidotic hyperglycaemic coma, fulminant type 1 diabetes mellitus, latent autoimmune diabetes in adults, type 1 diabetes mellitus

C Confidential

Other immune-mediated events
Uveitis Iritis, uveitis, cyclitis, intermediate uveitis, iridocyclitis
Pancreatitis Pancreatitis, Autoimmune pancreatitis, Pancreatitis acute, Pancreatitis haemorrhagic, Pancreatitis necrotizing
Myositis Myositis, Necrotising myositis, Polymyositis, Immune-mediated necrotising myopathy, Rhabdomyolysis, Myopathy
Guillain-Barré Syndrome Demyelinating polyneuropathy, Guillain-Barre syndrome, Axonal neuropathy, Multifocal motor neuropathy, Polyneuropathy idiopathic progressive, Miller Fisher syndrome
Skin *Any grade from severe cutaneous reactions SMQ narrow*: Acute generalised exanthematous pustulosis, Cutaneous vasculitis, Dermatitis bullous, Dermatitis exfoliative, Dermatitis exfoliative generalized, Drug reaction with eosinophilia and systemic symptoms, Epidermal necrosis, Erythema multiforme, Exfoliative rash, Oculomucocutaneous syndrome, Skin necrosis, Stevens-Johnson syndrome, Toxic epidermal necrolysis and Toxic skin eruption *If ≥ Grade 3*: Any event from the Epidermal and dermal conditions HLGT of the Skin and subcutaneous tissue disorders SOC
Infusion reactions Hypersensitivity, drug hypersensitivity, anaphylactic reaction, cytokine release syndrome, serum sickness, serum sickness-like reaction, infusion related reaction
Important potential risks
Myasthenic syndrome Myasthenic syndrome, Myasthenia gravis, Myasthenia gravis crisis, Ocular myasthenia
Other AEOSI
Hematologic: Autoimmune haemolytic anaemia, cold type haemolytic anaemia, warm type haemolytic anaemia, autoimmune pancytopenia Neuropathy: Autoimmune neuropathy, small fibre neuropathy Myocarditis: Myocarditis, Autoimmune myocarditis Pericarditis: Pericarditis, Pleuropericarditis Vasculitis: Vasculitis, Vasculitis necrotising, Anti-neutrophil cytoplasmic antibody positive vasculitis, Granulomatosis with polyangiitis, Diffuse vasculitis, Pulmonary vasculitis

Abbreviations: HLGT = high level group terms; SMQ = standardized MedDRA query; SOC = system organ class.

Confidential

付録 2.7.4- 61　　免疫関連の肺臓炎の AEOSI 解析

001 試験＋002 試験＋006 試験＋010 試験

MK-3475 を投与された悪性黒色腫及び非小細胞肺癌患者（安全性解析対象集団）

Adverse Event Summary
AEOSI - Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	31	(4.5)	54	(4.4)	40	(2.6)	94	(3.4)
with no adverse event	651	(95.5)	1,178	(95.6)	1,527	(97.4)	2,705	(96.6)
with drug-related† adverse events	29	(4.3)	51	(4.1)	36	(2.3)	87	(3.1)
with Grade 3- 5 adverse events	14	(2.1)	25	(2.0)	11	(0.7)	36	(1.3)
with Grade 3- 5 drug-related adverse events	12	(1.8)	23	(1.9)	11	(0.7)	34	(1.2)
with serious adverse events	18	(2.6)	33	(2.7)	16	(1.0)	49	(1.8)
with serious drug-related adverse events	16	(2.3)	31	(2.5)	16	(1.0)	47	(1.7)
who died	3	(0.4)	4	(0.3)	0	(0.0)	4	(0.1)
with drug-related death	3	(0.4)	4	(0.3)	0	(0.0)	4	(0.1)
discontinued‡ due to an adverse event	12	(1.8)	24	(1.9)	12	(0.8)	36	(1.3)
discontinued due to a drug-related adverse event	12	(1.8)	24	(1.9)	12	(0.8)	36	(1.3)
discontinued due to a serious adverse event	9	(1.3)	20	(1.6)	9	(0.6)	29	(1.0)
discontinued due to a serious drug-related adverse event	9	(1.3)	20	(1.6)	9	(0.6)	29	(1.0)

Grades are based on NCI CTCAE version 4.0.
†Determined by the investigator to be related to the drug.
‡Study medication withdrawn.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

Summary of AEOSI - Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1232		1567		2799	
Subjects with Pneumonitis	31	(4.5)	54	(4.4)	40	(2.6)	94	(3.4)
Time to Onset of First Pneumonitis (days)†								
Mean (Std)	111.4 (100.5)		113.4 (102.8)		171.4 (121.3)		138.1 (114.1)	
Median	87.0		86.0		169.0		99.5	
Range	6 to 381		4 to 393		2 to 588		2 to 588	
Total episodes of Pneumonitis	35		59		45		104	
Average Episodes per subject	1.13		1.09		1.13		1.11	
Episode duration (days)‡								

C Confidential

Summary of AEOSI - Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Median	35.0		35.0		87.0		46.0	
Range	2 to 264+		1 to 523+		4+ to 459+		1 to 523+	

(%) = Number of subjects with Pneumonitis / Number of subjects in population.
† Time to onset statistics are based on number of subjects with Pneumonitis.
‡ From product-limit (Kaplan-Meier) method for censored data. If an adverse event is not resolved at the time of analysis or the patient died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occurred first.
+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.
Std = Standard Deviation.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	31	(4.5)	54	(4.4)	40	(2.6)	94	(3.4)
Grade 1	6	(0.9)	10	(0.8)	12	(0.8)	22	(0.8)
Grade 2	11	(1.6)	19	(1.5)	17	(1.1)	36	(1.3)
Grade 3	7	(1.0)	14	(1.1)	11	(0.7)	25	(0.9)
Grade 4	4	(0.6)	7	(0.6)	0	(0.0)	7	(0.3)
Grade 5	3	(0.4)	4	(0.3)	0	(0.0)	4	(0.1)
with no adverse events	651	(95.5)	1,178	(95.6)	1,527	(97.4)	2,705	(96.6)
Respiratory, thoracic and mediastinal disorders	**31**	**(4.5)**	**54**	**(4.4)**	**40**	**(2.6)**	**94**	**(3.4)**
Grade 1	6	(0.9)	10	(0.8)	12	(0.8)	22	(0.8)
Grade 2	11	(1.6)	19	(1.5)	17	(1.1)	36	(1.3)
Grade 3	7	(1.0)	14	(1.1)	11	(0.7)	25	(0.9)
Grade 4	4	(0.6)	7	(0.6)	0	(0.0)	7	(0.3)
Grade 5	3	(0.4)	4	(0.3)	0	(0.0)	4	(0.1)
Interstitial lung disease	3	(0.4)	4	(0.3)	3	(0.2)	7	(0.3)
Grade 1	2	(0.3)	2	(0.2)	1	(0.1)	3	(0.1)
Grade 2	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
Grade 3	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 5	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.0)
Pneumonitis	28	(4.1)	50	(4.1)	37	(2.4)	87	(3.1)
Grade 1	4	(0.6)	8	(0.6)	11	(0.7)	19	(0.7)
Grade 2	10	(1.5)	18	(1.5)	16	(1.0)	34	(1.2)
Grade 3	7	(1.0)	14	(1.1)	10	(0.6)	24	(0.9)

Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Pneumonitis	28	(4.1)	50	(4.1)	37	(2.4)	87	(3.1)
Grade 4	4	(0.6)	7	(0.6)	0	(0.0)	7	(0.3)
Grade 5	3	(0.4)	3	(0.2)	0	(0.0)	3	(0.1)

Every subject is counted a single time for each applicable specific adverse event. A subject with multiple adverse events within a system organ class is counted a single time for that system organ class.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns is greater than or equal to the incidence specified in the report title, after rounding.

Only the highest reported grade of a given adverse event is counted for the individual subject.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Pneumonitis PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010 (N=682)		PN001 Lung, PN010 (N=1232)		PN001 Mel, PN002, PN006 (N=1567)		PN001,PN002, PN006, PN010 (N=2799)	
	n	%	n	%	n	%	n	%
Subjects with one or more Pneumonitis	31		54		40		94	
Treated with systemic corticosteroid	24	77.4	42	77.8	21	52.5	63	67.0
High starting dose†	18	58.1	34	63.0	16	40.0	50	53.2
Low starting dose‡	6	19.4	8	14.8	5	12.5	13	13.8
Not treated with systemic corticosteroid	7	22.6	12	22.2	19	47.5	31	33.0

The number of Subjects with one or more Pneumonitis is used as the denominator for the percentage calculation.
† High starting dose corticosteroid treatment is defined as >= 40 mg/day prednisone or equivalent.
‡ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Pneumonitis Episodes PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010	PN001 Lung, PN010	PN001 Mel, PN002, PN006	PN001,PN002, PN006, PN010
Total Episodes	35	59	45	104
High Starting Dose (%) †	**21 (60.0)**	**38 (64.4)**	**16 (35.6)**	**54 (51.9)**
Starting dose (mg/day)				
Mean (Std)	167 (282)	131 (212)	95 (55)	120 (180)
Median (Range)	60 (40-1250)	61 (40-1250)	73 (40-200)	68 (40-1250)
Duration (days)§				
Mean (Std)	14 (28)	16 (28)	28 (75)	19 (47)
Median (Range)	6 (1-128)	8 (1-128)	8 (1-307)	8 (1-307)
Low Starting Dose (%) ‡	**6 (17.1)**	**8 (13.6)**	**5 (11.1)**	**13 (12.5)**
Starting dose (mg/day)				
Mean (Std)	25 (11)	23 (12)	20 (10)	22 (11)
Median (Range)	28 (7-38)	28 (5-38)	20 (10-31)	27 (5-38)
Duration (days)§				
Mean (Std)	11 (8)	9 (8)	35 (48)	19 (31)
Median (Range)	10 (2-21)	6 (1-21)	21 (1-117)	6 (1-117)
Not Treated with Systemic Corticosteroid (%)	**8 (22.9)**	**13 (22.0)**	**24 (53.3)**	**37 (35.6)**

† High starting dose corticosteroid treatment is defined as ≥ 40 mg/day prednisone or equivalent.
‡ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.
§ Ongoing corticosteroid treatment is censored at the cutoff date or date of death, whichever occurs first.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0008, Subject ID=000319, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=437										
000319	Treatment Cycle 7	136	Pneumonitis	3.75 Months	Mild	1		Y		Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000265, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=211										
000265	Treatment Cycle 8	170	Pneumonitis	1.86 Weeks	Severe	3	Y	Y	Interrupted	Resolved
		183	Pneumonitis	4 Weeks	Moderate	2		N	Interrupted	Resolved
	Treatment Cycle 9	211	Pneumonitis	2.57 Weeks	Mild	1		N	N/A	Resolved
	Safety Follow-up	229	Pneumonitis	5.16 Months	Moderate	2	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000287, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
000287	Treatment Cycle 4	82	Interstitial lung disease	Continuing	Mild	1		Y	N/A	Not Resolved
Trial Number=3475-001, Site Number=0091, Subject ID=003019, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=207										
003019	Treatment Cycle 8	176	Pneumonitis	4.29 Weeks	Moderate	2	Y	Y	Interrupted	Resolved
	Safety Follow-up	226	Pneumonitis	Continuing	Severe	4	Y	Y	Discontinued	Not Resolved
Trial Number=3475-001, Site Number=0134, Subject ID=003045, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=1										
003045	Safety Follow-up	13	Pneumonitis	Continuing	Severe	3	Y	Y	Discontinued	Not Resolved
Trial Number=3475-002, Site Number=0010, Subject ID=101263, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=										
101263	Treatment Cycle 9	170	Pneumonitis	3.57 Weeks		1	N	N	None	Resolved
	Treatment Cycle 13	254	Pneumonitis	1.41 Months		1	N	N	None	Resolved

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-002, Site Number=0054, Subject ID=100135, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=										
100135	Treatment Cycle 5	125	Pneumonitis	2.79 Months		1	N	N	None	Resolved
Trial Number=3475-002, Site Number=0091, Subject ID=100138, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=253										
100138	Safety Follow-up	273	Pneumonitis	1.58 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0111, Subject ID=102122, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=113										
102122	Treatment Cycle 4	84	Pneumonitis	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-010, Site Number=0004, Subject ID=300573, Gender=M, Race=, Age=70 Years, Rel Day of Study Medication Discontinuance†=28										
300573	Treatment Cycle 1	6	Pneumonitis	3 Weeks		3	Y	N	Interrupted	Resolved
Trial Number=3475-010, Site Number=0026, Subject ID=304255, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=51										
304255	Safety Follow-up	58	Pneumonitis	1.15 Months		4	Y	Y	Discontinued	Resolved
Trial Number=3475-010, Site Number=0046, Subject ID=309525, Gender=M, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=68										
309525	Extended Safety Follow-up	122	Pneumonitis	1.57 Weeks		4	Y	Y	N/A	Resolved
Trial Number=3475-010, Site Number=0136, Subject ID=306797, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=23										
306797	Safety Follow-up	32	Pneumonitis	2.29 Weeks		2	Y	Y	N/A	Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-010, Site Number=0167, Subject ID=308717, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=										
308717	Treatment Cycle 18	378	Pneumonitis	3.57 Weeks		1	N	Y	None	Resolved
Trial Number=3475-010, Site Number=0200, Subject ID=306369, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=21										
306369	Safety Follow-up	39	Pneumonitis	1.15 Months		5	Y	Y	Discontinued	Fatal
Trial Number=3475-010, Site Number=0201, Subject ID=300176, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=368										
300176	Treatment Cycle 6	127	Pneumonitis	1.29 Weeks		2	N	Y	Interrupted	Resolved
Trial Number=3475-010, Site Number=0204, Subject ID=306723, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=154										
306723	Treatment Cycle 5	92	Pneumonitis	1.12 Months		2	N	Y	Reduced	Resolved
Trial Number=3475-010, Site Number=0207, Subject ID=303570, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=128										
303570	Treatment Cycle 3	64	Pneumonitis	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-010, Site Number=0209, Subject ID=313318, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=279										
313318	Safety Follow-up	283	Pneumonitis	3.71 Weeks		4	Y	Y	Discontinued	Resolved
Trial Number=3475-010, Site Number=0284, Subject ID=307284, Gender=M, Race=Asian, Age=47 Years, Rel Day of Study Medication Discontinuance†=29										
307284	Treatment Cycle 1 Safety Follow-up	12 41	Pneumonitis Pneumonitis	1.71 Weeks 3 Days		3 5	Y Y	N Y	Interrupted None	Resolved Fatal

Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-010, Site Number=0361, Subject ID=306719, Gender=F, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=92										
306719	Safety Follow-up	97	Pneumonitis	6.11 Months		2	N	Y	Discontinued	Resolved
Trial Number=3475-010, Site Number=0602, Subject ID=302229, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=176										
302229	Treatment Cycle 3	62	Pneumonitis	2.17 Months		2	N	Y	Interrupted	Resolved
	Safety Follow-up	190	Pneumonitis	Continuing		2	N	Y	Discontinued	Not Resolved
Trial Number=3475-010, Site Number=1080, Subject ID=305559, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=1										
305559	Safety Follow-up	16	Pneumonitis	Continuing		3	Y	Y	Discontinued	Resolving
Trial Number=3475-010, Site Number=1243, Subject ID=303301, Gender=M, Race=Asian, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
303301	Treatment Cycle 4	87	Pneumonitis	3.71 Weeks		1	N	Y	None	Resolved
Trial Number=3475-010, Site Number=1422, Subject ID=308873, Gender=M, Race=Asian, Age=70 Years, Rel Day of Study Medication Discontinuance†=										
308873	Treatment Cycle 9	191	Interstitial lung disease	Continuing		1	N	Y	None	Not Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0001, Subject ID=001240, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=244										
001240	Treatment Cycle 10	195	Pneumonitis	4.14 Weeks	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 11	224	Pneumonitis	Continuing	Mild	1		Y	N/A	Not Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0010, Subject ID=000143, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000143	Treatment Cycle 27	588	Pneumonitis	Continuing	Mild	1		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000180, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=1										
000180	Safety Follow-up	4	Pneumonitis	Continuing	Severe	3	Y	Y	Discontinued	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000181, Gender=F, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance†=85										
000181	Safety Follow-up	106	Pneumonitis	Continuing	Moderate	2	Y	Y	Discontinued	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000815, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=421										
000815	Treatment Cycle 12	253	Pneumonitis	2.43 Weeks	Mild	1		Y	N/A	Resolved
	Treatment Cycle 13	270	Pneumonitis	2.57 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000171, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=302										
000171	Treatment Cycle 9	169	Pneumonitis	Continuing	Mild	1		Y	N/A	Not Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000822, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=170										
000822	Treatment Cycle 7	128	Pneumonitis	1.64 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000915, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=										
000915	Treatment Cycle 19	393	Pneumonitis	Continuing	Moderate	2		Y	Interrupted	Not Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=000940, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=107										
000940	Extended Safety Follow-up	191	Pneumonitis	2.86 Weeks	Moderate	2	Y	Y		Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000947, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=										
000947	Treatment Cycle 2	50	Pneumonitis	Continuing	Mild	1		Y	N/A	Not Resolved
Trial Number=3475-001, Site Number=0012, Subject ID=000088, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=274										
000088	Treatment Cycle 12	252	Pneumonitis	1.41 Months	Mild	1		Y	N/A	Resolved
	Safety Follow-up	295	Pneumonitis	4.6 Months	Moderate	2		Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000801, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=20										
000801	Safety Follow-up	26	Pneumonitis	1 Weeks	Moderate	2		Y		Resolved
		33	Pneumonitis	4 Days	Severe	4	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000803, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance†=83										
000803	Treatment Cycle 2	23	Pneumonitis	2.86 Weeks	Moderate	2		Y	Interrupted	Resolved
		42	Pneumonitis	3 Weeks	Mild	1		Y		Resolved
Trial Number=3475-001, Site Number=0016, Subject ID=001078, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=										
001078	Treatment Cycle 15	316	Pneumonitis	Continuing	Mild	1		N	N/A	Not Resolved

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0018, Subject ID=001266, Gender=M, Race=White, Age=37 Years, Rel Day of Study Medication Discontinuance†=										
001266	Treatment Cycle 12	253	Pneumonitis	Continuing	Mild	1		Y	N/A	Not Resolved
Trial Number=3475-001, Site Number=0018, Subject ID=001281, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=										
001281	Treatment Cycle 8	169	Pneumonitis	Continuing	Mild	1		Y	N/A	Not Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000148, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=										
000148	Treatment Cycle 12	259	Pneumonitis	3.29 Weeks	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000827, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=240										
000827	Safety Follow-up	259	Pneumonitis	3 Days	Moderate	2	Y	Y		Resolved
		261	Pneumonitis	2.04 Months	Mild	1		Y	Discontinued	Resolved
	Extended Safety Follow-up	323	Pneumonitis	4 Days	Moderate	2	Y	Y		Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000203, Gender=M, Race=Asian, Age=48 Years, Rel Day of Study Medication Discontinuance†=1										
000203	Extended Safety Follow-up	48	Pneumonitis	1 Days	Moderate	2	Y	Y		Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000205, Gender=F, Race=White, Age=37 Years, Rel Day of Study Medication Discontinuance†=293										
000205	Safety Follow-up	302	Pneumonitis	1.18 Months	Mild	1		Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0020, Subject ID=000205, Gender=F, Race=White, Age=37 Years, Rel Day of Study Medication Discontinuance†=293										
000205	Extended Safety Follow-up	338	Pneumonitis	1.43 Weeks	Moderate	2	Y	Y		Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001439, Gender=M, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance†=20										
001439	Extended Safety Follow-up	83	Pneumonitis	6 Days	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000271, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=										
000271	Treatment Cycle 1	6	Pneumonitis	1.87 Months	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 4	62	Pneumonitis	1.41 Months	Mild	1		Y		Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=000603, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000603	Treatment Cycle 7	147	Pneumonitis	Continuing	Mild	1		Y		Not Resolved
Trial Number=3475-001, Site Number=0026, Subject ID=000968, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=43										
000968	Safety Follow-up	51	Pneumonitis	1 Weeks	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0026, Subject ID=001510, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=169										
001510	Safety Follow-up	179	Pneumonitis	Continuing	Severe	3	Y	Y	Discontinued	Not Resolved
Trial Number=3475-001, Site Number=0033, Subject ID=001060, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=1										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0033, Subject ID=001060, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=1										
001060	Safety Follow-up	12	Interstitial lung disease	5 Days	Severe	5	Y	Y	Discontinued	Fatal
Trial Number=3475-002, Site Number=0010, Subject ID=101857, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=64										
101857	Safety Follow-up	93	Pneumonitis	2 Weeks		2	Y	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0011, Subject ID=100139, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=22										
100139	Safety Follow-up	35	Pneumonitis	3.57 Weeks		3	Y	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0032, Subject ID=101271, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=63										
101271	Safety Follow-up	77	Pneumonitis	1.74 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0180, Subject ID=101272, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=64										
101272	Safety Follow-up	85	Interstitial lung disease	Continuing		3	Y	Y	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=0003, Subject ID=364744, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=106										
364744	Extended Safety Follow-up	187	Pneumonitis	2.43 Weeks		2	Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=0003, Subject ID=365319, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=										
365319	Treatment Cycle 17	355	Pneumonitis	Continuing		3	Y	Y	Interrupted	Resolving

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=0007, Subject ID=366702, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
366702	Treatment Cycle 12	247	Pneumonitis	2.86 Months		1	N	Y	None	Resolved
	Treatment Cycle 16	334	Pneumonitis	1.25 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0309, Subject ID=366971, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=1										
366971	Safety Follow-up	29	Pneumonitis	3.88 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=363708, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=										
363708	Treatment Cycle 11	216	Interstitial lung disease	3.48 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1708, Subject ID=366213, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=309										
366213	Treatment Cycle 8	169	Pneumonitis	4.14 Weeks		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1804, Subject ID=367122, Gender=F, Race=White, Age=89 Years, Rel Day of Study Medication Discontinuance†=190										
367122	Safety Follow-up	209	Pneumonitis	Continuing		2	N	Y	N/A	Not Resolved
Trial Number=3475-006, Site Number=1810, Subject ID=364795, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=357										
364795	Extended Safety Follow-up	419	Pneumonitis	Continuing		3	Y	Y	Discontinued	Resolving
Trial Number=3475-006, Site Number=1812, Subject ID=362552, Gender=M, Race=White, Age=87 Years, Rel Day of Study Medication Discontinuance†=22										
362552	Safety Follow-up	40	Pneumonitis	Continuing		2	N	N	None	Not Resolved

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-010, Site Number=0003, Subject ID=300217, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=99										
300217	Treatment Cycle 4	92	Pneumonitis	1.18 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-010, Site Number=0045, Subject ID=300012, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=45										
300012	Safety Follow-up	64	Pneumonitis	2.29 Weeks		4	Y	Y	Discontinued	Resolved
Trial Number=3475-010, Site Number=0063, Subject ID=313714, Gender=M, Race=White, Age=84 Years, Rel Day of Study Medication Discontinuance†=211										
313714	Treatment Cycle 2	45	Pneumonitis	Continuing		2	Y	Y	Reduced	Resolving
Trial Number=3475-010, Site Number=0095, Subject ID=303533, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=211										
303533	Treatment Cycle 6	118	Interstitial lung disease	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-010, Site Number=0204, Subject ID=308211, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
308211	Treatment Cycle 5	85	Pneumonitis	3.43 Weeks		1	N	Y	None	Resolved
		109	Pneumonitis	2 Weeks		2	N	Y	Reduced	Resolved
Trial Number=3475-010, Site Number=0360, Subject ID=313958, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=1										
313958	Safety Follow-up	8	Pneumonitis	Continuing		3	Y	Y	Discontinued	Resolving
Trial Number=3475-010, Site Number=0560, Subject ID=307270, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=										
307270	Treatment Cycle 18	381	Pneumonitis	1.84 Months		2	N	Y	Interrupted	Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-010, Site Number=0560, Subject ID=309087, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=359										
309087	Treatment Cycle 16	319	Pneumonitis	1.35 Months		2	Y	Y	Interrupted	Resolved
	Safety Follow-up	362	Pneumonitis	1.35 Months		2	N	Y	Discontinued	Resolved
Trial Number=3475-010, Site Number=0561, Subject ID=300941, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=45										
300941	Safety Follow-up	64	Pneumonitis	Continuing		3	Y	Y	Discontinued	Not Resolved
Trial Number=3475-010, Site Number=0561, Subject ID=306075, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=64										
306075	Extended Safety Follow-up	120	Pneumonitis	1.29 Weeks		3	Y	Y	None	Resolved
Trial Number=3475-010, Site Number=0920, Subject ID=308160, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=120										
308160	Safety Follow-up	133	Pneumonitis	2 Days		5	Y	Y	Discontinued	Fatal
Trial Number=3475-010, Site Number=1003, Subject ID=310688, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=47										
310688	Safety Follow-up	56	Pneumonitis	1.29 Weeks		3	Y	Y	Discontinued	Resolved
Trial Number=3475-010, Site Number=1240, Subject ID=301043, Gender=M, Race=Asian, Age=71 Years, Rel Day of Study Medication Discontinuance†=										
301043	Treatment Cycle 8	150	Pneumonitis	Continuing		1	N	Y	None	Not Resolved
Trial Number=3475-010, Site Number=1401, Subject ID=311426, Gender=F, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=1										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-010, Site Number=1401, Subject ID=311426, Gender=F, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=1										
311426	Extended Safety Follow-up	50	Pneumonitis	1.87 Months		3	Y	N	N/A	Sequelae
Trial Number=3475-010, Site Number=1410, Subject ID=307796, Gender=M, Race=Asian, Age=69 Years, Rel Day of Study Medication Discontinuance†=										
307796	Treatment Cycle 4	102	Interstitial lung disease	Continuing		2	Y	Y	Interrupted	Not Resolved
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0001, Subject ID=001393, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=71										
001393	Safety Follow-up	83	Pneumonitis	1.57 Weeks	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0002, Subject ID=000097, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=										
000097	Treatment Cycle 6	85	Pneumonitis	8.74 Months	Mild	1		Y		Resolved
	Treatment Cycle 21	392	Pneumonitis	2.83 Months	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0003, Subject ID=000066, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=162										
000066	Treatment Cycle 5	71	Pneumonitis	4.14 Weeks	Moderate	2		Y	Interrupted	Resolved
	Treatment Cycle 8	141	Pneumonitis	4.17 Months	Mild	1		Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000045, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=441										
000045	Treatment Cycle 18	252	Pneumonitis	1.84 Months	Moderate	2		Y	Interrupted	Resolved

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0010, Subject ID=000045, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=441										
000045	Treatment Cycle 18	308	Pneumonitis	3.71 Months	Mild	1	Y	Y	N/A	Resolved
	Safety Follow-up	463	Pneumonitis	Continuing	Mild	1	Y	Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000051, Gender=M, Race=White, Age=94 Years, Rel Day of Study Medication Discontinuance†=72										
000051	Safety Follow-up	94	Pneumonitis	1 Weeks	Moderate	2		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001728, Gender=F, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance†=43										
001728	Safety Follow-up	46	Pneumonitis	1.71 Weeks	Severe	3	Y	Y	Discontinued	Resolved
		57	Pneumonitis	6 Days	Moderate	2		Y		Resolved
		62	Pneumonitis	1.14 Weeks	Mild	1		Y	N/A	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000038, Gender=F, Race=White, Age=89 Years, Rel Day of Study Medication Discontinuance†=313										
000038	Treatment Cycle 20	291	Pneumonitis	1.14 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=001119, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=15										
001119	Safety Follow-up	35	Pneumonitis	2.43 Weeks	Severe	3	Y	Y		Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000076, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=1										
000076	Safety Follow-up	2	Pneumonitis	2.37 Months	Moderate	2		Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=001006, Gender=M, Race=Asian, Age=67 Years, Rel Day of Study Medication Discontinuance†=1										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0023, Subject ID=001006, Gender=M, Race=Asian, Age=67 Years, Rel Day of Study Medication Discontinuance†=1										
001006	Safety Follow-up	30	Pneumonitis	1.71 Weeks	Severe	4	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0081, Subject ID=001139, Gender=M, Race=Asian, Age=57 Years, Rel Day of Study Medication Discontinuance†=126										
001139	Treatment Cycle 4	57	Pneumonitis	4.14 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0081, Subject ID=001577, Gender=M, Race=Asian, Age=64 Years, Rel Day of Study Medication Discontinuance†=113										
001577	Safety Follow-up	126	Pneumonitis	2 Weeks	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=364232, Gender=F, Race=White, Age=34 Years, Rel Day of Study Medication Discontinuance†=121										
364232	Treatment Cycle 2	29	Pneumonitis	4.14 Weeks		2	Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=369195, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=156										
369195	Extended Safety Follow-up	188	Pneumonitis	1.51 Months		3	Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1807, Subject ID=366429, Gender=M, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1807, Subject ID=366429, Gender=M, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance[†]=										
366429	Treatment Cycle 21	285	Pneumonitis	Continuing		1	N	Y	None	Not Resolved

[†]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-001, Site Number=0010, Subject ID=000265, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance[‡]=211											
000265	182	22	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	170	182	3
	182	22	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	183	210	2
	204	2	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	183	210	2
	206	2	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	183	210	2
	208	2	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	183	210	2
	210	1	Prednisone	5	QD	Oral Administration	5.00	Pneumonitis	183	210	2
	229	10	Prednisone	80	QD	Oral Administration	80.00	Pneumonitis	229	385	2
	239	7	Prednisone	70	QD	Oral Administration	70.00	Pneumonitis	229	385	2
	246	8	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	229	385	2
	254	5	Prednisone	50	QD	Oral Administration	50.00	Pneumonitis	229	385	2
	259	8	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	229	385	2
	267	16	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	229	385	2
	283	61	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	229	385	2
	344	42	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	229	385	2
Trial Number=3475-001, Site Number=0091, Subject ID=003019, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance[‡]=207											

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
003019	176	18	Methylprednisolone	80	BID	Intravenous Administration	100.00	Pneumonitis	176	205	2
	228	1	Methylprednisolone	120	BID	Intravenous Administration	150.00	Pneumonitis	226	.	4
	229	19	Methylprednisolone	40	BID	Intravenous Administration	50.00	Pneumonitis	226	.	4
	248	5	Methylprednisolone	60	BID	Intravenous Administration	75.00	Pneumonitis	226	.	4
	193	35	Prednisone	60	BID	Oral Administration	60.00	Pneumonitis	176	205	2
	228	39	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	226	.	4
Trial Number=3475-001, Site Number=0134, Subject ID=003045, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance‡=1											
003045	15	6	Prednisone	85	QD	Oral Administration	85.00	Pneumonitis	13	.	3
	21	3	Prednisone	50	5 TIMES PER DAY	Oral Administration	50.00	Pneumonitis	13	.	3
	24	3	Prednisone	40	QID	Oral Administration	40.00	Pneumonitis	13	.	3
	27	2	Prednisone	30	TID	Oral Administration	30.00	Pneumonitis	13	.	3
	29	3	Prednisone	20	BID	Oral Administration	20.00	Pneumonitis	13	.	3
	34	10	Prednisone	30	TID	Oral Administration	30.00	Pneumonitis	13	.	3
Trial Number=3475-010, Site Number=0004, Subject ID=300573, Gender=M, Race=, Age=70 Years, Rel Day of Study Medication Discontinuance‡=28											
300573	8	36	Prednisone	80	QD	Oral	80.00	Pneumonitis	6	26	3
Trial Number=3475-010, Site Number=0026, Subject ID=304255, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance‡=51											
304255	59	6	Methylprednisolone	500	OTHER	Intravenous	625.00	Pneumonitis	58	92	4

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	65	4	Methylprednisolone	375	TID	Intravenous	468.75	Pneumonitis	58	92	4
	69	2	Methylprednisolone	250	BID	Intravenous	312.50	Pneumonitis	58	92	4
	72	3	Methylprednisolone	125	QD	Intravenous	156.25	Pneumonitis	58	92	4
	75	4	Methylprednisolone	64	QD	Oral	80.00	Pneumonitis	58	92	4
	79	6	Methylprednisolone	32	QD	Oral	40.00	Pneumonitis	58	92	4
	85	5	Methylprednisolone	16	QD	Oral	20.00	Pneumonitis	58	92	4
	90	6	Methylprednisolone	8	QD	Oral	10.00	Pneumonitis	58	92	4
	96	.	Methylprednisolone	4	QD	Oral	5.00	Pneumonitis	58	92	4
	71	2	Prednisone	300	BID	Oral	300.00	Pneumonitis	58	92	4
Trial Number=3475-010, Site Number=0046, Subject ID=309525, Gender=M, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance‡=68											
309525	124	1	Methylprednisolone	250	QD	Intravenous	312.50	Pneumonitis	122	132	4
	125	1	Methylprednisolone	500	QID	Intravenous	625.00	Pneumonitis	122	132	4
	126	1	Methylprednisolone	375	BID	Intravenous	468.75	Pneumonitis	122	132	4
	127	2	Methylprednisolone	250	BID	Intravenous	312.50	Pneumonitis	122	132	4
	129	4	Methylprednisolone	120	BID	Intravenous	150.00	Pneumonitis	122	132	4
	134	1	Methylprednisolone	125	ONCE	Intravenous	156.25	Pneumonitis	122	132	4
	133	3	Prednisone	70	UNKNOWN	Oral	70.00	Pneumonitis	122	132	4

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	136	27	Prednisone	80	QD	Oral	80.00	Pneumonitis	122	132	4
Trial Number=3475-010, Site Number=0136, Subject ID=306797, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance[‡]=23											
306797	43	.	Prednisolone	40	QD	Oral	40.00	Pneumonitis	32	47	2
Trial Number=3475-010, Site Number=0200, Subject ID=306369, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance[‡]=21											
306369	41	2	Dexamethasone	8	PRN	Intravenous	53.36	Pneumonitis	39	73	5
Trial Number=3475-010, Site Number=0201, Subject ID=300176, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance[‡]=368											
300176	130	5	Prednisone	30	QD	Oral	30.00	Pneumonitis	127	135	2
	136	5	Prednisone	5	QD	Oral	5.00	Pneumonitis	127	135	2
Trial Number=3475-010, Site Number=0204, Subject ID=306723, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance[‡]=154											
306723	92	13	Prednisone	60	OTHER	Oral	60.00	Pneumonitis	92	125	2
	105	3	Prednisone	30	QD	Oral	30.00	Pneumonitis	92	125	2
	108	2	Prednisone	23	QD	Oral	22.50	Pneumonitis	92	125	2
	110	6	Prednisone	15	QD	Oral	15.00	Pneumonitis	92	125	2
Trial Number=3475-010, Site Number=0209, Subject ID=313318, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance[‡]=279											
313318	285	1	Methylprednisolone	100	BID	Intravenous	125.00	Pneumonitis	283	308	4
	286	8	Methylprednisolone	40	QD	Intravenous	50.00	Pneumonitis	283	308	4
	296	5	Methylprednisolone	30	ONCE	Intravenous	37.50	Pneumonitis	283	308	4

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	301	3	Methylprednisolone	20	ONCE	Intravenous	25.00	Pneumonitis	283	308	4
	304	4	Methylprednisolone	16	ONCE	Oral	20.00	Pneumonitis	283	308	4
	308	1	Methylprednisolone	8	ONCE	Oral	10.00	Pneumonitis	283	308	4
Trial Number=3475-010, Site Number=0284, Subject ID=307284, Gender=M, Race=Asian, Age=47 Years, Rel Day of Study Medication Discontinuance‡=29											
307284	42	1	Hydrocortisone	200			50.00	Pneumonitis	41	43	5
Trial Number=3475-010, Site Number=0361, Subject ID=306719, Gender=F, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance‡=92											
306719	120	3	Prednisolone	50	QD	Oral	50.00	Pneumonitis	97	282	2
	123	.	Prednisolone	25	QD	Oral	25.00	Pneumonitis	97	282	2
Trial Number=3475-010, Site Number=0602, Subject ID=302229, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance‡=176											
302229	198	1	Dexamethasone	10	QD	Intravenous	66.70	Pneumonitis	190	.	2
	71	9	Prednisolone	60	TID	Oral	60.00	Pneumonitis	62	127	2
	84	27	Prednisolone	20	QD	Oral	20.00	Pneumonitis	62	127	2
	111	24	Prednisolone	10	QD	Oral	10.00	Pneumonitis	62	127	2
	197	8	Prednisolone	40	BID	Oral	40.00	Pneumonitis	190	.	2
	209	2	Prednisolone	30	QD	Oral	30.00	Pneumonitis	190	.	2
Trial Number=3475-010, Site Number=1080, Subject ID=305559, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance‡=1											
305559	19	4	Dexamethasone	4	BID	Oral	26.68	Pneumonitis	16	.	3

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	23	10	Dexamethasone	8	BID	Oral	53.36	Pneumonitis	16	.	3
	33	.	Dexamethasone	8	QD	Oral	53.36	Pneumonitis	16	.	3
MK-3475 10 mg/kg Q3W											
Trial Number=3475-001, Site Number=0001, Subject ID=001240, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance‡=244											
001240	209	.	Prednisone	10	OTHER	Oral Administration	10.00	Pneumonitis	195	223	2
Trial Number=3475-001, Site Number=0010, Subject ID=000180, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance‡=1											
000180	4	6	Methylprednisolone Sodium Succinate	125	ONCE	Intravenous Bolus	156.25	Pneumonitis	4	.	3
	4	6	Prednisone	100	BID	Oral Administration	100.00	Pneumonitis	4	.	3
Trial Number=3475-001, Site Number=0010, Subject ID=000181, Gender=F, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance‡=85											
000181	148	16	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	106	.	2
	164	7	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	106	.	2
	171	8	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	106	.	2
	179	11	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	106	.	2
	190	49	Prednisone	5	QD	Oral Administration	5.00	Pneumonitis	106	.	2
Trial Number=3475-001, Site Number=0010, Subject ID=000815, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance‡=421											
000815	270	1	Methylprednisolone	24	ONCE	Oral Administration	30.00	Pneumonitis	270	287	2
	271	1	Methylprednisolone	20	ONCE	Oral Administration	25.00	Pneumonitis	270	287	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	272	1	Methylprednisolone	16	ONCE	Oral Administration	20.00	Pneumonitis	270	287	2
	273	1	Methylprednisolone	12	ONCE	Oral Administration	15.00	Pneumonitis	270	287	2
	274	1	Methylprednisolone	8	ONCE	Oral Administration	10.00	Pneumonitis	270	287	2
	275	1	Methylprednisolone	4	ONCE	Oral Administration	5.00	Pneumonitis	270	287	2
Trial Number=3475-001, Site Number=0011, Subject ID=000915, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance‡=											
000915	409	33	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	393	.	2
Trial Number=3475-001, Site Number=0011, Subject ID=000940, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance‡=107											
000940	191	20	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	191	210	2
	211	.	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	191	210	2
Trial Number=3475-001, Site Number=0012, Subject ID=000088, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance‡=274											
000088	337	34	Prednisone	60	BID	Oral Administration	60.00	Pneumonitis	295	434	2
	371	21	Prednisone	40	BID	Oral Administration	40.00	Pneumonitis	295	434	2
	392	43	Prednisone	20	BID	Oral Administration	20.00	Pneumonitis	295	434	2
	435	34	Prednisone	4.285	3 TIMES PER WEEK	Oral Administration	4.29	Pneumonitis	295	434	2
Trial Number=3475-001, Site Number=0015, Subject ID=000801, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance‡=20											
000801	26	8	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	26	32	2
	26	8	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	33	36	4

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	34	8	Prednisone	50	QD	Oral Administration	50.00	Pneumonitis	33	36	4
	42	8	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	33	36	4
	50	8	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	33	36	4
	58	8	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	33	36	4
Trial Number=3475-001, Site Number=0015, Subject ID=000803, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance‡=83											
000803	23	17	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	23	42	2
	40	7	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	42	62	1
	47	8	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	42	62	1
	55	8	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	42	62	1
Trial Number=3475-001, Site Number=0019, Subject ID=000827, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance‡=240											
000827	259	1	Methylprednisolone	60	OTHER	Intravenous Administration	75.00	Pneumonitis	259	261	2
	260	2	Methylprednisolone	120	BID	Intravenous Administration	150.00	Pneumonitis	259	261	2
	323	1	Methylprednisolone	60	ONCE	Intravenous Administration	75.00	Pneumonitis	323	326	2
	261	1	Prednisone	80	ONCE	Oral Administration	80.00	Pneumonitis	259	261	2
	261	1	Prednisone	80	ONCE	Oral Administration	80.00	Pneumonitis	261	322	1
	268	1	Prednisone	80	ONCE	Oral Administration	80.00	Pneumonitis	261	322	1
	268	7	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	261	322	1

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	275	8	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	261	322	1
	283	7	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	261	322	1
	290	7	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	261	322	1
	297	7	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	261	322	1
Trial Number=3475-001, Site Number=0020, Subject ID=000205, Gender=F, Race=White, Age=37 Years, Rel Day of Study Medication Discontinuance‡=293											
000205	339	3	Prednisone	100	BID	Oral Administration	100.00	Pneumonitis	338	347	2
	342	15	Prednisone	50	QD	Oral Administration	50.00	Pneumonitis	338	347	2
	378	6	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	338	347	2
Trial Number=3475-001, Site Number=0020, Subject ID=001439, Gender=M, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance‡=20											
001439	83	1	Methylprednisolone Sodium Succinate	150	QD	Oral Administration	187.50	Pneumonitis	83	88	3
	83	6	Prednisone	75	QD	Oral Administration	75.00	Pneumonitis	83	88	3
	89	7	Prednisone	50	QD	Oral Administration	50.00	Pneumonitis	83	88	3
	96	7	Prednisone	25	QD	Oral Administration	25.00	Pneumonitis	83	88	3
	103	7	Prednisone	15	QD	Oral Administration	15.00	Pneumonitis	83	88	3
	110	14	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	83	88	3
	124	11	Prednisone	5	QD	Oral Administration	5.00	Pneumonitis	83	88	3
Trial Number=3475-001, Site Number=0026, Subject ID=000968, Gender=M, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance‡=43											

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
000968	57	1	Prednisone	125	QD	Oral Administration	125.00	Pneumonitis	51	57	3
	60	7	Prednisone	80	QD	Oral Administration	80.00	Pneumonitis	51	57	3
	67	3	Prednisone	70	QD	Oral Administration	70.00	Pneumonitis	51	57	3
	70	3	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	51	57	3
	73	3	Prednisone	50	QD	Oral Administration	50.00	Pneumonitis	51	57	3
	76	3	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	51	57	3
	79	3	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	51	57	3
	82	3	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	51	57	3
	85	3	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	51	57	3
Trial Number=3475-001, Site Number=0026, Subject ID=001510, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance‡=169											
001510	181	128	Prednisone	80	QD	Oral Administration	80.00	Pneumonitis	179	.	3
	309	.	Prednisone	15	QD	Oral Administration	15.00	Pneumonitis	179	.	3
Trial Number=3475-001, Site Number=0033, Subject ID=001060, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance‡=1											
001060	15	2	Methylprednisolone Sodium Succinate	120	QD	Oral Administration	150.00	Interstitial lung disease	12	16	5
	13	2	Prednisone	120	QD	Oral Administration	120.00	Interstitial lung disease	12	16	5
Trial Number=3475-002, Site Number=0010, Subject ID=101857, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance‡=64											
101857	93	14	Prednisone	70	QD	Oral	70.00	Pneumonitis	93	106	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
Trial Number=3475-002, Site Number=0011, Subject ID=100139, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance‡=22											
100139	45	12	Prednisone	60	QD	Oral	60.00	Pneumonitis	35	59	3
	57	.	Prednisone	20	QD	Oral	20.00	Pneumonitis	35	59	3
Trial Number=3475-002, Site Number=0032, Subject ID=101271, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance‡=63											
101271	77	1	Methylprednisolone Sodium Succinate	25	ONCE	Intravenous	31.25	Pneumonitis	77	129	3
	77	5	Methylprednisolone Sodium Succinate	25	QID	Intravenous	31.25	Pneumonitis	77	129	3
	81	7	Prednisone	100	QD	Oral	100.00	Pneumonitis	77	129	3
	95	7	Prednisone	60	QD	Oral	60.00	Pneumonitis	77	129	3
Trial Number=3475-006, Site Number=0003, Subject ID=364744, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance‡=106											
364744	197	.	Prednisone	50	QD	Oral	50.00	Pneumonitis	187	203	2
Trial Number=3475-006, Site Number=0003, Subject ID=365319, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance‡=											
365319	358	1	Hydrocortisone	100	ONCE	Intravenous	25.00	Pneumonitis	355	.	3
	358	7	Prednisone	80	QD	Oral	80.00	Pneumonitis	355	.	3
	365	.	Prednisone	70	QD	Oral	70.00	Pneumonitis	355	.	3
Trial Number=3475-006, Site Number=0007, Subject ID=366702, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance‡=											
366702	344	14	Prednisolone	75	QD	Oral	75.00	Pneumonitis	334	371	2
	358	7	Prednisolone	50	QD	Oral	50.00	Pneumonitis	334	371	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	365	7	Prednisolone	25	QD	Oral	25.00	Pneumonitis	334	371	2
Trial Number=3475-006, Site Number=0309, Subject ID=366971, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance[‡]=1											
366971	29	1	Dexamethasone	20	OTHER	Oral	133.40	Pneumonitis	29	146	3
	30	1	Dexamethasone	16	QID	Oral	106.72	Pneumonitis	29	146	3
	31	4	Dexamethasone	8	BID	Oral	53.36	Pneumonitis	29	146	3
	35	132	Dexamethasone	4	QD	Oral	26.68	Pneumonitis	29	146	3
Trial Number=3475-006, Site Number=0611, Subject ID=363708, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance[‡]=											
363708	345	7	Prednisolone Sodium Metazoate	8	QD	Oral	7.50	Interstitial lung disease	216	321	2
	352	7	Prednisolone Sodium Metazoate	5	QD	Oral	5.00	Interstitial lung disease	216	321	2
	359	7	Prednisolone Sodium Metazoate	3	QD	Oral	2.50	Interstitial lung disease	216	321	2
	278	10	Prednisone	90	QD	Oral	90.00	Interstitial lung disease	216	321	2
	288	12	Prednisone	60	QD	Oral	60.00	Interstitial lung disease	216	321	2
	300	7	Prednisone	40	QD	Oral	40.00	Interstitial lung disease	216	321	2
	307	7	Prednisone	35	QD	Oral	35.00	Interstitial lung disease	216	321	2
	314	7	Prednisone	30	QD	Oral	30.00	Interstitial lung disease	216	321	2
	321	7	Prednisone	25	QD	Oral	25.00	Interstitial lung disease	216	321	2
	328	7	Prednisone	20	QD	Oral	20.00	Interstitial lung disease	216	321	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	335	5	Prednisone	15	QD	Oral	15.00	Interstitial lung disease	216	321	2
	340	5	Prednisone	10	QD	Oral	10.00	Interstitial lung disease	216	321	2
Trial Number=3475-006, Site Number=1708, Subject ID=366213, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance‡=309											
366213	172	5	Prednisolone	40	QD	Oral	40.00	Pneumonitis	169	197	2
	177	7	Prednisolone	50	QD	Oral	50.00	Pneumonitis	169	197	2
	184	7	Prednisolone	30	QD	Oral	30.00	Pneumonitis	169	197	2
	191	13	Prednisolone	10	QD	Oral	10.00	Pneumonitis	169	197	2
Trial Number=3475-006, Site Number=1804, Subject ID=367122, Gender=F, Race=White, Age=89 Years, Rel Day of Study Medication Discontinuance‡=190											
367122	212	21	Prednisone	10	QD	Oral	10.00	Pneumonitis	209	.	2
	233	.	Prednisone	5	QD	Oral	5.00	Pneumonitis	209	.	2
Trial Number=3475-006, Site Number=1810, Subject ID=364795, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance‡=357											
364795	423	3	Prednisone	20	QD	Oral	20.00	Pneumonitis	419	.	3
	426	7	Prednisone	10	QD	Oral	10.00	Pneumonitis	419	.	3
	433	.	Prednisone	10	QOD	Oral	10.00	Pneumonitis	419	.	3
Trial Number=3475-010, Site Number=0003, Subject ID=300217, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance‡=99											
300217	93	2	Prednisone	80	QD	Oral	80.00	Pneumonitis	92	127	2
Trial Number=3475-010, Site Number=0045, Subject ID=300012, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance‡=45											

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
300012	69	1	Methylprednisolone Sodium Succinate	120	BID	Intravenous	150.00	Pneumonitis	64	79	4
	70	1	Methylprednisolone Sodium Succinate	370	OTHER	Intravenous	462.50	Pneumonitis	64	79	4
	71	1	Methylprednisolone Sodium Succinate	1250	OTHER	Intravenous	1562.50	Pneumonitis	64	79	4
	72	1	Methylprednisolone Sodium Succinate	560	BID	Intravenous	700.00	Pneumonitis	64	79	4
	73	3	Methylprednisolone Sodium Succinate	180	TID	Intravenous	225.00	Pneumonitis	64	79	4
	76	1	Methylprednisolone Sodium Succinate	80	OTHER	Intravenous	100.00	Pneumonitis	64	79	4
	77	1	Methylprednisolone Sodium Succinate	20	BID	Intravenous	25.00	Pneumonitis	64	79	4
	77	.	Prednisone	10	QD	Oral	10.00	Pneumonitis	64	79	4
Trial Number=3475-010, Site Number=0063, Subject ID=313714, Gender=M, Race=White, Age=84 Years, Rel Day of Study Medication Discontinuance‡=211											
313714	45	14	Prednisone	40	QD	Oral	40.00	Pneumonitis	45	.	2
	59	21	Prednisone	20	QD	Oral	20.00	Pneumonitis	45	.	2
	80	14	Prednisone	5	QD	Oral	5.00	Pneumonitis	45	.	2
	94	94	Prednisone	10	QD	Oral	10.00	Pneumonitis	45	.	2
Trial Number=3475-010, Site Number=0204, Subject ID=308211, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance‡=											
308211	86	20	Dexamethasone	1	QD	Oral	6.67	Pneumonitis	85	108	1
	106	3	Dexamethasone	4	QD	Oral	26.68	Pneumonitis	85	108	1
	109	13	Dexamethasone	8	BID	Oral	53.36	Pneumonitis	109	122	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	122	31	Dexamethasone	4	QD	Oral	26.68	Pneumonitis	109	122	2
	153	83	Dexamethasone	2	QD	Oral	13.34	Pneumonitis	109	122	2
	236	28	Dexamethasone	1	QD	Oral	6.67	Pneumonitis	109	122	2
Trial Number=3475-010, Site Number=0360, Subject ID=313958, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance[‡]=1											
313958	22	5	Prednisolone	150	QD	Oral	150.00	Pneumonitis	8	.	3
	27	8	Prednisolone	100	QD	Oral	100.00	Pneumonitis	8	.	3
	35	8	Prednisolone	75	QD	Oral	75.00	Pneumonitis	8	.	3
	43	44	Prednisolone	50	QD	Oral	50.00	Pneumonitis	8	.	3
Trial Number=3475-010, Site Number=0560, Subject ID=307270, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance[‡]=											
307270	387	21	Prednisolone	20	QD	Oral	20.00	Pneumonitis	381	436	2
	408	28	Prednisolone	20	QD	Oral	20.00	Pneumonitis	381	436	2
	436	.	Prednisolone	8	QD	Oral	7.50	Pneumonitis	381	436	2
Trial Number=3475-010, Site Number=0560, Subject ID=309087, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance[‡]=359											
309087	319	14	Prednisolone	60	QD	Oral	60.00	Pneumonitis	319	359	2
	333	7	Prednisolone	40	QD	Oral	40.00	Pneumonitis	319	359	2
	340	7	Prednisolone	30	QD	Oral	30.00	Pneumonitis	319	359	2
	347	7	Prednisolone	20	QD	Oral	20.00	Pneumonitis	319	359	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	354	7	Prednisolone	10	QD	Oral	10.00	Pneumonitis	319	359	2
	362	14	Prednisolone	40	QD	Oral	40.00	Pneumonitis	362	402	2
	376	14	Prednisolone	30	QD	Oral	30.00	Pneumonitis	362	402	2
	390	14	Prednisolone	20	QD	Oral	20.00	Pneumonitis	362	402	2
Trial Number=3475-010, Site Number=0561, Subject ID=300941, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance‡=45											
300941	64	.	Prednisolone	60	QD	Oral	60.00	Pneumonitis	64	.	3
Trial Number=3475-010, Site Number=0920, Subject ID=308160, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=120											
308160	134	1	Hydrocortisone	500	ONCE	Intravenous	125.00	Pneumonitis	133	134	5
Trial Number=3475-010, Site Number=1003, Subject ID=310688, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance‡=47											
310688	63	.	Dexamethasone	4	QD	Oral	26.68	Pneumonitis	56	64	3
	62	2	Hydrocortisone	150	TID	Intravenous	37.50	Pneumonitis	56	64	3
Trial Number=3475-010, Site Number=1401, Subject ID=311426, Gender=F, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance‡=1											
311426	50	3	Methylprednisolone Sodium Succinate	1000	BID	Intravenous	1250.00	Pneumonitis	50	106	3
	65	16	Prednisolone	30	QD	Oral	30.00	Pneumonitis	50	106	3
	53	12	Prednisone	40	UNKNOWN	Intravenous	40.00	Pneumonitis	50	106	3
	81	21	Prednisone	25	QD	Oral	25.00	Pneumonitis	50	106	3
Trial Number=3475-010, Site Number=1410, Subject ID=307796, Gender=M, Race=Asian, Age=69 Years, Rel Day of Study Medication Discontinuance‡=											

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
307796	104	14	Prednisolone	30	QD	Oral	30.00	Interstitial lung disease	102	.	2
	118	14	Prednisolone	20	QD	Oral	20.00	Interstitial lung disease	102	.	2
	132	.	Prednisolone	10	QD	Oral	10.00	Interstitial lung disease	102	.	2
MK-3475 10 mg/kg Q2W											
Trial Number=3475-001, Site Number=0010, Subject ID=000045, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance[‡]=441											
000045	281	3	Prednisone	60	QD	Oral Administration	60.00	Pneumonitis	252	307	2
	284	3	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	252	307	2
	287	3	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	252	307	2
	290	3	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	252	307	2
	293	8	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	252	307	2
	301	7	Prednisone	5	QD	Oral Administration	5.00	Pneumonitis	252	307	2
Trial Number=3475-001, Site Number=0011, Subject ID=001728, Gender=F, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance[‡]=43											
001728	47	8	Prednisone	50	QD	Oral Administration	50.00	Pneumonitis	46	57	3
	55	4	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	46	57	3
	55	4	Prednisone	40	QD	Oral Administration	40.00	Pneumonitis	57	62	2
	62	15	Prednisone	20	BID	Oral Administration	20.00	Pneumonitis	62	69	1
	77	15	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	57	62	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
Trial Number=3475-001, Site Number=0015, Subject ID=000038, Gender=F, Race=White, Age=89 Years, Rel Day of Study Medication Discontinuance‡=313											
000038	292	1	Dexamethasone	10	ONCE	Oral Administration	66.70	Pneumonitis	291	298	2
	292	3	Prednisone	40	ONCE	Oral Administration	40.00	Pneumonitis	291	298	2
	295	2	Prednisone	20	QD	Oral Administration	20.00	Pneumonitis	291	298	2
	297	2	Prednisone	10	QD	Oral Administration	10.00	Pneumonitis	291	298	2
Trial Number=3475-001, Site Number=0019, Subject ID=001119, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance‡=15											
001119	35	6	Methylprednisolone	4	BID	Oral Administration	5.00	Pneumonitis	35	51	3
	41	5	Methylprednisolone	150	BID	Intravenous Administration	187.50	Pneumonitis	35	51	3
	46	1	Methylprednisolone	80	BID	Intravenous Administration	100.00	Pneumonitis	35	51	3
	47	5	Methylprednisolone Sodium Succinate	2	BID	Oral Administration	1.25	Pneumonitis	35	51	3
Trial Number=3475-001, Site Number=0021, Subject ID=000076, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance‡=1											
000076	41	33	Prednisone	30	QD	Oral Administration	30.00	Pneumonitis	2	73	2
Trial Number=3475-001, Site Number=0023, Subject ID=001006, Gender=M, Race=Asian, Age=67 Years, Rel Day of Study Medication Discontinuance‡=1											
001006	31	5	Dexamethasone	16	BID	Oral Administration	106.72	Pneumonitis	30	41	4
	36	6	Dexamethasone	8	QD	Oral Administration	53.36	Pneumonitis	30	41	4
Trial Number=3475-001, Site Number=0081, Subject ID=001139, Gender=M, Race=Asian, Age=57 Years, Rel Day of Study Medication Discontinuance‡=126											
001139	57	14	Prednisolone	60	QD	Oral Administration	60.00	Pneumonitis	57	85	2

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	71	7	Prednisolone	30	QD	Oral Administration	30.00	Pneumonitis	57	85	2
	78	7	Prednisolone	20	QD	Oral Administration	20.00	Pneumonitis	57	85	2
Trial Number=3475-001, Site Number=0081, Subject ID=001577, Gender=M, Race=Asian, Age=64 Years, Rel Day of Study Medication Discontinuance†=113											
001577	126	14	Methylprednisolone	50	QD	Intravenous Administration	62.50	Pneumonitis	126	139	3
Trial Number=3475-006, Site Number=1710, Subject ID=364232, Gender=F, Race=White, Age=34 Years, Rel Day of Study Medication Discontinuance†=121											

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
364232	78	4	Dexamethasone	6	QD	Oral	40.02	Pneumonitis	29	57	2
	29	8	Hydrocortisone	800	QID	Intravenous	200.00	Pneumonitis	29	57	2
	38	5	Prednisolone	40	QD	Oral	40.00	Pneumonitis	29	57	2
	43	7	Prednisolone	20	QD	Oral	20.00	Pneumonitis	29	57	2
	50	7	Prednisolone	10	QD	Oral	10.00	Pneumonitis	29	57	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Pneumonitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	57	6	Prednisolone	5	QD	Oral	5.00	Pneumonitis	29	57	2
Trial Number=3475-006, Site Number=1710, Subject ID=369195, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance‡=156											
369195	206	4	Hydrocortisone	800	QID	Intravenous	200.00	Pneumonitis	188	233	3

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
†: Prednisone equivalent total daily dose.
‡Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Subjects With Adverse Events by Outcome (Incidence > 0% in One or More Treatment Groups)
AEOSI- Pneumonitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

		P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	Outcome	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population		682		1,232		1,567		2,799	
With one or more adverse events	Overall	31	(4.5)	54	(4.4)	40	(2.6)	94	(3.4)
	Fatal	3	(0.4)	4	(0.3)	0	(0.0)	4	(0.1)
	Not Resolved	7	(1.0)	16	(1.3)	12	(0.8)	28	(1.0)
	Resolved	17	(2.5)	30	(2.4)	26	(1.7)	56	(2.0)
	Resolving	3	(0.4)	3	(0.2)	2	(0.1)	5	(0.2)
	Sequelae	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
	Unknown	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)

Outcome: Resolved = RECOVERED/RESOLVED, Not resolved = NOT RECOVERED/NOT RESOLVED.
Every subject is counted once for the AE outcome, with the order: Fatal>Not Resolved>Resolving>Unknown>Sequelae>Resolved.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

付録 2.7.4- 62　　免疫関連の大腸炎の AEOSI 解析

001 試験＋002 試験＋006 試験＋010 試験

MK-3475 を投与された悪性黒色腫及び非小細胞肺癌患者（安全性解析対象集団）

Adverse Event Summary
AEOSI - Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	6	(0.9)	13	(1.1)	36	(2.3)	49	(1.8)
with no adverse event	676	(99.1)	1,219	(98.9)	1,531	(97.7)	2,750	(98.2)
with drug-related† adverse events	5	(0.7)	10	(0.8)	30	(1.9)	40	(1.4)
with Grade 3- 5 adverse events	4	(0.6)	9	(0.7)	24	(1.5)	33	(1.2)
with Grade 3- 5 drug-related adverse events	4	(0.6)	8	(0.6)	20	(1.3)	28	(1.0)
with serious adverse events	3	(0.4)	7	(0.6)	26	(1.7)	33	(1.2)
with serious drug-related adverse events	3	(0.4)	6	(0.5)	21	(1.3)	27	(1.0)
who died	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
with drug-related death	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
discontinued‡ due to an adverse event	0	(0.0)	2	(0.2)	13	(0.8)	15	(0.5)
discontinued due to a drug-related adverse event	0	(0.0)	2	(0.2)	13	(0.8)	15	(0.5)
discontinued due to a serious adverse event	0	(0.0)	1	(0.1)	11	(0.7)	12	(0.4)
discontinued due to a serious drug-related adverse event	0	(0.0)	1	(0.1)	11	(0.7)	12	(0.4)

Grades are based on NCI CTCAE version 4.0.
†Determined by the investigator to be related to the drug.
‡Study medication withdrawn.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted].
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

Summary of AEOSI - Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1232		1567		2799	
Subjects with Colitis	6	(0.9)	13	(1.1)	36	(2.3)	49	(1.8)
Time to Onset of First Colitis (days)†								
Mean (Std)	128.0 (81.2)		88.8 (72.1)		143.1 (104.7)		128.7 (99.4)	
Median	116.0		68.0		116.0		107.0	
Range	16 to 238		9 to 238		10 to 494		9 to 494	
Total episodes of Colitis	7		15		41		56	
Average Episodes per subject	1.17		1.15		1.14		1.14	
Episode duration (days)‡								

C Confidential

Summary of AEOSI - Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Median	23.0		20.0		43.0		39.0	
Range	3 to 106+		3 to 107+		1 to 266+		1 to 266+	

(%) = Number of subjects with Colitis / Number of subjects in population.
† Time to onset statistics are based on number of subjects with Colitis.
‡ From product-limit (Kaplan-Meier) method for censored data. If an adverse event is not resolved at the time of analysis or the patient died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occurred first.
+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.
Std = Standard Deviation.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	6	(0.9)	13	(1.1)	36	(2.3)	49	(1.8)
Grade 1	2	(0.3)	3	(0.2)	3	(0.2)	6	(0.2)
Grade 2	0	(0.0)	1	(0.1)	9	(0.6)	10	(0.4)
Grade 3	4	(0.6)	9	(0.7)	22	(1.4)	31	(1.1)
Grade 4	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
with no adverse events	676	(99.1)	1,219	(98.9)	1,531	(97.7)	2,750	(98.2)
Gastrointestinal disorders	**6**	**(0.9)**	**13**	**(1.1)**	**36**	**(2.3)**	**49**	**(1.8)**
Grade 1	2	(0.3)	3	(0.2)	3	(0.2)	6	(0.2)
Grade 2	0	(0.0)	1	(0.1)	9	(0.6)	10	(0.4)
Grade 3	4	(0.6)	9	(0.7)	22	(1.4)	31	(1.1)
Grade 4	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Colitis	6	(0.9)	13	(1.1)	33	(2.1)	46	(1.6)
Grade 1	2	(0.3)	3	(0.2)	2	(0.1)	5	(0.2)
Grade 2	0	(0.0)	1	(0.1)	8	(0.5)	9	(0.3)
Grade 3	4	(0.6)	9	(0.7)	21	(1.3)	30	(1.1)
Grade 4	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Colitis microscopic	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Grade 1	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 2	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Enterocolitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Enterocolitis	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 3	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

Every subject is counted a single time for each applicable specific adverse event. A subject with multiple adverse events within a system organ class is counted a single time for that system organ class.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns is greater than or equal to the incidence specified in the report title, after rounding.

Only the highest reported grade of a given adverse event is counted for the individual subject.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted].

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted].

(MK-3475 PN002 Database Cutoff Date: [redacted].

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Colitis PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010 (N=682)		PN001 Lung, PN010 (N=1232)		PN001 Mel, PN002, PN006 (N=1567)		PN001,PN002, PN006, PN010 (N=2799)	
	n	%	n	%	n	%	n	%
Subjects with one or more Colitis	6		13		36		49	
Treated with systemic corticosteroid	3	50.0	9	69.2	24	66.7	33	67.3
High starting dose[†]	1	16.7	4	30.8	23	63.9	27	55.1
Low starting dose[‡]	2	33.3	5	38.5	1	2.8	6	12.2
Not treated with systemic corticosteroid	3	50.0	4	30.8	12	33.3	16	32.7

The number of Subjects with one or more Colitis is used as the denominator for the percentage calculation.
[†] High starting dose corticosteroid treatment is defined as >= 40 mg/day prednisone or equivalent.
[‡] Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Colitis Episodes PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010	PN001 Lung, PN010	PN001 Mel, PN002, PN006	PN001,PN002, PN006, PN010
Total Episodes	7	15	41	56
High Starting Dose (%) †	**1 (14.3)**	**4 (26.7)**	**25 (61.0)**	**29 (51.8)**
Starting dose (mg/day)				
Mean (Std)	50 (.)	74 (55)	81 (45)	80 (46)
Median (Range)	50 (50-50)	50 (40-156)	75 (40-234)	70 (40-234)
Duration (days)§				
Mean (Std)	1 (.)	6 (6)	16 (33)	15 (31)
Median (Range)	1 (1-1)	4 (1-14)	7 (1-162)	7 (1-162)
Low Starting Dose (%) ‡	**2 (28.6)**	**5 (33.3)**	**1 (2.4)**	**6 (10.7)**
Starting dose (mg/day)				
Mean (Std)	30 (0)	30 (2)	20 (.)	28 (4)
Median (Range)	30 (30-30)	30 (27-33)	20 (20-20)	30 (20-33)
Duration (days)§				
Mean (Std)	3 (0)	7 (7)	6 (.)	7 (7)
Median (Range)	3 (3-3)	3 (3-20)	6 (6-6)	5 (3-20)
Not Treated with Systemic Corticosteroid (%)	**4 (57.1)**	**6 (40.0)**	**15 (36.6)**	**21 (37.5)**

† High starting dose corticosteroid treatment is defined as ≥ 40 mg/day prednisone or equivalent.
‡ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.
§ Ongoing corticosteroid treatment is censored at the cutoff date or date of death, whichever occurs first.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0004, Subject ID=003042, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=83										
003042	Treatment Cycle 2	28	Colitis	Continuing	Mild	1		N		Not Resolved
Trial Number=3475-001, Site Number=0008, Subject ID=003039, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=45										
003039	Treatment Cycle 2	43	Colitis	1.48 Months	Severe	3	Y	Y		Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000503, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=197										
000503	Treatment Cycle 4	70	Colitis	2.6 Months	Moderate	2	Y	Y	Interrupted	Resolved
	Safety Follow-up	211	Colitis	1.77 Months	Severe	3	Y	Y		Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000177, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=253										
000177	Safety Follow-up	263	Colitis	4 Days	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0121, Subject ID=003024, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=										
003024	Treatment Cycle 8	149	Colitis	6 Days	Moderate	2		Y		Resolved
		154	Colitis	1.14 Weeks	Severe	3	Y	Y		Resolved
		161	Colitis	Continuing	Moderate	2		Y		Not Resolved
Trial Number=3475-002, Site Number=0062, Subject ID=100665, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=358										
100665	Extended Safety Follow-up	390	Colitis	6.57 Months		3	Y	Y	None	Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-002, Site Number=0080, Subject ID=100910, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance†=274										
100910	Treatment Cycle 10	191	Colitis	1.38 Months		2	Y	Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0150, Subject ID=100667, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
100667	Treatment Cycle 3	87	Colitis	1.64 Months		2	Y	N	Interrupted	Resolved
Trial Number=3475-010, Site Number=0282, Subject ID=307169, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=331										
307169	Treatment Cycle 6	114	Colitis	2.86 Weeks		2	N	Y	Interrupted	Resolved
	Treatment Cycle 8	179	Colitis	2 Weeks		3	Y	Y	None	Resolved
Trial Number=3475-010, Site Number=0401, Subject ID=311762, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=										
311762	Treatment Cycle 11	238	Colitis	3 Days		1	N	N	None	Resolved
Trial Number=3475-010, Site Number=1080, Subject ID=304049, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=64										
304049	Safety Follow-up	79	Colitis	3.29 Weeks		3	Y	Y	N/A	Resolved
Trial Number=3475-010, Site Number=1405, Subject ID=304574, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=										
304574	Treatment Cycle 4	118	Colitis	Continuing		3	Y	Y	Interrupted	Resolving
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=000511, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=64										

Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0011, Subject ID=000511, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=64										
000511	Extended Safety Follow-up	109	Colitis	5 Days	Severe	3	Y	Y		Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001327, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=141										
001327	Treatment Cycle 3	80	Colitis	Continuing	Mild	1	Y	N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001372, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=208										
001372	Safety Follow-up	222	Colitis	3.29 Weeks	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001399, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=										
001399	Treatment Cycle 5	107	Colitis	2 Weeks	Severe	3	Y	Y		Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001566, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=300										
001566	Treatment Cycle 3	54 63	Colitis Colitis	1.29 Weeks 1 Weeks	Severe Mild	3 1		Y Y	Interrupted	Resolved Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000476, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=295										
000476	Safety Follow-up	296	Colitis	1.35 Months	Moderate	2	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0028, Subject ID=001132, Gender=F, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=1										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0028, Subject ID=001132, Gender=F, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=1										
001132	Extended Safety Follow-up	36	Colitis	2 Weeks	Severe	3	Y	Y	Discontinued	Resolved
		68	Colitis	4 Days	Severe	3	Y	Y		Resolved
Trial Number=3475-002, Site Number=0016, Subject ID=100113, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=										
100113	Treatment Cycle 1	10	Colitis	1.12 Months		2	N	Y	None	Resolved
Trial Number=3475-002, Site Number=0016, Subject ID=100627, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=127										
100627	Safety Follow-up	143	Colitis	3.58 Months		3	N	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0053, Subject ID=100661, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=211										
100661	Treatment Cycle 6	123	Colitis	4.21 Months		3	N	Y	Discontinued	Resolved
Trial Number=3475-002, Site Number=0070, Subject ID=100108, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=148										
100108	Extended Safety Follow-up	213	Colitis	2.23 Months		3	Y	N	N/A	Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100313, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=421										
100313	Treatment Cycle 17	337	Colitis	1.84 Months		3	Y	Y	None	Resolved
Trial Number=3475-002, Site Number=0151, Subject ID=101217, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=632										

Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-002, Site Number=0151, Subject ID=101217, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=632										
101217	Treatment Cycle 24	494	Colitis	3.42 Months		2	N	Y	None	Resolved
Trial Number=3475-006, Site Number=0309, Subject ID=363895, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=115										
363895	Treatment Cycle 5	96	Colitis	23 Hours		3	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0701, Subject ID=360019, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=64										
360019	Treatment Cycle 3	57	Colitis	3.94 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1201, Subject ID=368020, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=										
368020	Treatment Cycle 6	125	Colitis	Continuing		3	N	N	None	Not Resolved
Trial Number=3475-006, Site Number=1402, Subject ID=368856, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=85										
368856	Treatment Cycle 3	54	Colitis	6.57 Months		1	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1500, Subject ID=363996, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=22										
363996	Safety Follow-up	37	Colitis	1.64 Months		2	Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1601, Subject ID=364335, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=45										
364335	Treatment Cycle 2	41	Colitis	1.41 Months		4	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1804, Subject ID=364357, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=182										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=1804, Subject ID=364357, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=182										
364357	Treatment Cycle 7	134	Colitis	1.51 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1809, Subject ID=361785, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
361785	Treatment Cycle 4	73	Colitis	6 Days		3	Y	N	None	Resolved
Trial Number=3475-006, Site Number=1815, Subject ID=360878, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=63										
360878	Treatment Cycle 3	46	Colitis	6.34 Months		4	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1816, Subject ID=364466, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=250										
364466	Treatment Cycle 7	128	Colitis	2 Weeks		2	N	Y	None	Resolved
	Treatment Cycle 8	160	Colitis	1.14 Weeks		2	N	Y	None	Resolved
	Treatment Cycle 9	186	Colitis	1.12 Months		2	N	Y	None	Resolved
	Safety Follow-up	259	Colitis	3.86 Weeks		3	N	Y	N/A	Resolved
Trial Number=3475-010, Site Number=0200, Subject ID=308329, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=469										
308329	Treatment Cycle 9	203	Colitis	1.22 Months		1	N	Y	Interrupted	Resolved
Trial Number=3475-010, Site Number=1405, Subject ID=312141, Gender=M, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance†=40										
312141	Treatment Cycle 1	16	Colitis	1.81 Months		3	N	Y	Interrupted	Resolved
MK-3475 10 mg/kg Q2W										

Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-001, Site Number=0001, Subject ID=001218, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=183										
001218	Treatment Cycle 7	103	Colitis	4 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0001, Subject ID=001734, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=										
001734	Treatment Cycle 1	9	Colitis	3 Days	Severe	3	Y	N		Resolved
		12	Colitis	1.71 Weeks	Moderate	2		N		Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000031, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=										
000031	Treatment Cycle 10	130	Colitis microscopic	3.61 Months	Mild	1	Y	Y		Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=001340, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=83										
001340	Safety Follow-up	95	Colitis	1.45 Months	Severe	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=001267, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=										
001267	Treatment Cycle 13	223	Colitis	4 Days	Severe	3	Y	N		Resolved
Trial Number=3475-001, Site Number=0018, Subject ID=001308, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=165										
001308	Treatment Cycle 13	165	Enterocolitis	1.86 Weeks	Severe	3	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=001715, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=56										
001715	Safety Follow-up	68	Colitis	1 Weeks	Moderate	2		Y	Discontinued	Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0301, Subject ID=362932, Gender=M, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†=										
362932	Treatment Cycle 6	78	Colitis	17.05 Hours		3	Y	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360713, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=153										
360713	Treatment Cycle 9	125	Colitis	2.5 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=362930, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=85										
362930	Safety Follow-up	87	Colitis	1.12 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1705, Subject ID=365415, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=197										
365415	Treatment Cycle 6	72	Colitis	2.57 Weeks		2	N	Y	None	Resolved
	Safety Follow-up	204	Colitis	Continuing		3	Y	Y	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=1808, Subject ID=366961, Gender=F, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=141										

Confidential

Listing of Subjects With Adverse Events
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1808, Subject ID=366961, Gender=F, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance[†]=141										
366961	Safety Follow-up	148	Colitis microscopic	Continuing		2	N	Y	None	Not Resolved

[†]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-001, Site Number=0004, Subject ID=003042, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=83											
003042	27	14	Dexamethasone	8	BID	Oral Administration	53.36	Colitis	28	.	1
	41	20	Dexamethasone	4	QD	Oral Administration	26.68	Colitis	28	.	1
	61	.	Dexamethasone	2	QD	Oral Administration	13.34	Colitis	28	.	1
Trial Number=3475-001, Site Number=0008, Subject ID=003039, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance‡=45											
003039	66	1	Methylprednisolone Sodium Succinate	125	ONCE	Intravenous Administration	156.25	Colitis	43	87	3
	67	6	Prednisone	40	QD	Oral Administration	40.00	Colitis	43	87	3
	73	13	Prednisone	10	QD	Oral Administration	10.00	Colitis	43	87	3
	86	.	Prednisone	40	QD	Oral Administration	40.00	Colitis	43	87	3
Trial Number=3475-001, Site Number=0011, Subject ID=000503, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance‡=197											
000503	114	4	Prednisone	60	QD	Oral Administration	60.00	Colitis	70	148	2
	119	5	Prednisone	40	QD	Oral Administration	40.00	Colitis	70	148	2
	124	5	Prednisone	30	QD	Oral Administration	30.00	Colitis	70	148	2
	129	15	Prednisone	20	QD	Oral Administration	20.00	Colitis	70	148	2
Trial Number=3475-001, Site Number=0121, Subject ID=003024, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance‡=											
003024	159	3	Prednisolone	33	QD	Oral Administration	32.50	Colitis	154	161	3

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	159	3	Prednisolone	33	QD	Oral Administration	32.50	Colitis	161	.	2
	162	5	Prednisolone	13	QD	Oral Administration	12.50	Colitis	161	.	2
	167	3	Prednisolone	3	QD	Oral Administration	2.50	Colitis	161	.	2
	170	3	Prednisolone	13	QD	Oral Administration	12.50	Colitis	161	.	2
	173	3	Prednisolone	33	QD	Oral Administration	32.50	Colitis	161	.	2
	176	8	Prednisolone	13	QD	Oral Administration	12.50	Colitis	161	.	2
	184	2	Prednisolone	8	ONCE	Oral Administration	7.50	Colitis	161	.	2
	186	.	Prednisolone	3	QD	Oral Administration	2.50	Colitis	161	.	2
Trial Number=3475-002, Site Number=0062, Subject ID=100665, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance‡=358											
100665	454	11	Prednisone	40	QD	Oral	40.00	Colitis	390	.	3
	465	5	Prednisone	30	QD	Oral	30.00	Colitis	390	.	3
	470	26	Prednisone	20	QD	Oral	20.00	Colitis	390	.	3
	496	7	Prednisone	15	QD	Oral	15.00	Colitis	390	.	3
	503	17	Prednisone	10	QD	Oral	10.00	Colitis	390	.	3
Trial Number=3475-002, Site Number=0080, Subject ID=100910, Gender=F, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance‡=274											
100910	212	6	Methylprednisolone	60	QD	Oral	75.00	Colitis	191	232	2
	218	4	Methylprednisolone	30	QD	Oral	37.50	Colitis	191	232	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	222	4	Methylprednisolone	10	QD	Oral	12.50	Colitis	191	232	2
	226	4	Methylprednisolone	4	QD	Oral	5.00	Colitis	191	232	2
	230	3	Methylprednisolone	2	QD	Oral	2.50	Colitis	191	232	2
	250	7	Methylprednisolone	60	QD	Oral	75.00	Colitis	191	232	2
	257	7	Methylprednisolone	40	QD	Oral	50.00	Colitis	191	232	2
	264	5	Methylprednisolone	30	QD	Oral	37.50	Colitis	191	232	2
	269	4	Methylprednisolone	16	QD	Oral	20.00	Colitis	191	232	2
	273	8	Methylprednisolone	8	QD	Oral	10.00	Colitis	191	232	2
	281	.	Methylprednisolone	6	QD	Oral	7.50	Colitis	191	232	2
Trial Number=3475-010, Site Number=0282, Subject ID=307169, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=331											
307169	191	7	Methylprednisolone	32	QD	Oral	40.00	Colitis	179	192	3
	189	1	Methylprednisolone Sodium Succinate	40	ONCE	Intravenous	50.00	Colitis	179	192	3
Trial Number=3475-010, Site Number=1405, Subject ID=304574, Gender=M, Race=Asian, Age=66 Years, Rel Day of Study Medication Discontinuance†=											
304574	118	3	Prednisolone	30	QD	Intravenous	30.00	Colitis	118	.	3
	121	10	Prednisolone	30	BID	Oral	30.00	Colitis	118	.	3
	131	14	Prednisolone	20	QD	Oral	20.00	Colitis	118	.	3
	145	11	Prednisolone	15	QD	Oral	15.00	Colitis	118	.	3

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	156	38	Prednisolone	10	QD	Oral	10.00	Colitis	118	.	3
	194	.	Prednisolone	5	QD	Oral	5.00	Colitis	118	.	3
MK-3475 10 mg/kg Q3W											
Trial Number=3475-001, Site Number=0011, Subject ID=001372, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance‡=208											
001372	222	3	Methylprednisolone	80	BID	Intravenous Administration	100.00	Colitis	222	244	3
	224	.	Prednisone	80	BID	Oral Administration	80.00	Colitis	222	244	3
Trial Number=3475-001, Site Number=0011, Subject ID=001399, Gender=F, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance‡=											
001399	110	.	Prednisone	60	QD	Oral Administration	60.00	Colitis	107	120	3
Trial Number=3475-001, Site Number=0020, Subject ID=001566, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance‡=300											
001566	63	7	Prednisone	50	QD	Oral Administration	50.00	Colitis	63	69	1
	70	8	Prednisone	40	QD	Oral Administration	40.00	Colitis	63	69	1
	78	3	Prednisone	30	QD	Oral Administration	30.00	Colitis	63	69	1
	81	3	Prednisone	20	QD	Oral Administration	20.00	Colitis	63	69	1
	84	3	Prednisone	10	QD	Oral Administration	10.00	Colitis	63	69	1
Trial Number=3475-001, Site Number=0021, Subject ID=000476, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance‡=295											
000476	296	41	Prednisolone	120	BID	Oral Administration	120.00	Colitis	296	336	2
Trial Number=3475-001, Site Number=0028, Subject ID=001132, Gender=F, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance‡=1											

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
001132	36	14	Prednisone	40	QD	Oral Administration	40.00	Colitis	36	49	3
Trial Number=3475-002, Site Number=0016, Subject ID=100627, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance‡=127											
100627	145	10	Prednisone	50	OTHER	Oral	50.00	Colitis	143	251	3
	155	3	Prednisone	40	QID	Oral	40.00	Colitis	143	251	3
	158	3	Prednisone	30	TID	Oral	30.00	Colitis	143	251	3
	161	3	Prednisone	20	BID	Oral	20.00	Colitis	143	251	3
	164	3	Prednisone	10	QD	Oral	10.00	Colitis	143	251	3
	167	6	Prednisone	5	QOD	Oral	5.00	Colitis	143	251	3
Trial Number=3475-002, Site Number=0053, Subject ID=100661, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=211											
100661	228	19	Prednisone	40	QD	Oral	40.00	Colitis	123	250	3
	228	39	Prednisone	30	QD	Oral	30.00	Colitis	123	250	3
	267	14	Prednisone	20	QD	Oral	20.00	Colitis	123	250	3
	281	28	Prednisone	10	QD	Oral	10.00	Colitis	123	250	3
	309	22	Prednisone	5	QD	Oral	5.00	Colitis	123	250	3
Trial Number=3475-002, Site Number=0070, Subject ID=100108, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance‡=148											
100108	224	57	Prednisone	80	QD	Oral	80.00	Colitis	213	280	3
	281	59	Prednisone	30	QD	Oral	30.00	Colitis	213	280	3

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	340	.	Prednisone	5	QD	Oral	5.00	Colitis	213	280	3
Trial Number=3475-002, Site Number=0080, Subject ID=100313, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance‡=421											
100313	343	13	Prednisolone	120	QD	Intravenous	120.00	Colitis	337	392	3
	356	13	Prednisolone Sodium Succinate	40	QD	Intravenous	40.00	Colitis	337	392	3
	369	3	Prednisolone Sodium Succinate	37	QD	Intravenous	37.00	Colitis	337	392	3
	372	3	Prednisolone Sodium Succinate	34	QD	Intravenous	34.00	Colitis	337	392	3
Trial Number=3475-006, Site Number=0309, Subject ID=363895, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance‡=115											
363895	96	4	Dexamethasone	20	QD	Intravenous	133.40	Colitis	96	.	3
Trial Number=3475-006, Site Number=0701, Subject ID=360019, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=64											
360019	85	8	Methylprednisolone	280	QD	Intravenous	350.00	Colitis	57	176	3
	96	25	Methylprednisolone	150	QD	Oral	187.50	Colitis	57	176	3
	120	4	Methylprednisolone	140	QD	Intravenous	175.00	Colitis	57	176	3
	124	24	Methylprednisolone	80	QD	Oral	100.00	Colitis	57	176	3
	148	15	Methylprednisolone	40	QD	Oral	50.00	Colitis	57	176	3
	163	14	Methylprednisolone	20	QD	Oral	25.00	Colitis	57	176	3
	79	7	Prednisolone	140	QD	Oral	140.00	Colitis	57	176	3
Trial Number=3475-006, Site Number=1402, Subject ID=368856, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance‡=85											

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
368856	106	3	Methylprednisolone	32	BID	Oral	40.00	Colitis	54	253	1
	109	3	Methylprednisolone	28	BID	Oral	35.00	Colitis	54	253	1
	112	3	Methylprednisolone	24	BID	Oral	30.00	Colitis	54	253	1
	115	3	Methylprednisolone	20	BID	Oral	25.00	Colitis	54	253	1
	118	3	Methylprednisolone	16	BID	Oral	20.00	Colitis	54	253	1
	121	3	Methylprednisolone	12	BID	Oral	15.00	Colitis	54	253	1
	124	3	Methylprednisolone	8	QD	Oral	10.00	Colitis	54	253	1
	127	3	Methylprednisolone	4	QD	Oral	5.00	Colitis	54	253	1
	134	3	Methylprednisolone	8	BID	Oral	10.00	Colitis	54	253	1
	137	1	Methylprednisolone	4	QD	Oral	5.00	Colitis	54	253	1
	138	28	Methylprednisolone	8	BID	Oral	10.00	Colitis	54	253	1
	240	2	Methylprednisolone	32	BID	Oral	40.00	Colitis	54	253	1
	242	11	Methylprednisolone	48	TID	Oral	60.00	Colitis	54	253	1
	253	17	Methylprednisolone	32	BID	Oral	40.00	Colitis	54	253	1
	270	11	Methylprednisolone	24	OTHER	Oral	30.00	Colitis	54	253	1
Trial Number=3475-006, Site Number=1500, Subject ID=363996, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance[‡]=22											
363996	50	10	Methylprednisolone	60	QD	Intravenous	75.00	Colitis	37	86	2

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	60	4	Methylprednisolone	60	QD	Oral	75.00	Colitis	37	86	2
	64	7	Methylprednisolone	50	QD	Oral	62.50	Colitis	37	86	2
	71	7	Methylprednisolone	40	QD	Oral	50.00	Colitis	37	86	2
	78	7	Methylprednisolone	30	QD	Oral	37.50	Colitis	37	86	2
	85	3	Methylprednisolone	20	QD	Oral	25.00	Colitis	37	86	2
Trial Number=3475-006, Site Number=1601, Subject ID=364335, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance‡=45											
364335	58	7	Methylprednisolone Sodium Succinate	188	QD	Intravenous	234.38	Colitis	41	83	4
	64	7	Prednisolone	10	QD	Oral	10.00	Colitis	41	83	4
	64	38	Prednisolone	10	QD	Oral	10.00	Colitis	41	83	4
Trial Number=3475-006, Site Number=1804, Subject ID=364357, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance‡=182											
364357	148	8	Prednisone	40	QD	Oral	40.00	Colitis	134	179	2
	156	5	Prednisone	20	QD	Oral	20.00	Colitis	134	179	2
Trial Number=3475-006, Site Number=1815, Subject ID=360878, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance‡=63											
360878	143	2	Methylprednisolone Sodium Succinate	.		Intravenous	.	Colitis	46	238	4
	72	3	Prednisone	80	BID	Oral	80.00	Colitis	46	238	4
	75	6	Prednisone	50	QD	Oral	50.00	Colitis	46	238	4
	81	7	Prednisone	30	QD	Oral	30.00	Colitis	46	238	4

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	88	9	Prednisone	15	QD	Oral	15.00	Colitis	46	238	4
	144	15	Prednisone	70	QD	Oral	70.00	Colitis	46	238	4
	159	17	Prednisone	60	QD	Oral	60.00	Colitis	46	238	4
	176	5	Prednisone	40	QD	Oral	40.00	Colitis	46	238	4
	181	7	Prednisone	20	QD	Oral	20.00	Colitis	46	238	4
	188	7	Prednisone	10	QD	Oral	10.00	Colitis	46	238	4
	195	8	Prednisone	5	QD	Oral	5.00	Colitis	46	238	4
	203	7	Prednisone	5	QOD	Oral	5.00	Colitis	46	238	4
Trial Number=3475-006, Site Number=1816, Subject ID=364466, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance‡=250											
364466	271	1	Dexamethasone Sodium Phosphate	20	1 TIME PER WEEK	Intravenous	133.40	Colitis	259	285	3
	164	6	Prednisone	20	QD	Oral	20.00	Colitis	160	167	2
	205	12	Prednisone	40	BID	Oral	40.00	Colitis	186	219	2
	272	.	Prednisone	80	QD	Oral	80.00	Colitis	259	285	3
Trial Number=3475-010, Site Number=1405, Subject ID=312141, Gender=M, Race=Asian, Age=74 Years, Rel Day of Study Medication Discontinuance‡=40											
312141	16	3	Prednisolone	30	QD	Intravenous	30.00	Colitis	16	70	3
	19	3	Prednisolone	30	BID	Oral	30.00	Colitis	16	70	3
	23	7	Prednisolone	20	BID	Oral	20.00	Colitis	16	70	3

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	30	17	Prednisolone	10	BID	Oral	10.00	Colitis	16	70	3
	47	19	Prednisolone	30	BID	Oral	30.00	Colitis	16	70	3
MK-3475 10 mg/kg Q2W											
Trial Number=3475-001, Site Number=0001, Subject ID=001218, Gender=M, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance‡=183											
001218	103	7	Prednisone	40	QD	Oral Administration	40.00	Colitis	103	130	2
	110	7	Prednisone	30	QD	Oral Administration	30.00	Colitis	103	130	2
	117	32	Prednisone	10	QD	Oral Administration	10.00	Colitis	103	130	2
Trial Number=3475-001, Site Number=0011, Subject ID=001340, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance‡=83											
001340	95	5	Prednisone	60	QD	Oral Administration	60.00	Colitis	95	138	3
Trial Number=3475-001, Site Number=0018, Subject ID=001308, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance‡=165											
001308	170	5	Prednisone	70	QD	Oral Administration	70.00	Enterocolitis	165	177	3
	175	5	Prednisone	60	QD	Oral Administration	60.00	Enterocolitis	165	177	3
	180	5	Prednisone	50	QD	Oral Administration	50.00	Enterocolitis	165	177	3
	185	5	Prednisone	40	QD	Oral Administration	40.00	Enterocolitis	165	177	3
	190	5	Prednisone	30	QD	Oral Administration	30.00	Enterocolitis	165	177	3
	195	5	Prednisone	20	QD	Oral Administration	20.00	Enterocolitis	165	177	3
	200	5	Prednisone	10	QD	Oral Administration	10.00	Enterocolitis	165	177	3

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
Trial Number=3475-001, Site Number=0020, Subject ID=001715, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance‡=56											
001715	69	7	Prednisone	30	QD	Oral Administration	30.00	Colitis	68	74	2
	76	14	Prednisone	15	QD	Oral Administration	15.00	Colitis	68	74	2
Trial Number=3475-006, Site Number=0605, Subject ID=360713, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=153											
360713	184	1	Methylprednisolone Sodium Succinate	60	QD	Intravenous	75.00	Colitis	125	200	3
	185	3	Methylprednisolone Sodium Succinate	120	QD	Intravenous	150.00	Colitis	125	200	3
	188	1	Methylprednisolone Sodium Succinate	60	QD	Intravenous	75.00	Colitis	125	200	3
	189	21	Prednisone	60	QD	Oral	60.00	Colitis	125	200	3
	210	7	Prednisone	50	QD	Oral	50.00	Colitis	125	200	3
	217	7	Prednisone	40	QD	Oral	40.00	Colitis	125	200	3
	224	7	Prednisone	30	QD	Oral	30.00	Colitis	125	200	3
	231	7	Prednisone	20	QD	Oral	20.00	Colitis	125	200	3
	238	7	Prednisone	15	1 TIME PER WEEK	Oral	15.00	Colitis	125	200	3
	245	7	Prednisone	10	QD	Oral	10.00	Colitis	125	200	3
	252	7	Prednisone	8	QD	Oral	7.50	Colitis	125	200	3
	259	7	Prednisone	5	QD	Oral	5.00	Colitis	125	200	3
	266	10	Prednisone	3	QD	Oral	2.50	Colitis	125	200	3

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
Trial Number=3475-006, Site Number=0605, Subject ID=362930, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance‡=85											
362930	101	6	Methylprednisolone Sodium Succinate	60	QD	Intravenous	75.00	Colitis	87	120	3
	107	15	Prednisolone Sodium Metazoate	80	BID	Oral	80.00	Colitis	87	120	3
	122	11	Prednisolone Sodium Metazoate	60	QD	Oral	60.00	Colitis	87	120	3
	133	11	Prednisolone Sodium Metazoate	50	QD	Oral	50.00	Colitis	87	120	3
	144	10	Prednisolone Sodium Metazoate	40	QD	Oral	40.00	Colitis	87	120	3
	154	11	Prednisolone Sodium Metazoate	30	QD	Oral	30.00	Colitis	87	120	3
	165	11	Prednisolone Sodium Metazoate	20	QD	Oral	20.00	Colitis	87	120	3
	176	10	Prednisolone Sodium Metazoate	15	QD	Oral	15.00	Colitis	87	120	3
	186	11	Prednisolone Sodium Metazoate	10	QD	Oral	10.00	Colitis	87	120	3
	197	11	Prednisolone Sodium Metazoate	5	QD	Oral	5.00	Colitis	87	120	3
Trial Number=3475-006, Site Number=1705, Subject ID=365415, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=197											
365415	318	4	Methylprednisolone	60	BID	Intravenous	75.00	Colitis	204	.	3
	213	2	Prednisolone	55	QD	Oral	55.00	Colitis	204	.	3
	215	3	Prednisolone	60	QD	Oral	60.00	Colitis	204	.	3
	218	5	Prednisolone	40	QD	Oral	40.00	Colitis	204	.	3
	223	5	Prednisolone	30	QD	Oral	30.00	Colitis	204	.	3

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	228	5	Prednisolone	20	QD	Oral	20.00	Colitis	204	.	3
	233	5	Prednisolone	10	QD	Oral	10.00	Colitis	204	.	3
	238	6	Prednisolone	5	QD	Oral	5.00	Colitis	204	.	3
	248	5	Prednisolone	30	QD	Oral	30.00	Colitis	204	.	3
	253	5	Prednisolone	15	QD	Oral	15.00	Colitis	204	.	3
	258	5	Prednisolone	5	QD	Oral	5.00	Colitis	204	.	3
	269	2	Prednisolone	25	QD	Oral	25.00	Colitis	204	.	3
	271	6	Prednisolone	30	QD	Oral	30.00	Colitis	204	.	3
	277	5	Prednisolone	100	QD	Oral	100.00	Colitis	204	.	3
	282	5	Prednisolone	90	QD	Oral	90.00	Colitis	204	.	3
	287	5	Prednisolone	80	QD	Oral	80.00	Colitis	204	.	3
	292	5	Prednisolone	70	QD	Oral	70.00	Colitis	204	.	3
	297	5	Prednisolone	60	QD	Oral	60.00	Colitis	204	.	3
	302	5	Prednisolone	50	QD	Oral	50.00	Colitis	204	.	3
	307	5	Prednisolone	40	QD	Oral	40.00	Colitis	204	.	3
	312	3	Prednisolone	30	QD	Oral	30.00	Colitis	204	.	3
	315	3	Prednisolone	60	QD	Oral	60.00	Colitis	204	.	3

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Colitis Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	321	.	Prednisolone	60	QD	Oral	60.00	Colitis	204	.	3

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
†: Prednisone equivalent total daily dose.
‡Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted].
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Subjects With Adverse Events by Outcome
(Incidence > 0% in One or More Treatment Groups)
AEOSI- Colitis
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

		P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	Outcome	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population		682		1,232		1,567		2,799	
With one or more adverse events	Overall	6	(0.9)	13	(1.1)	36	(2.3)	49	(1.8)
	Fatal	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	Not Resolved	0	(0.0)	2	(0.2)	4	(0.3)	6	(0.2)
	Resolved	5	(0.7)	10	(0.8)	32	(2.0)	42	(1.5)
	Resolving	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
	Unknown	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)

Outcome: Resolved = RECOVERED/RESOLVED, Not resolved = NOT RECOVERED/NOT RESOLVED.
Every subject is counted once for the AE outcome, with the order: Fatal>Not Resolved>Resolving>Unknown>Sequelae>Resolved.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted].
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

付録 2.7.4- 63　　免疫関連の肝炎の AEOSI 解析

001 試験＋002 試験＋006 試験＋010 試験

MK-3475 を投与された悪性黒色腫及び非小細胞肺癌患者（安全性解析対象集団）

Adverse Event Summary
AEOSI - Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	3	(0.4)	3	(0.2)	16	(1.0)	19	(0.7)
with no adverse event	679	(99.6)	1,229	(99.8)	1,551	(99.0)	2,780	(99.3)
with drug-related† adverse events	3	(0.4)	3	(0.2)	14	(0.9)	17	(0.6)
with Grade 3- 5 adverse events	1	(0.1)	1	(0.1)	13	(0.8)	14	(0.5)
with Grade 3- 5 drug-related adverse events	1	(0.1)	1	(0.1)	11	(0.7)	12	(0.4)
with serious adverse events	2	(0.3)	2	(0.2)	10	(0.6)	12	(0.4)
with serious drug-related adverse events	2	(0.3)	2	(0.2)	10	(0.6)	12	(0.4)
who died	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
with drug-related death	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
discontinued‡ due to an adverse event	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)
discontinued due to a drug-related adverse event	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)
discontinued due to a serious adverse event	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)
discontinued due to a serious drug-related adverse event	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)

Grades are based on NCI CTCAE version 4.0.
† Determined by the investigator to be related to the drug.
‡ Study medication withdrawn.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

Summary of AEOSI - Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1232		1567		2799	
Subjects with Hepatic	3	(0.4)	3	(0.2)	16	(1.0)	19	(0.7)
Time to Onset of First Hepatic (days)†								
Mean (Std)	68.0 (50.3)		68.0 (50.3)		101.9 (159.4)		96.6 (147.1)	
Median	62.0		62.0		34.5		40.0	
Range	21 to 121		21 to 121		8 to 651		8 to 651	
Total episodes of Hepatic	3		3		18		21	
Average Episodes per subject	1.00		1.00		1.13		1.11	
Episode duration (days)‡								

C Confidential

Summary of AEOSI - Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Median	Not reached		Not reached		46.5		54.0	
Range	29 to 87+		29 to 87+		8 to 635+		8 to 635+	

(%) = Number of subjects with Hepatic / Number of subjects in population.
† Time to onset statistics are based on number of subjects with Hepatic.
‡ From product-limit (Kaplan-Meier) method for censored data. If an adverse event is not resolved at the time of analysis or the patient died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occurred first.
+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.
Std = Standard Deviation.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	3	(0.4)	3	(0.2)	16	(1.0)	19	(0.7)
Grade 1	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 2	2	(0.3)	2	(0.2)	2	(0.1)	4	(0.1)
Grade 3	1	(0.1)	1	(0.1)	11	(0.7)	12	(0.4)
Grade 4	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
with no adverse events	679	(99.6)	1,229	(99.8)	1,551	(99.0)	2,780	(99.3)
Hepatobiliary disorders	**3**	**(0.4)**	**3**	**(0.2)**	**16**	**(1.0)**	**19**	**(0.7)**
Grade 1	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 2	2	(0.3)	2	(0.2)	2	(0.1)	4	(0.1)
Grade 3	1	(0.1)	1	(0.1)	11	(0.7)	12	(0.4)
Grade 4	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Autoimmune hepatitis	3	(0.4)	3	(0.2)	9	(0.6)	12	(0.4)
Grade 2	2	(0.3)	2	(0.2)	2	(0.1)	4	(0.1)
Grade 3	1	(0.1)	1	(0.1)	6	(0.4)	7	(0.3)
Grade 4	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Drug-induced liver injury	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Grade 3	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 4	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Hepatitis	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)
Grade 1	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)

C Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Hepatitis	0	(0.0)	0	(0.0)	6	(0.4)	6	(0.2)
Grade 3	0	(0.0)	0	(0.0)	5	(0.3)	5	(0.2)

Every subject is counted a single time for each applicable specific adverse event. A subject with multiple adverse events within a system organ class is counted a single time for that system organ class.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns is greater than or equal to the incidence specified in the report title, after rounding.

Only the highest reported grade of a given adverse event is counted for the individual subject.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010 (N=682)		PN001 Lung, PN010 (N=1232)		PN001 Mel, PN002, PN006 (N=1567)		PN001,PN002, PN006, PN010 (N=2799)	
	n	%	n	%	n	%	n	%
Subjects with one or more Hepatic	3		3		16		19	
Treated with systemic corticosteroid	2	66.7	2	66.7	11	68.8	13	68.4
High starting dose†	2	66.7	2	66.7	10	62.5	12	63.2
Low starting dose‡	0	0	0	0	1	6.3	1	5.3
Not treated with systemic corticosteroid	1	33.3	1	33.3	5	31.3	6	31.6

The number of Subjects with one or more Hepatic is used as the denominator for the percentage calculation.
† High starting dose corticosteroid treatment is defined as >= 40 mg/day prednisone or equivalent.
‡ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted].
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Hepatic Episodes PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010	PN001 Lung, PN010	PN001 Mel, PN002, PN006	PN001,PN002, PN006, PN010
Total Episodes	3	3	18	21
High Starting Dose (%) †	**2 (66.7)**	**2 (66.7)**	**10 (55.6)**	**12 (57.1)**
Starting dose (mg/day)				
Mean (Std)	45 (7)	45 (7)	139 (71)	123 (74)
Median (Range)	45 (40-50)	45 (40-50)	106 (53-300)	100 (40-300)
Duration (days)§				
Mean (Std)	14 (17)	14 (17)	5 (4)	6 (7)
Median (Range)	14 (2-26)	14 (2-26)	5 (1-14)	5 (1-26)
Low Starting Dose (%) ‡	**0 (0.0)**	**0 (0.0)**	**1 (5.6)**	**1 (4.8)**
Starting dose (mg/day)				
Mean (Std)	0 (0)	0 (0)	25 (.)	25 (.)
Median (Range)	0 (0-0)	0 (0-0)	25 (25-25)	25 (25-25)
Duration (days)§				
Mean (Std)	0 (0)	0 (0)	8 (.)	8 (.)
Median (Range)	0 (0-0)	0 (0-0)	8 (8-8)	8 (8-8)
Not Treated with Systemic Corticosteroid (%)	**1 (33.3)**	**1 (33.3)**	**7 (38.9)**	**8 (38.1)**

† High starting dose corticosteroid treatment is defined as ≥ 40 mg/day prednisone or equivalent.
‡ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.
§ Ongoing corticosteroid treatment is censored at the cutoff date or date of death, whichever occurs first.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Subjects With Adverse Events
AEOSI- Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-001, Site Number=0015, Subject ID=000336, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=1										
000336	Safety Follow-up	22	Autoimmune hepatitis	1.08 Months	Severe	4	Y	Y	Discontinued	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000318, Gender=F, Race=White, Age=35 Years, Rel Day of Study Medication Discontinuance†=519										
000318	Treatment Cycle 3	63	Hepatitis	1.14 Weeks	Mild	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0023, Subject ID=000126, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=										
000126	Treatment Cycle 30	651	Autoimmune hepatitis	1 Weeks	Severe	3		Y	N/A	Resolved
		658	Autoimmune hepatitis	2.14 Weeks	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0001, Subject ID=100094, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=										
100094	Treatment Cycle 5	127	Autoimmune hepatitis	1.28 Months		2	N	Y	Interrupted	Resolved
Trial Number=3475-010, Site Number=0183, Subject ID=314351, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=1										
314351	Safety Follow-up	21	Autoimmune hepatitis	Continuing		3	Y	Y	Interrupted	Not Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-001, Site Number=0020, Subject ID=001439, Gender=M, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance†=20										
001439	Safety Follow-up	22	Autoimmune hepatitis	2.2 Months	Moderate	2		Y	Interrupted	Resolved
Trial Number=3475-002, Site Number=0070, Subject ID=101879, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=43										

Confidential

Listing of Subjects With Adverse Events
AEOSI- Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-002, Site Number=0070, Subject ID=101879, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=43										
101879	Treatment Cycle 2	21	Hepatitis	Continuing		3	N	N	None	Not Resolved
Trial Number=3475-002, Site Number=0080, Subject ID=100913, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=1										
100913	Safety Follow-up	8	Autoimmune hepatitis	Continuing		3	Y	Y	Discontinued	Resolving
Trial Number=3475-006, Site Number=0309, Subject ID=366971, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=1										
366971	Safety Follow-up	29	Hepatitis	1.08 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=369338, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=										
369338	Treatment Cycle 8	154	Hepatitis	1.81 Months		3	N	N	None	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=364561, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=20										
364561	Treatment Cycle 1	17	Autoimmune hepatitis	3.12 Months		3	Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=365059, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=99										
365059	Treatment Cycle 2	22	Hepatitis	1.18 Months		3	Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1707, Subject ID=364658, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=1										
364658	Safety Follow-up	22 22	Drug-induced liver injury Drug-induced liver injury	3.71 Weeks 4.29 Weeks		4 3	Y Y	Y Y	Discontinued Interrupted	Resolved Resolved

Confidential

Listing of Subjects With Adverse Events
AEOSI- Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-010, Site Number=0014, Subject ID=302077, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=141										
302077	Treatment Cycle 3	62	Autoimmune hepatitis	4.14 Weeks		2	N	Y	Interrupted	Resolved
Trial Number=3475-010, Site Number=0138, Subject ID=305038, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=106										
305038	Safety Follow-up	121	Autoimmune hepatitis	Continuing		2	Y	Y	N/A	Resolving
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=0001, Subject ID=368185, Gender=F, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=279										
368185	Treatment Cycle 4	54	Autoimmune hepatitis	4.29 Weeks		3	Y	Y	Reduced	Resolved
Trial Number=3475-006, Site Number=0005, Subject ID=366940, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=										
366940	Treatment Cycle 3	40	Hepatitis	4.7 Months		3	Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=369195, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=156										
369195	Extended Safety Follow-up	188	Autoimmune hepatitis	3.71 Months		3	Y	Y	N/A	Resolved
		188	Drug-induced liver injury	3.71 Months		3	Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1824, Subject ID=360306, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=183										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W										
Trial Number=3475-006, Site Number=1824, Subject ID=360306, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance[†]=183										
360306	Safety Follow-up	191	Autoimmune hepatitis	1.77 Months		3	Y	Y	Discontinued	Resolved

[†]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted].

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted].

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-001, Site Number=0015, Subject ID=000336, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance‡=1											
000336	22	1	Methylprednisolone Sodium Succinate	80	ONCE	Intravenous Administration	100.00	Autoimmune hepatitis	22	54	4
	22	6	Methylprednisolone Sodium Succinate	1	QD	Intravenous Bolus	1.25	Autoimmune hepatitis	22	54	4
	27	6	Prednisone	80	QD	Oral Administration	80.00	Autoimmune hepatitis	22	54	4
	33	5	Prednisone	60	QD	Oral Administration	60.00	Autoimmune hepatitis	22	54	4
	38	4	Prednisone	40	QD	Oral Administration	40.00	Autoimmune hepatitis	22	54	4
	42	19	Prednisone	20	QD	Oral Administration	20.00	Autoimmune hepatitis	22	54	4
	61	16	Prednisone	10	QD	Oral Administration	10.00	Autoimmune hepatitis	22	54	4
	77	6	Prednisone	3	QD	Oral Administration	2.50	Autoimmune hepatitis	22	54	4
Trial Number=3475-002, Site Number=0001, Subject ID=100094, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance‡=											
100094	139	6	Prednisone	100	QD	Oral	100.00	Autoimmune hepatitis	127	165	2
	145	3	Prednisone	50	QD	Oral	50.00	Autoimmune hepatitis	127	165	2
	148	5	Prednisone	40	QD	Oral	40.00	Autoimmune hepatitis	127	165	2
	153	7	Prednisone	30	QD	Oral	30.00	Autoimmune hepatitis	127	165	2
	160	4	Prednisone	20	QD	Oral	20.00	Autoimmune hepatitis	127	165	2
	164	11	Prednisone	10	QD	Oral	10.00	Autoimmune hepatitis	127	165	2

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	175	14	Prednisone	5	QD	Oral	5.00	Autoimmune hepatitis	127	165	2
	189	49	Prednisone	10	QD	Oral	10.00	Autoimmune hepatitis	127	165	2
	238	44	Prednisone	8	QD	Oral	7.50	Autoimmune hepatitis	127	165	2
	282	24	Prednisone	5	QD	Oral	5.00	Autoimmune hepatitis	127	165	2
	306	.	Prednisone	3	QD	Oral	2.50	Autoimmune hepatitis	127	165	2
Trial Number=3475-010, Site Number=0183, Subject ID=314351, Gender=F, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance‡=1											
314351	86	2	Prednisolone	40	QD	Oral	40.00	Autoimmune hepatitis	21	.	3
MK-3475 10 mg/kg Q3W											
Trial Number=3475-001, Site Number=0020, Subject ID=001439, Gender=M, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance‡=20											
001439	22	8	Prednisone	25	QD	Oral Administration	25.00	Autoimmune hepatitis	22	88	2
	47	1	Prednisone	5	QD	Oral Administration	5.00	Autoimmune hepatitis	22	88	2
	48	8	Prednisone	60	QD	Oral Administration	60.00	Autoimmune hepatitis	22	88	2
	56	7	Prednisone	40	QD	Oral Administration	40.00	Autoimmune hepatitis	22	88	2
	63	21	Prednisone	30	QD	Oral Administration	30.00	Autoimmune hepatitis	22	88	2
Trial Number=3475-002, Site Number=0080, Subject ID=100913, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance‡=1											
100913	21	14	Prednisolone	170	QD	Intravenous	170.00	Autoimmune hepatitis	8	.	3
	35	4	Prednisolone	80	QD	Intravenous	80.00	Autoimmune hepatitis	8	.	3

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	39	3	Prednisolone	60	QD	Intravenous	60.00	Autoimmune hepatitis	8	.	3
	42	5	Prednisolone	40	QD	Intravenous	40.00	Autoimmune hepatitis	8	.	3
	52	4	Prednisolone	32	QD	Oral	32.00	Autoimmune hepatitis	8	.	3
	56	4	Prednisolone	28	QD	Oral	28.00	Autoimmune hepatitis	8	.	3
	60	4	Prednisolone	24	QD	Oral	24.00	Autoimmune hepatitis	8	.	3
	64	32	Prednisolone	20	QD	Oral	20.00	Autoimmune hepatitis	8	.	3
	96	12	Prednisolone	18	QD	Oral	18.00	Autoimmune hepatitis	8	.	3
	108	14	Prednisolone	12	QD	Oral	12.00	Autoimmune hepatitis	8	.	3
	122	19	Prednisolone	8	QD	Oral	8.00	Autoimmune hepatitis	8	.	3
	141	14	Prednisolone	4	QD	Oral	4.00	Autoimmune hepatitis	8	.	3
Trial Number=3475-006, Site Number=0611, Subject ID=364561, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance‡=20											
364561	38	4	Methylprednisolone Sodium Succinate	240	QD	Intravenous	300.00	Autoimmune hepatitis	17	111	3
	42	38	Prednisolone Sodium Metazoate	150	QD	Oral	150.00	Autoimmune hepatitis	17	111	3
	80	12	Prednisolone Sodium Metazoate	100	QD	Oral	100.00	Autoimmune hepatitis	17	111	3
	92	8	Prednisolone Sodium Metazoate	75	QD	Oral	75.00	Autoimmune hepatitis	17	111	3
	100	11	Prednisolone Sodium Metazoate	50	QD	Oral	50.00	Autoimmune hepatitis	17	111	3
Trial Number=3475-006, Site Number=0611, Subject ID=365059, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance‡=99											

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
365059	24	5	Methylprednisolone Sodium Succinate	120	QD	Intravenous	150.00	Hepatitis	22	57	3
	29	2	Prednisone	100	QD	Oral	100.00	Hepatitis	22	57	3
	31	26	Prednisone	80	QD	Oral	80.00	Hepatitis	22	57	3
	56	3	Prednisone	15	QD	Oral	15.00	Hepatitis	22	57	3
Trial Number=3475-006, Site Number=1707, Subject ID=364658, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance‡=1											
364658	25	5	Hydrocortisone	800	QID	Intravenous	200.00	Drug-induced liver injury	22	47	4
Trial Number=3475-010, Site Number=0138, Subject ID=305038, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance‡=106											
305038	126	.	Prednisolone	50	QD	Oral	50.00	Autoimmune hepatitis	121	.	2
MK-3475 10 mg/kg Q2W											
Trial Number=3475-006, Site Number=0001, Subject ID=368185, Gender=F, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance‡=279											
368185	56	1	Dexamethasone	8	ONCE	Oral	53.36	Autoimmune hepatitis	54	83	3
	57	10	Dexamethasone	12	BID	Oral	80.04	Autoimmune hepatitis	54	83	3
	67	10	Dexamethasone	12	QD	Oral	80.04	Autoimmune hepatitis	54	83	3
	77	7	Dexamethasone	4	QD	Oral	26.68	Autoimmune hepatitis	54	83	3
	84	7	Dexamethasone	2	QD	Oral	13.34	Autoimmune hepatitis	54	83	3
	91	17	Dexamethasone	2	QOD	Oral	13.34	Autoimmune hepatitis	54	83	3
	60	1	Methylprednisolone Sodium Succinate	1000	ONCE	Intravenous	1250.00	Autoimmune hepatitis	54	83	3

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	90	1	Methylprednisolone Sodium Succinate	500	ONCE	Intravenous	625.00	Autoimmune hepatitis	54	83	3
Trial Number=3475-006, Site Number=0005, Subject ID=366940, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance‡=											
366940	54	6	Prednisolone	100	QD	Oral	100.00	Hepatitis	40	182	3
	60	5	Prednisolone	75	QD	Oral	75.00	Hepatitis	40	182	3
	65	7	Prednisolone	50	QD	Oral	50.00	Hepatitis	40	182	3
	72	7	Prednisolone	38	QD	Oral	37.50	Hepatitis	40	182	3
	79	6	Prednisolone	25	QD	Oral	25.00	Hepatitis	40	182	3
	85	7	Prednisolone	13	QD	Oral	12.50	Hepatitis	40	182	3
Trial Number=3475-006, Site Number=1710, Subject ID=369195, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance‡=156											
369195	209	1	Methylprednisolone	80	ONCE	Intravenous	100.00	Autoimmune hepatitis	188	300	3
	209	1	Methylprednisolone	80	ONCE	Intravenous	100.00	Drug-induced liver injury	188	300	3
	210	6	Methylprednisolone	160	QID	Intravenous	200.00	Autoimmune hepatitis	188	300	3
	210	6	Methylprednisolone	160	QID	Intravenous	200.00	Drug-induced liver injury	188	300	3
	224	28	Methylprednisolone	160	QID	Intravenous	200.00	Autoimmune hepatitis	188	300	3
	224	28	Methylprednisolone	160	QID	Intravenous	200.00	Drug-induced liver injury	188	300	3
	256	3	Methylprednisolone	160	BID	Intravenous	200.00	Autoimmune hepatitis	188	300	3
	256	3	Methylprednisolone	160	BID	Intravenous	200.00	Drug-induced liver injury	188	300	3

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	259	1	Methylprednisolone	60	QD	Intravenous	75.00	Autoimmune hepatitis	188	300	3
	259	1	Methylprednisolone	80	ONCE	Intravenous	100.00	Autoimmune hepatitis	188	300	3
	259	1	Methylprednisolone	60	QD	Intravenous	75.00	Drug-induced liver injury	188	300	3
	259	1	Methylprednisolone	80	ONCE	Intravenous	100.00	Drug-induced liver injury	188	300	3
	260	3	Methylprednisolone	160	BID	Intravenous	200.00	Autoimmune hepatitis	188	300	3
	260	3	Methylprednisolone	160	BID	Intravenous	200.00	Drug-induced liver injury	188	300	3
	262	1	Methylprednisolone	70	ONCE	Intravenous	87.50	Autoimmune hepatitis	188	300	3
	262	1	Methylprednisolone	70	ONCE	Intravenous	87.50	Drug-induced liver injury	188	300	3
	263	3	Methylprednisolone	140	BID	Intravenous	175.00	Autoimmune hepatitis	188	300	3
	263	3	Methylprednisolone	140	BID	Intravenous	175.00	Drug-induced liver injury	188	300	3
	219	6	Prednisolone	60	QD	Oral	60.00	Autoimmune hepatitis	188	300	3
	219	6	Prednisolone	60	QD	Oral	60.00	Drug-induced liver injury	188	300	3
	252	4	Prednisolone	100	QD	Oral	100.00	Autoimmune hepatitis	188	300	3
	252	4	Prednisolone	100	QD	Oral	100.00	Drug-induced liver injury	188	300	3
	254	1	Prednisolone	50	QD	Oral	50.00	Autoimmune hepatitis	188	300	3
	254	1	Prednisolone	50	QD	Oral	50.00	Drug-induced liver injury	188	300	3

Trial Number=3475-006, Site Number=1824, Subject ID=360306, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance‡=183

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
360306	196	4	Methylprednisolone	90	BID	Intravenous	112.50	Autoimmune hepatitis	191	244	3
	199	5	Prednisone	100	BID	Oral	100.00	Autoimmune hepatitis	191	244	3
	204	1	Prednisone	180	OTHER	Oral	180.00	Autoimmune hepatitis	191	244	3
	205	6	Prednisone	80	BID	Oral	80.00	Autoimmune hepatitis	191	244	3
	211	1	Prednisone	140	OTHER	Oral	140.00	Autoimmune hepatitis	191	244	3

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	212	6	Prednisone	60	BID	Oral	60.00	Autoimmune hepatitis	191	244	3
	218	1	Prednisone	100	OTHER	Oral	100.00	Autoimmune hepatitis	191	244	3
	219	6	Prednisone	40	BID	Oral	40.00	Autoimmune hepatitis	191	244	3
	232	5	Prednisone	20	BID	Oral	20.00	Autoimmune hepatitis	191	244	3
	237	1	Prednisone	30	OTHER	Oral	30.00	Autoimmune hepatitis	191	244	3

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Hepatic Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	238	6	Prednisone	10	BID	Oral	10.00	Autoimmune hepatitis	191	244	3
	238	6	Prednisone	10	BID	Oral	10.00	Autoimmune hepatitis	191	244	3
	244	1	Prednisone	15	OTHER	Oral	15.00	Autoimmune hepatitis	191	244	3
	245	6	Prednisone	5	BID	Oral	5.00	Autoimmune hepatitis	191	244	3
	251	8	Prednisone	5	QD	Oral	5.00	Autoimmune hepatitis	191	244	3

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
†: Prednisone equivalent total daily dose.
‡Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Subjects With Adverse Events by Outcome
(Incidence > 0% in One or More Treatment Groups)
AEOSI- Hepatic
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

		P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	Outcome	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population		682		1,232		1,567		2,799	
With one or more adverse events	Overall	3	(0.4)	3	(0.2)	16	(1.0)	19	(0.7)
	Fatal	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	Not Resolved	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
	Resolved	1	(0.1)	1	(0.1)	14	(0.9)	15	(0.5)
	Resolving	1	(0.1)	1	(0.1)	1	(0.1)	2	(0.1)
	Unknown	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)

Outcome: Resolved = RECOVERED/RESOLVED, Not resolved = NOT RECOVERED/NOT RESOLVED.
Every subject is counted once for the AE outcome, with the order: Fatal>Not Resolved>Resolving>Unknown>Sequelae>Resolved.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted].
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted].
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

付録 2.7.4- 64　　免疫関連の腎炎の AEOSI 解析

001 試験＋002 試験＋006 試験＋010 試験

MK-3475 を投与された悪性黒色腫及び非小細胞肺癌患者（安全性解析対象集団）

Adverse Event Summary
AEOSI - Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
with no adverse event	681	(99.9)	1,231	(99.9)	1,564	(99.8)	2,795	(99.9)
with drug-related† adverse events	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
with Grade 3- 5 adverse events	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
with Grade 3- 5 drug-related adverse events	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
with serious adverse events	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
with serious drug-related adverse events	1	(0.1)	1	(0.1)	2	(0.1)	3	(0.1)
who died	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
with drug-related death	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
discontinued‡ due to an adverse event	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
discontinued due to a drug-related adverse event	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
discontinued due to a serious adverse event	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
discontinued due to a serious drug-related adverse event	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

Grades are based on NCI CTCAE version 4.0.

† Determined by the investigator to be related to the drug.

‡ Study medication withdrawn.

Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) were observed that are not reported on the table.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

Summary of AEOSI - Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1232		1567		2799	
Subjects with Renal	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
Time to Onset of First Renal (days)†								
Mean (Std)	20.0		20.0		149.7 (84.7)		117.3 (94.8)	
Median	20.0		20.0		156.0		109.0	
Range	20 to 20		20 to 20		62 to 231		20 to 231	
Total episodes of Renal	1		1		3		4	
Average Episodes per subject	1.00		1.00		1.00		1.00	

C Confidential

Summary of AEOSI - Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001,PN002, PN006, PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Episode duration (days)‡								
Median	Not reached		Not reached		33.0		Not reached	
Range	247+ to 247+		247+ to 247+		12 to 272+		12 to 272+	

(%) = Number of subjects with Renal / Number of subjects in population.

† Time to onset statistics are based on number of subjects with Renal.

‡ From product-limit (Kaplan-Meier) method for censored data. If an adverse event is not resolved at the time of analysis or the patient died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occurred first.

+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.

Std = Standard Deviation.

Grades are based on NCI CTCAE version 4.0.

Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) of the AEOSI-Renal were observed that are not reported on the table.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	682		1,232		1,567		2,799	
with one or more adverse events	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
Grade 1	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 2	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Grade 3	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
with no adverse events	681	(99.9)	1,231	(99.9)	1,564	(99.8)	2,795	(99.9)
Renal and urinary disorders	**1**	**(0.1)**	**1**	**(0.1)**	**3**	**(0.2)**	**4**	**(0.1)**
Grade 1	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 2	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
Grade 3	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
Tubulointerstitial nephritis	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
Grade 1	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
Grade 2	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)

Confidential

Subjects With Adverse Events by Maximum Toxicity Grade
(Incidence >0% in One or More Treatment Groups)
AEOSI- Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	n	(%)	n	(%)	n	(%)	n	(%)
Tubulointerstitial nephritis	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
Grade 3	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)

Every subject is counted a single time for each applicable specific adverse event. A subject with multiple adverse events within a system organ class is counted a single time for that system organ class.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns is greater than or equal to the incidence specified in the report title, after rounding.

Only the highest reported grade of a given adverse event is counted for the individual subject.

Grades are based on NCI CTCAE version 4.0.

Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) of the AEOSI-Renal were observed that are not reported on the table.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

	P010 (N=682)		PN001 Lung, PN010 (N=1232)		PN001 Mel, PN002, PN006 (N=1567)		PN001,PN002, PN006, PN010 (N=2799)	
	n	%	n	%	n	%	n	%
Subjects with one or more Renal	1		1		3		4	
Treated with systemic corticosteroid	1	100.0	1	100.0	2	66.7	3	75.0
High starting dose†	1	100.0	1	100.0	2	66.7	3	75.0
Low starting dose‡	0	0	0	0	0	0	0	0
Not treated with systemic corticosteroid	0	0	0	0	1	33.3	1	25.0

The number of Subjects with one or more Renal is used as the denominator for the percentage calculation.

† High starting dose corticosteroid treatment is defined as >= 40 mg/day prednisone or equivalent.

‡ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.

Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) of the AEOSI-Renal were observed that are not reported on the table.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

C Confidential

Summary of Concomitant Corticosteroid Use for AEOSI - Renal Episodes PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475 (APaT Population)

	P010	PN001 Lung, PN010	PN001 Mel, PN002, PN006	PN001,PN002, PN006, PN010
Total Episodes	1	1	3	4
High Starting Dose (%) †	**1 (100.0)**	**1 (100.0)**	**2 (66.7)**	**3 (75.0)**
Starting dose (mg/day)				
Mean (Std)	80 (.)	80 (.)	85 (21)	83 (15)
Median (Range)	80 (80-80)	80 (80-80)	85 (70-100)	80 (70-100)
Duration (days)§				
Mean (Std)	3 (.)	3 (.)	9 (8)	7 (7)
Median (Range)	3 (3-3)	3 (3-3)	9 (3-15)	3 (3-15)
Low Starting Dose (%) ‡	**0 (0.0)**	**0 (0.0)**	**0 (0.0)**	**0 (0.0)**
Not Treated with Systemic Corticosteroid (%)	**0 (0.0)**	**0 (0.0)**	**1 (33.3)**	**1 (25.0)**

† High starting dose corticosteroid treatment is defined as ≥ 40 mg/day prednisone or equivalent.
‡ Low starting dose corticosteroid treatment is defined as < 40 mg/day prednisone or equivalent.
§ Ongoing corticosteroid treatment is censored at the cutoff date or date of death, whichever occurs first.
Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) of the AEOSI-Renal were observed that are not reported on the table.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted]).
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Subjects With Adverse Events
AEOSI- Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W										
Trial Number=3475-002, Site Number=0112, Subject ID=101216, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=41										
101216	Safety Follow-up	62	Tubulointerstitial nephritis	Continuing		2	Y	Y	Interrupted	Resolving
Trial Number=3475-010, Site Number=0562, Subject ID=301548, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=1										
301548	Safety Follow-up	20	Tubulointerstitial nephritis	Continuing		3	Y	Y	Discontinued	Not Resolved
MK-3475 10 mg/kg Q3W										
Trial Number=3475-002, Site Number=0083, Subject ID=100651, Gender=F, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=355										
100651	Treatment Cycle 11	231	Tubulointerstitial nephritis	1.71 Weeks		1	N	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0902, Subject ID=361025, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=										

C Confidential

Listing of Subjects With Adverse Events
AEOSI- Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W										
Trial Number=3475-006, Site Number=0902, Subject ID=361025, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance[†]=										
361025	Treatment Cycle 7	156	Tubulointerstitial nephritis	1.08 Months		2	Y	Y	Interrupted	Resolved

[†]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0.

Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) of the AEOSI-Renal were observed that are not reported on the table.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Renal Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.† (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
MK-3475 2 mg/kg Q3W											
Trial Number=3475-002, Site Number=0112, Subject ID=101216, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance‡=41											
101216	75	15	Prednisone	100	QD	Oral	100.00	Tubulointerstitial nephritis	62	.	2
	90	13	Prednisone	60	QD	Oral	60.00	Tubulointerstitial nephritis	62	.	2
	103	14	Prednisone	30	QD	Oral	30.00	Tubulointerstitial nephritis	62	.	2
	117	15	Prednisone	20	QD	Oral	20.00	Tubulointerstitial nephritis	62	.	2
	132	.	Prednisone	10	QD	Oral	10.00	Tubulointerstitial nephritis	62	.	2
Trial Number=3475-010, Site Number=0562, Subject ID=301548, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance‡=1											
301548	28	3	Prednisolone	80	OTHER	Oral	80.00	Tubulointerstitial nephritis	20	.	3
MK-3475 10 mg/kg Q3W											
Trial Number=3475-006, Site Number=0902, Subject ID=361025, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance‡=											
361025	174	3	Prednisone	70	QD	Oral	70.00	Tubulointerstitial nephritis	156	188	2
	177	3	Prednisone	60	QD	Oral	60.00	Tubulointerstitial nephritis	156	188	2
	180	3	Prednisone	50	QD	Oral	50.00	Tubulointerstitial nephritis	156	188	2
	183	3	Prednisone	40	QD	Oral	40.00	Tubulointerstitial nephritis	156	188	2
	186	3	Prednisone	30	QD	Oral	30.00	Tubulointerstitial nephritis	156	188	2
	189	21	Prednisone	10	QD	Oral	10.00	Tubulointerstitial nephritis	156	188	2

C Confidential

Listing of Concomitant Systemic Corticosteroid Use for AEOSI - Renal Adverse Events
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

Subject ID	Med. Start Day	Med. Duration (Days)	Med. Name	Total Daily Dose	Frequency	Route	Prednisone Equiv.[†] (mg)	Adverse Event for Use	AE Start Day	AE End Day	AE Toxicity Grade
	210	20	Prednisone	5	QD	Oral	5.00	Tubulointerstitial nephritis	156	188	2

Med.: Medication.
Equiv.: Equivalent.
AE: Adverse Event.
[†]: Prednisone equivalent total daily dose.
[‡]Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.
AE start date is defined as the start day of the adverse event for the subject relative to the start of study medication.
Grades are based on NCI CTCAE version 4.0.
Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) of the AEOSI-Renal were observed that are not reported on the table.
(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).
(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).
(MK-3475 PN002 Database Cutoff Date: [redacted].
(MK-3475 PN006 Database Cutoff Date: 03MAR2015).
(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential

Subjects With Adverse Events by Outcome
(Incidence > 0% in One or More Treatment Groups)
AEOSI- Renal
PN001, PN002, PN006 and PN010 Subjects Treated with MK-3475
(APaT Population)

		P010		PN001 Lung, PN010		PN001 Mel, PN002, PN006		PN001 PN002 PN006 PN010	
	Outcome	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population		682		1,232		1,567		2,799	
With one or more adverse events	Overall	1	(0.1)	1	(0.1)	3	(0.2)	4	(0.1)
	Fatal	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	Not Resolved	1	(0.1)	1	(0.1)	0	(0.0)	1	(0.0)
	Resolved	0	(0.0)	0	(0.0)	2	(0.1)	2	(0.1)
	Resolving	0	(0.0)	0	(0.0)	1	(0.1)	1	(0.0)
	Unknown	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)

Outcome: Resolved = RECOVERED/RESOLVED, Not resolved = NOT RECOVERED/NOT RESOLVED.

Every subject is counted once for the AE outcome, with the order: Fatal>Not Resolved>Resolving>Unknown>Sequelae>Resolved.

Five additional cases (subject 000054 in PN001 with autoimmune nephritis, subject 000048 in PN001 with renal failure acute, subject 000058 in PN001 with renal failure, subject 368852 in PN006 with renal failure acute, subject 363218 in PN006 with renal failure) of the AEOSI-Renal were observed that are not reported on the table.

(MK-3475 PN001 Database Cutoff Date for MEL: [redacted]).

(MK-3475 PN001 Database Cutoff Date for Lung: [redacted]).

(MK-3475 PN002 Database Cutoff Date: [redacted]).

(MK-3475 PN006 Database Cutoff Date: 03MAR2015).

(MK-3475 PN010 Database Cutoff Date: 30SEP2015).

Confidential